# EDGAR Filing Document

**Accession Number:** 0001178660
**File Stem:** 0001683168-26-002770
**Filing Date:** 2026-4
**Character Count:** 308817
**Document Hash:** 136943c76da33e13a3f4e0b04dfdd569
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-002770.hdr.sgml**: 20260409

**ACCESSION NUMBER**: 0001683168-26-002770

**CONFORMED SUBMISSION TYPE**: 1-K

**PUBLIC DOCUMENT COUNT**: 5

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260409

**DATE AS OF CHANGE**: 20260409

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Standard Dental Labs Inc.
- **CENTRAL INDEX KEY:** 0001178660
- **STANDARD INDUSTRIAL CLASSIFICATION:** DENTAL EQUIPMENT & SUPPLIES [3843]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 880411500
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 1-K
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 24R-01002
- **FILM NUMBER:** 26850780

**BUSINESS ADDRESS:**
- **STREET 1:** 424 E CENTRAL BLVD
- **STREET 2:** SUITE 308
- **CITY:** ORLANDO
- **STATE:** FL
- **ZIP:** 32801
- **BUSINESS PHONE:** 321-465-9899

**MAIL ADDRESS:**
- **STREET 1:** 424 E CENTRAL BLVD
- **STREET 2:** SUITE 308
- **CITY:** ORLANDO
- **STATE:** FL
- **ZIP:** 32801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** COSTAS INC
- **DATE OF NAME CHANGE:** 20020724

## Part

[**Table of Contents**](#a_003)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 1-K**

**ANNUAL REPORT PURSUANT TO REGULATION A** 

**OF THE SECURITIES ACT OF 1933**

**For the fiscal year ended December 31, 2025**

**<u>STANDARD DENTAL LABS INC.</u>**

(Exact name of issuer as specified in its charter)

---

| | |
|:---|:---|
| **Nevada** | **88-0411500** |
| (State or other jurisdiction of <br> incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

**<u>424 E Central Blvd #308</u>**

**<u>Orlando, FL 32801, USA</u>**

(Full mailing address of principal executive offices)

**<u>(407) 789-1923</u>**

(Issuer's telephone number, including area code)

**<u>Common Stock</u>**

Title of each class of securities issued pursuant to Regulation A

**TABLE OF CONTENT**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| Item 1. | [Business](#a_001) | 1 |
| Item 2. | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#a_002) | 8 |
| Item 3. | [Directors and Officers](#a_007) | 12 |
| Item 4. | [Security Ownership of Management and Certain Securityholders](#a_004) | 17 |
| Item 5. | [Interest of Management and Others in Certain Transactions](#a_008) | 18 |
| Item 6. | [Other Information](#a_005) | 18 |
| Item 7. | [Financial Statements](#a_006) | 18 |
| Item 8. | [Exhibits](#a_009) | 19 |

---

i

Except as otherwise indicated by the context and for the purposes of this annual report only, references in this annual report to "Standard Dental Labs," "SDL," "we," "us," "our," "our company" and the "Company" refer to Standard Dental Labs Inc., a Nevada corporation.

**Special Note Regarding Forward-Looking Statements**

This annual report and the documents incorporated by reference herein contain, in addition to historical information, certain "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation and availability of resources. These forward-looking statements include, without limitation: statements concerning predictions, expectations, estimates or forecasts for our business, financial and operating results and future economic performance; statements of management's goals and objectives; trends affecting our financial condition, results of operations or future prospects; statements regarding our financing plans or growth strategies; statements concerning litigation or other matters; and other similar expressions concerning matters that are not historical facts. Words such as "may," "will," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes" and "estimates," and similar expressions, as well as statements in future tense, identify forward-looking statements.

Potential investors should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Potential investors should not make an investment decision based solely on our company's projections, estimates or expectations.

The specific discussions herein about our company include future expectations about our company's business. The expectations are presented in this annual report only as a guide about future possibilities and do not represent actual amounts or assured events. All estimates are based exclusively on our company management's own assessment of its business, the industry in which it works and the economy at large and other operational factors, including capital resources and liquidity, financial condition, fulfillment of contracts and opportunities. The actual results may differ significantly from our expectations.

ii

**ITEM 1. BUSINESS**

**Corporate History**

Standard Dental Labs Inc. (f/k/a Costas, Inc.) was incorporated in the State of Nevada on December 10, 1998. Prior to its current business, Standard Dental Labs was a development stage company that had a primary business plan to acquire, improve, and re-market undeveloped real estate in Las Vegas, Nevada and its surrounding communities.

On January 21, 2015, the Company engaged Mr. James Brooks under a consulting agreement pursuant to which Mr. Brooks agreed to devote his full-time efforts to build and develop our technological and marketing platforms. On September 18, 2017, the court entered an order in favor of Mr. Brooks granting a judgment in the amount of $1,114,500 against the Company. On December 23, 2021, we entered into an 8% Convertible Promissory Note with Brooks in the amount of $1,171,727 in satisfaction of the outstanding judgment. The convertible promissory note bears interest rate at 8% per annum for a period of 12 months. The holder has the right to convert any or all of the outstanding principal into shares of our common stock at a conversion price of $0.001 per share. Shortly thereafter, Brooks converted $175,000 of the balance due and owing under the Note into 15,000,000 shares, which resulted in Mr. Brooks becoming our controlling stockholder. On October 21, 2020, Mr. Brooks, as a majority shareholder, filed a motion requesting the appointment of a Receiver over our company. On March 25, 2021, the Receiver filed a motion with the Court requesting approval to appoint Mr. Brooks as an officer and director of our company and to increase our authorized capital and subsequently to issue sufficient common and preferred shares on terms to be finalized with Mr. Brooks, whereby Mr. Brooks became the controlling stockholder of our company. On December 30, 2021, Mr. James Brooks was appointed our sole officer and director in place of Mr. Fred Waid. On March 2, 2023, Mr. Brooks assigned $10,000 of his convertible note leaving the principal amount of $1,161,727 due and payable.

On February 9, 2022, an Order was entered by the Eighth Judicial District Court, Clark County, Nevada, Case No. A-17-749977D, terminating the receivership for our company.

On May 6, 2022, we entered into an asset purchase agreement with Standard Dental Labs Inc. ("**SDL**"), a Wyoming corporation controlled by our CEO, James Brooks, to acquire certain assets including: (i) a ready to implement business model and platform for the identification and acquisition of small to medium sized dental labs in the United States, and (ii) a fully developed branding package created around SDL, including logo, website, presentation materials and corporate name. Under the terms of the acquisition agreement, assets valued at $75,900 were acquired through the issuance of a total of 1,583,088 shares of our restricted common stock to SDL. With the conclusion of this acquisition, we planned to operate in the dental lab industry, paving the way for future acquisitions and consolidations in the industry. The assets acquired from SDL did not constitute an operating business, but rather an immediately actionable plan and branding concept from which we identified our first operating dental lab targets.

On August 15, 2022, we announced the completion of a definitive agreement to acquire the assets of Prime Dental Lab LLC ("**Prime Dental**" or "**PDL**"), an Orlando-based dental lab in operation since 2012. The purchased assets consisted of (i) accounts receivable; (ii) inventories; (iii) deposits, advances, pre-paid expenses and credits relating to prepaid packages; (iv) furniture, fixtures, machinery, equipment, computer hardware and software, and all other tangible assets; (v) intellectual property including the right to continue using the name "Prime Dental Lab LLC"; (vi) permits and licenses; and (vii) all information (including client lists), files, databases, correspondence, records, data, plans, reports, etc. We accounted for the August 15, 2022 transaction with Prime Dental as a reverse recapitalization whereby Prime Dental was determined as the accounting acquirer and Standard Dental as the accounting acquiree. This determination was primarily based on Standard Dental acquiring all of the operating assets of Prime Dental, Standard Dental first commencing operating activities following completion of the transaction and the Prime Dental assets acquired in the transaction accounting for the majority of Standard Dental's operating assets upon commencement of operations. While Standard Dental Labs was the legal acquirer, because Prime Dental was determined the accounting acquirer, the historical financial statements of Prime Dental became the historical financial statement of Standard Dental, upon consummation of the transaction, and the comparative financial information reflects the historical operations and financial position of Prime Dental prior to the transaction. As a result, the financial statements included in the accompanying consolidated financial statements reflect (i) the historical operating results of Prime Dental prior to the transaction; (ii) the combined results of Standard Dental and Prime Dental following the closing of the transaction; (iii) the assets and liabilities of Standard Dental at their historical cost with no goodwill or step-up in asset values; and (iv) Standard Dental's equity structure for all periods presented (restated to reflect the legal capital structure of Standard Dental).

Upon completion of the asset purchase, and by virtue of the fact we acquired all rights to the name and branding associated with Prime Dental, PDL changed its name to Smile Dental (all references hereinafter to *Prime Dental*, *Prime Dental Lab*, and *PDL* shall be construed and interpreted as references to *Smile Dental*). We agreed to total consideration of $700,000 comprised of $560,000 in stock (the "**Share Consideration**"), $140,000 in cash (the "**Cash Consideration**"), and up to 10% of the Share Consideration in additional stock options. The Cash Consideration was payable in two installments of $70,000 with the first installment due at closing and the second installment due upon our success achieving a registered financing under an S-1 registration statement, or on such earlier date as may be agreed in writing by the Parties. The Asset Purchase Agreement does not have any termination provisions.

The Share Consideration is subject to a lock-up agreement for a term of twenty-four months from the issuance date, whereunder Smile Dental is entitled to receive a quarterly release of 12.5% of the total Share Consideration, subject to confirmation that the quarterly revenues generated by the PDL purchased assets exceed 12.5% percent of the PDL's 2021 annual revenue.

In order to facilitate ongoing lab operations and to seamlessly service its acquired customer base, we entered into a subcontractor agreement with Smile Dental on August 31, 2022, as amended April 30, 2023, whereunder Smile Dental agreed to provide ongoing labor, quality control and delivery services during a period of up to two years from the latest date as a subcontractor to Standard Dental. Currently, all labor in our dental lab is performed under the Smile Dental subcontractor agreement. Any and all disputes arising under the Subcontractor Agreement must be resolved through binding arbitration through the Florida Circuit – Civil Mediator Society.

Concurrent with the closing of the acquisition of certain assets from Smile Dental, we entered into a subcontractor agreement with Mr. John Kim for the provision of certain services including labor, materials, supplies and manufacturing expertise with respect to the servicing of our client list for dental prosthetics and orthotics. Mr. Kim shall be available for our exclusive use certain acquired assets in order to facilitate the provision of finished products. As consideration under the terms of the agreement, Mr. Kim and his management company, Smile Dental, shall be entitled to retain all gross profits from the sale of such finished goods, net the cost of use of the production equipment, as management fees. The agreement has an initial term of up to two (2) years and either we or Mr. Kim may terminate the agreement with six (6) months' written notice, in order to provide us with sufficient time to identify, hire and train a suitable replacement.

Upon acquisition of the customers and operational assets of Smile Dental, we immediately commenced revenue generating operations effective September 1, 2022, and reported gross revenues of $173,329 in the four-month period ended December 31, 2022, and associated costs of goods sold totaling $101,054 for gross profit of $72,275.

On February 2, 2025 Smile Dental Management LLC was sold to Bravo Dental Lab LLC, a non-arm's length company owned by SDL president James Brooks' spouse. On July 1, 2025, SDL entered into a management agreement with Bravo Dental Lab to begin providing services on January 1st, 2026. Bravo Dental continues to provide lab and staffing services related to the operations of SDL in the same way it was provided by Smile Dental Management. Strategically, the intended goal is to use Bravo Dental as a staff management service for SDL for all technical positions related to manufacturing and lab management. SDL maintains ownership of its labs and all related equipment and manages the staff provided by Bravo Dental Lab in relation to conducting the day-to-day operations of SDL in its labs.

***Recent Developments***

On September 30, 2025 SDL closed a private placement of units of the Company to certain investors with whom the Company had a pre-existing relationship. Pursuant to the private placement the Company issued 2,350,020 Common Shares and 2,350,020 Common Share purchase warrants ("**Warrants**") as units at a price of $0.05 per unit for aggregate cash proceeds to the Company of $117,501. The Warrants are exercisable for a period of one year from the date of issuance at an exercise price of $0.35 per share in relation to 450,000 of the Warrants and $0.25 per share for the remaining 1,900,020 Warrants.

On November 4, 2025, we entered into an asset purchase agreement with Dream Dentistry Labs, LLC, a Florida limited liability company, to acquire certain assets including substantially all operating assets of the seller, including tangible assets, contracts, goodwill, and intellectual property, while assuming certain liabilities and the seller retaining specified excluded assets. Under the terms of the acquisition agreement, assets valued at $800,000 were to be acquired through the issuance of cash and common stock.

On December 31, 2025, we entered into Amendment No. 1 with Dream Dentistry Labs, LLC to the November 4, 2025 asset purchase agreement to extend the end date of the agreement from December 31, 2025 to January 7, 2026.

On January 7, 2026, the asset purchase agreement with Dream Dentistry Labs, LLC, was terminated pursuant to its terms as the transaction had not closed by the end date of January 7, 2026 and neither party pursued a further extension of the end date.

On January 30, 2026, we entered into an asset purchase agreement with Brlit Dental Laboratory Inc., a Florida corporation, to acquire certain assets including substantially all operating assets of the seller, including tangible assets, contracts, goodwill, and intellectual property, while assuming certain liabilities and the seller retaining specified excluded assets. Under the terms of the acquisition agreement, assets valued at $900,000 are to be acquired through the issuance of cash and common stock. Cash consideration will be $300,000 with $150,000 paid at closing and $150,000 on the date that is 180 days following closing, conditioned upon maintaining a minimum of 80% of the pro-rata revenue of the acquired assets, average over the past 24 months. The remaining purchase price will be paid in shares of common stock based on the volume-weighted average price for the five trading days immediately proceeding closing. Closing of the transaction is currently contemplated for March 31, 2026.

Effective March 30, 2026 all parties to the BRLIT Dental Laboratory Inc. acquisition agreed to extend the date of the agreement period through to April 30, 2026 to allow more time to complete due diligence requirements.

**Intellectual Property**

We do not own any material intellectual property assets. While pursuant to our Asset Purchase Agreement with PDL, we acquired a PDL Websites, URL's, domain names, methods, know-how, and specifically the right to continue to use the name "Prime Dental Lab LLC", there were no material patents, copyrights or trademarks in the assets of PDL.

**Corporate Information**

Our principal executive offices are located at 424 E. Central Boulevard, Suite 308, Orlando, Florida 32801; our telephone number is (321) 465-9899; our corporate website is located at http://sdl.care. No information found on our company's website is part of this Annual Report on Form 1-K.

**Our Current Business**

Our current business activities include operating and developing our dental lab business. We currently have one operating dental lab, which is staffed by Bravo Dental Lab and managed by SDL pursuant to our subcontractor agreement as described above. The premises, lab equipment, materials and all other manufacturing related assets are the property of, or leased by, SDL.

Standard Dental Labs produces several kinds of dental prosthetics. We use state-of-the-art equipment such as 3D scanners, printers and 5-axis milling machines, along with several other types of machinery needed to complete jobs for dental clinics, all of which are wholly owned by the company.

The consolidation of dental and medical clinics has been an increasing trend over the past two decades, but only recently have investors focused on dental labs. We see this as an opportunity to apply similar strategies to what has been learned from other consolidations.

We are open to acquiring additional independent dental laboratories that are looking to exit the market. However, we do not currently have any plans or strategies in place to identify potential acquisition targets. We are primarily focused on growing the existing business organically and believe that, in so doing, we will be able to identify and uncover opportunities for potential acquisitions.

We operate day-to-day as a full-service dental lab. With 6 dental clinics as clients, we produce roughly 500 dental prosthetics each month. As per industry standards, we do not have any definitive agreements in place with these dental clinics. The items we manufacture and produce are shipped using standard carriers and are often delivered the day they are completed.

Manufacturing of dental prosthetics is performed by technicians employed by Bravo Dental, managed directly by the Company as well as all client relationships are managed directly by Standard Dental Labs. Management expects, based on operations to date, that costs related to operations will remain approximately the same as under the subcontracting agreement and expects that costs will decrease as we grow the size and number of labs we operate, due to economies of scale.

Our goal is to open a large and modern facility in Orlando, Florida to accommodate 75 full-time employees, including dental lab technicians. We have not undertaken specific steps at this time for this facility and would not anticipate doing so until we have acquired at least 3 additional dental labs, including the pending acquisition of Brlit Dental Laboratory Inc.

We sell our dental lab products and market these products to our clients using our tradename Standard Dental Labs Inc. Prior to July 1, 2025, we compensated Smile Dental pursuant to their services contract. Smile Dental in turn reimbursed us for the use of our acquired dental lab equipment. In the past two fiscal years ended December 31, 2025 and 2024, we compensated Smile Dental $63,000 and $98,642, respectively, for services under their contract. Following termination of the services contract on July 1, 2025, we incurred approximately $62,871 in costs of good sold as we now directly handles labor and manufacturing.

The 500 orders that are delivered each month are completed by the contracted dental lab techs. With 60+ techs working in the new facility, we expect tech productivity to factor on par or better than current levels due to improved support technologies and equipment in our new facility.

**Products and Services**

Dental labs supply dentists and dental clinics with dental prosthetics such as crowns, bridges, and implants. Although they manufacture many other prosthetics, these represent a large majority of what is supplied, and would be called the "bread and butter" of the industry.

Our products are grouped into the following three main categories:

*Restorative Products.* Restorative products that our dental laboratories sell consist primarily of crowns and bridges. A crown replaces the part of a tooth that is visible, and is usually made of gold, porcelain or zirconia. A bridge is a restoration of one or more missing teeth that is permanently attached to the natural teeth or roots. In addition to the traditional crown, we also make onlays, which are partial crowns which do not cover all of the visible tooth; inlays, which are restorations made to fit a prepared tooth cavity and then cemented into place and precision crowns, which are restorations designed to receive and connect a removable partial denture. We also mill crowns and bridges from zirconia using CAD-CAM (computer-assisted design and computer-assisted manufacturing) technologies.

*Reconstructive Products.* Reconstructive products sold by our dental laboratories consist primarily of partial dentures and full dentures. Partial dentures are removable dental prostheses that replace missing teeth and associated structures. Full dentures are dental prostheses that substitute for the total loss of teeth and associated structures. We also sell precision attachments, which connect a crown and an artificial prosthesis, and implants, which are fixtures anchored securely in the bone of the mouth to which a crown, a partial denture or full denture is secured by means of screws or clips.

*Cosmetic Products.* Cosmetic products sold by our dental laboratories consist primarily of porcelain veneers and ceramic crowns. Porcelain veneers are thin coverings of porcelain cemented to the front of a tooth to enhance personal appearance. Ceramic crowns are crowns made from ceramic materials that most closely replicate natural teeth. We also sell composite inlays and onlays, which replace silver fillings for a more natural appearance, and orthodontic appliances, which are products fabricated to move existing teeth to enhance function and appearance.

We have a specific process to make sure that we comply with the deadlines. We are responsible for the distribution of our products and for making contact with our various suppliers. The resources needed to produce the dental prosthetics are readily available and can be sourced from a variety of suppliers. As such, we do not have agreements in place with any specific suppliers.

The type of dental labs we have and will continue to acquire typically serve 20 to 25 dental clinics each and employ 4 to 6 dental lab technicians who prepare dental prosthetics for dentists. The dentists are normally responsible for the final fitting with the patient, but most of the work is done by the lab.

Over the past 5 years, 3D printing and modelling technology has become more mainstream. As most of this technology has been unaffordable for small business owners, advanced technology is uncommon in these smaller operations.

**The Market**

The transition from skilled labor to computer driven technology in the dental lab industry, although in its infancy, is well underway. The changeover of skilled artisans to 3D printers and milling equipment is causing a shift in the perception for would-be investors. No one can predict how this technology might evolve, how long it will take, or how it may impact the industry in the long term.

The uncertain future of dental labs means there is less interest from investors in the field. The erosion of the one, two, and three person businesses is certain. (Forbes, Nov. 2019). The result: A generation of lab owners that may not be able to sell their business for retirement or raise the necessary capital to retool this advancing technology.

**Competition**

The biggest competition to the private dental lab owner in the United States is large, Chinese factory labs operating in southern China. We estimate that a large percentage of dental prosthetics are now sourced through these offshore manufacturers. This is detrimental to the local industry, and there is very little an individual lab owner can do to protect himself from the market erosion caused by this competitor.

However, this may represent an opportunity for us to lobby the state government to enact legislation requiring the materials be "certified" prior to being used to supply the industry with the raw materials required to manufacture dental products.

Certified materials could only become certified through local inspectors which could be funded through a state or national association. So far in the US, the only such association is The National Association of Dental Laboratories, located in Tallahassee, Florida.

As a start-up company in the dental lab industry, we will be at a significant disadvantage to other more established and better capitalized companies that we are in competition with for the acquisition of additional dental labs. As we are able to acquire additional labs and enhance our revenue, when appropriate we will seek to uplist to the OTCQB Market or a more senior exchange to further enhance liquidity benefits for stockholders and vendors of dental lab assets.

**Compliance with Government Regulation**

In a 2009, American Dental Association member survey, nearly 65 percent of dentists responded that they believe dental technicians and laboratories are regulated in their state. This is not the case. In fact, only four states in the United States require either certification or continuing education.

However, 12 states require basic minimum standards be met for laboratories, which include state registration. The most up-to-date regulations were last set in 2019, in Washington State, but most haven't updated their requirements for 25 years or longer. We feel that there is an opportunity to contribute to the industry by proposing new, more current legislation that addresses the importation of materials from foreign countries. New legislation that requires certification of materials could greatly enhance the safety of the materials for patients, and also contribute to the success of US based dental labs.

Other than the payment of a modest registration fee every two years to maintain our dental lab registration with the State of Florida, ongoing continuing education of 18 hours biennially by one certified lab technician in the lab in accordance with Florida Administrative Code Rule Chapter 64B-5, we do not require any governmental approvals or authorizations for the operation of our existing dental lab in Florida. Further, we are not aware of any pending or probable regulations that would have an impact upon our operations.

---

| | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **FL** | **IL** | **KY** | **MN** | **MO** | **NC** | **OH** | **OK** | **PA** | **SC** | **TX** | **VA** | **WA** |
| **Year of Initial Enactment** | *1987* | *1993* | *1977* | *2012* | *1995* | *1962* | *2008* | *1992* | *1987* | *1942* | *1985* | *2012* | *2019* |
| **Laboratory Registration Fee** | $200/2<br> yrs | N/A | $150/yr | $50/yr | N/A | N/A | N/A | $300/yr | $25/yr | $150/2<br> yrs | $135/yr | N/A | $250 |
| **Laboratory Registration** | Yes | No | Yes | Yes | No | No | No | Yes | Yes | Yes | Yes | No | Yes |
| **Technician Registration Fee** | No | No | No | No | No | No | No | No | No | $100<br> Initial,<br> $150<br> Renewal | No | No | No |
| **Certificate to Perform Dental Technology** | No | No | No | No | No | No | No | No | No | Yes ‡ | No | No | No |
| **CDT or Equivalent Required** | No | No † | Yes | No | No | No | No | No | No | Yes | Yes | No | Yes<br> (2025) |
| **State Laws and Rules Exam Required** | No | No | No | No | No | No | No | No | No | Yes | Yes | No | No |
| **Out-of-State Laboratories Required to Register** | No | No | Yes | No | No | No | No | Yes | No ‡ | Yes | Yes | No | Yes |
| **Dentists Required to Use Registered Laboratory** | No | No | Yes | Yes # | No | No | No | Yes | No | Yes | Yes | No | Yes |
| **Materials Disclosure** | Yes | Yes | Yes | Yes | Yes + | Yes | Yes | No | No | Yes | No | Yes | Yes |
| **Point of Origin Disclosure** | Yes | Yes | Yes | Yes | Yes + | Yes | Yes | No | No | Yes | Yes | Yes | Yes |
| **CE for One Technician in Each Laboratory** | Yes | No | Yes | No | No | No | No | No | No | Yes | Yes | No | Yes |

---

Our current lab operations in Florida are not subject to OSHA regulations or regulations governing the handling or disposing of medical waste. There are currently no specific OSHA standards for dentistry, however the labs follow best practices including:

&nbsp;&nbsp;&nbsp;&nbsp;(a) having a lab space that is clean and orderly and in good repair, with regard to normal fabrication procedures;

(b) All waste materials properly disposed of at the end of each day;

(c) Maintaining on the laboratory premises a copy of the laboratory registration so it is readily available for inspection by Department personnel;

(d) Maintaining on the laboratory premises, for each separate appliance and for a period of four years, a work order from a licensed dentist authorizing construction or repair of the specified artificial oral appliance; and

(e) Maintaining on the laboratory premises a written policy and procedure document on sanitation. Said policy shall include, but not necessarily be limited to: Intake and disinfection procedure for each appliance, impression, bite, or other material posing a possible contamination risk received by the laboratory.

In the State of Florida the prosthetics and other oral appliances manufactured and repaired by the lab do not for the most part meet the definition of medical waste according to the Florida Department of Health which includes, "Any solid or liquid waste which may present a threat of infection to humans, including nonliquid tissue, body parts, blood, blood products, and body fluids from humans and other primates; laboratory and veterinary wastes which contain human disease-causing agents; and discarded sharps." Most prosthetics and appliances coming to the lab from a dental office have been disinfected prior to intake. However, our lab operations follow the recommended procedures for waste including properly labeled and identified waste bags, proper seals on waste containers and proper disposal of waste in accordance with the State of Florida department of health chapter 64E-16 of the Florida Administrative Code.

**Significant Acquisitions and Pending Acquisitions**

In May of 2022, Standard Dental Labs Inc. acquired certain assets of Standard Dental Labs Inc., a privately owned Wyoming corporation controlled by our CEO, James Brooks, which is in the business of providing consulting services, including the creation of business plans for identifying and purchasing operating assets in various industry sectors. Immediately following our acquisition of the aforementioned assets, including the tradename "Standard Dental Labs Inc.", SDL changed its name to "Fastbend Holdings Inc." in order to continue its ongoing operations. We have since adopted the name "Standard Dental Labs Inc." effective March 21<sup>st</sup>, 2024.

The business model acquired from SDL includes metrics and data in order to allow us to quickly identify and purchase privately owned dental lab operations in the United States, allowing for these operations to be consolidated regionally, and to operate them efficiently applying economies of scale.

*Prime Dental*

On August 15, 2022, we announced the completion of a definitive agreement to acquire the assets of Prime Dental. The purchased assets consisted of (i) accounts receivable; (ii) inventories; (iii) deposits, advances, pre-paid expenses and credits relating to prepaid packages; (iv) furniture, fixtures, machinery, equipment, computer hardware and software, and all other tangible assets; (v) intellectual property including the right to continue using the name "Prime Dental Lab LLC"; (vi) permits and licenses; and (vii) all information (including client lists), files, databases, correspondence, records, data, plans, reports, etc.

In order to facilitate ongoing lab operations and seamlessly service its acquired customer base, we entered into a subcontractor contract with Smile Dental on August 31, 2022, as amended April 30, 2023, whereunder Smile Dental would provide ongoing labor, quality control and delivery services and management oversight during a period of up to two years. Under the terms of the agreement, as amended, with Smile Dental, we or Smile Dental may terminate the agreement with six (6) months written notice, in order to provide us sufficient time to identify, hire and train a suitable replacement.

We operated using our acquired tradename Prime Dental Labs LLC. We did not acquire the building where the manufacturing of Prime Dental appliances and prosthetics takes place. We and Smile Dental agreed that the cost of manufacturing goods paid by us to Smile Dental shall include overhead costs including applied costs on a per item bases for the use of the space where the lab operations take place. There is no separate agreement for the rental or lease of the space where the prosthetics are manufactured.

As noted above, on July 1, 2025, we and Smile Dental mutually agreed to the termination of the subcontracting agreement. We are now managing our own lab facility and are leasing the building and property, while continuing to use Bravo Dental as a labor management partner. Manufacturing of dental prosthetics is now performed by Company chosen technicians and client relationships are managed directly by Standard Dental Labs. Management expects, based on operations to date, that costs related to operations will remain approximately the same as under the subcontracting agreement and expects that costs will decrease as we grow the size and number of labs we operate, due to economies of scale.

*Dream Dentistry*

 

On November 4, 2025, we entered into an asset purchase agreement with Dream Dentistry Labs, LLC, a Florida limited liability company, to acquire certain assets including substantially all operating assets of the seller, including tangible assets, contracts, goodwill, and intellectual property, while assuming certain liabilities and the seller retaining specified excluded assets. Under the terms of the acquisition agreement, assets valued at $800,000 were to be acquired through the issuance of cash and common stock.

On December 31, 2025, we entered into Amendment No. 1 with Dream Dentistry Labs, LLC to the November 4, 2025 asset purchase agreement to extend the end date of the agreement from December 31, 2025 to January 7, 2026.

On January 7, 2026, the asset purchase agreement with Dream Dentistry Labs, LLC, was terminated pursuant to its terms as the transaction had not closed by the end date of January 7, 2026 and neither party pursued a further extension of the end date.

 

*Brlit Dental Laboratory*

 

On January 30, 2026, we entered into an asset purchase agreement (the "Brlit APA") with Brlit Dental Laboratory Inc., a Florida corporation ("Brlit"), to acquire certain assets as described below. Under the terms of the acquisition agreement, assets valued at $900,000 (the "Gross Consideration") are to be acquired through the issuance of cash and common stock. Cash consideration will be $300,000 with $150,000 paid at closing and $150,000 on the date that is 180 days following closing, conditioned upon maintaining a minimum of 80% of the pro-rata revenue of the acquired assets, average over the past 24 months. The remaining purchase price will be paid in shares of common stock based on the volume-weighted average price for the five trading days immediately proceeding closing. Closing of the transaction is currently contemplated for March 31, 2026.

Effective March 30, 2026 all parties to the BRLIT Dental Laboratory Inc. acquisition agreed to extend the date of the agreement period through to April 30, 2026 to allow more time to complete due diligence requirements.

The assets acquired from Brlit include (a) all fixed assets, including furniture, fixtures, machinery, equipment, computer hardware and software, and all other tangible assets and personal property of the Brlit other than excluded assets; (b) all rights and benefits of the Brlit under the contracts as listed on schedules to the Asset Purchase Agreement; (c) all goodwill, going concern value, patents, patent applications, patent rights, copyrights, copyright applications, Websites, URL's, domain names, methods, know-how, software, technical documentation, computer programs, engineering drawings, product concepts, and ideas under development, processes, process charts, procedures, inventions, trade secrets, trademarks, trade names, trade dress, logos, business names (and specifically the right to continue to use the name "Brlit Dental Laboratory, Inc."), telephone numbers, confidential information, franchises, customer lists, customer files, , marketing materials, advertising records, advertising rights with respect to all media, service marks, service names, registered user names, technology, research records, data, designs, plans, drawings, manufacturing know-how and formulas, whether patentable or unpatentable, and other intellectual or proprietary rights (and all rights thereto and applications therefor), including the intellectual property; (d) all rights to causes of action, lawsuits, judgments, claims, and demands of any nature available to or being pursued by the Brlit, including all rights and claims against manufacturers and vendors of the Brlit, relating to the subject matter of this Agreement, whether arising by way of counterclaim or otherwise; (e) all rights in and under all express or implied guarantees, warranties, representations, covenants, indemnities, and similar rights in favor of the Brlit related to the subject matter of this Agreement; (f) all Permits, licenses or similar rights to the extent that they are assignable; and (g) all information, files, databases, correspondence, records, data, plans, reports, and Contracts, including any and all information and records relating to investment, insurance and other current and past customers, client files, customer, supplier, price and mailing lists, business contacts, and investment, underwriting, and claims files together with all usual and customary records in connection therewith, and all accounting or other books and records of Brlit in whatever media retained or stored, including computer programs and disks (collectively, the "Purchased Assets").

Certain assets of the Brlit were excluded including (a) all ownership and other rights with respect to Brlit's employee benefit plans; (b) all rights of Brlit under any excluded contracts; (c) all accounts receivable outstanding as at the closing date; (d) any permit or license that by its terms is not transferable to the Company; (e) all contracts other than assigned contracts; (f) all equity interests in the Brlit or any subsidiary of the Brlit; (g) all of such Brlit's federal, state, and local income tax returns and records (provided that the Brlit has made available copies of such tax returns and records to the Company prior to the closing) and any rights to tax refunds, including without limitation any rights to Employee Retention Tax Credits of the Brlit; (h) all personnel files and payroll records related to employees of the Brlit; (i) all causes of action, judgments, claims, reimbursements and demands, of whatever nature, in favor of Brlit which relate to the excluded assets or retained liabilities and all counterclaims, crossclaims, and defenses in regard to any claims or causes of action currently or hereafter pending or threatened against Brlit; (j) all losses, loss carry forwards, loss carry backs, and rights to receive refunds, rebates, offsets, credits or credit carry forwards with respect solely to taxes of Brlit; (k) any insurance policies maintained by Brlit and any claims under such policies and all obligations under those insurance policies including costs associated with defense of any actions; (l) the charter documents, minute books, stock ledgers, tax returns, books of account and other constituent records relating to the corporate organization of the Brlit; and (m) any other items listed on schedules to the Asset Purchase Agreement (collectively, the "Excluded Assets").

The Company assumed certain liabilities related to the Purchased Assets and the Brlit retained certain liabilities related to the Excluded Assets.

The share consideration (the "Share Consideration") will consist of such number of shares of common stock of the Company (the "Common Shares") equal to the quotient of (A) the Gross Consideration less the Cash Consideration (as defined below), divided by (B) the volume weighted average price of the Common Shares as quoted on the OTCQB for the five trading days immediately preceding the closing (the "Per Share Value") and shall be issued and payable by the Company to the Brlit on the closing date, subject to the certain share holdbacks and lock-ups.

The Shares Consideration will be subject to a share holdback of 20% for a period of 12 months to cover indemnity obligations of the Brlit to the Company and to the following contractual lock-up restrictions. Specifically, the Share Consideration will be held in escrow by the Company at the closing and released to the Brlit in eight (8) equal quarterly instalments beginning at the end of the first full fiscal quarter to occur after the closing date (the "Share Lock-Up"), further subject to reduction pursuant to the Earn-Out Adjustment described below.

The Share Consideration shall be subject to reduction based on the confirmation of the annual billings generated by the Purchased Assets (the "Annual Gross Billings") for the 12 months following the closing date (the "Earn-Out Period") relative to the Annual Earn-Out Target. The "Annual Earn-Out Target" means 80% of Brlit Target Gross Billings. The "Brlit Target Gross Billings" means the annualized average monthly billings of the Brlit from the Purchased Assets for each of three months ended prior to the closing date as certified by the completion of an independent audit providing confirmation of such monthly billings for each such month.

The cash consideration (the "Cash Consideration") shall be equal to $300,000 with $150,000 paid at closing and $150,000 on the date that is 180 days following closing, conditioned upon maintaining a minimum of 80% of the pro-rata revenue of the Purchased Assets, average over the past 24 months.

The Brlit APA contains customary representations, warranties, covenants and indemnification provisions. Closing the Transaction is subject to certain closing conditions, including satisfactory completion of due diligence by the Company of the Brlit. The Brlit APA may be terminated by mutual consent of the parties, by either party if the Transaction does not close by April 30, 2026, by either party if the other party is in material breach that is not cured upon notice thereof and by the Company if its due diligence review is not completed to its reasonable satisfaction by April 30, 2026.

The Brlit APA and the schedules thereto are not intended to provide any other factual information about the Company or Brlit or their respective subsidiaries and affiliates. The Brlit APA contains representations and warranties by each of Brlit and the Company, which representations and warranties were made solely for the benefit of the parties to the Brlit APA and (i) should not be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; (ii) may have been qualified, modified or excepted in the Brlit APA by confidential disclosures that were made to the other party in connection with the negotiation of the Brlit APA; (iii) may apply contractual standards of "materiality" that are different from "materiality" under applicable securities laws; and (iv) were made only as of the date of the Brlit APA or such other date or dates as may be specified in the Brlit APA and may change after the date of the Brlit APA, which subsequent information may or may not be fully reflected in public disclosures. Accordingly, investors and stockholders should not rely on the representations and warranties in the Brlit APA as characterizations of the actual state of facts or condition of the Company or the Brlit or their respective subsidiaries or affiliates.

The foregoing description of the Brlit APA is qualified in its entirety by the full terms of the Brlit APA, which is filed as [Exhibit 6.11](https://www.sec.gov/Archives/edgar/data/1178660/000168316825008153/standard_ex6.htm) to this annual report.

**Offices**

The mailing address of our company is # 424 E Central Blvd, Suite 308, Orlando, FL, 32801. Our main telephone number is 321-465-9899. Our lab is located at 1008 N Pine Hills Rd, Orlando, FL 32808.

**Employees**

We currently have 3 employees. Our sole officer is also a member of our board of directors, James Brooks.

We do expect material changes in the number of employees over the next 12-month period as a result of our growth and expansion plans. Also, we do and will continue to outsource contract employment as needed.

**Litigation**

We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial stockholder, is an adverse party or has a material interest adverse to our company.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

***Forward-Looking Statements***

The following discussion should be read in conjunction with the financial statements as at and for the years ended December 31, 2025 and 2024 and the related notes that appear elsewhere in this document. Certain statements in this Management's Discussion and Analysis of Financial Condition and Results of Operations constitute "forward-looking statements". The words "anticipate", "believe", "estimate", "expect", "plan", "intend" and other similar expressions are intended to identify these forward-looking statements, but are not the exclusive means of identifying them. Forward-looking statements included in this Annual Report on Form 1-K involve known and unknown risks, uncertainties, and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon our best estimates based upon current conditions and the most recent results of operations. Various risks, uncertainties and contingencies could cause our actual results, performance or achievements to differ materially from those expressed in, or implied by, the forward-looking statements contained in this Annual Report on Form 1-K. We assume no obligation to update these forward-looking statements contained in this report, whether as a result of new information, future events, or otherwise, except as required by law.

 ****

Our financial statements are stated in United States Dollars ($) except as otherwise indicated and are prepared in accordance with United States Generally Accepted Accounting Principles.

**Plan of Operation**

During the next twelve-month period (beginning January 1, 2025), we intend to identify and secure sources of equity and/or debt financing for additional acquisitions.

We anticipate that we will incur the following operating expenses during this period:

**Estimated Funding Required During the 12 Months beginning January 1, 2026**

---

| | |
|:---|:---|
| <br>**Expenses** | **Amount**<br>**($)** |
| Improvements to planned corporate facility | 20000 |
| Executive salaries, including new hires | 120000 |
| Administrative support | 60000 |
| Professional fees | 60000 |
| General and administrative expense including rent, transfer agent, travel, office and sundry | 65000 |
| Advertising, marketing, and website costs | 150000 |
| **Total operating expense** | 415000 |
| Cash required for lab acquisitions | 2500000 |
| **Total** | 2915000 |

---

**Terminated Service Contract**

We are now managing our own lab facility and are leasing the building and property. Manufacturing dental prosthetics is now performed by Company technicians and client relationships are managed directly by Standard Dental Labs. The management agreement between Standard Dental Labs and Smile Dental Management LLC was terminated on July 1<sup>st</sup>, 2025. Management expects, based on operations to date, that costs related to operations will remain approximately the same as under the subcontracting agreement and expects that costs will decrease as we grow the size and number of labs we operate, due to economies of scale.

***Results of Operations for our Years Ended December 31, 2025 and 2024***

 ****

---

| | | | |
|:---|:---|:---|:---|
|  | **For the Year Ended** | **For the Year Ended** | |
|  | **December 31,** | **December 31,** | |
|  | **2025** | **2024** |<br>**Change** |
| Revenue | $236234 | $284095 | $(47861) |
| Cost of goods sold | 145833 | 166610 | (20777) |
| Gross profit | 90401 | 117485 | (27084) |
| Operating expenses: |  |  |  |
| &nbsp;&nbsp;&nbsp;Selling and marketing expense | 10282 | 123836 | (113554) |
| &nbsp;&nbsp;&nbsp;General and administrative expenses | 706051 | 65138 | 640913 |
| &nbsp;&nbsp;&nbsp;Professional fees | 216961 | 146047 | 70914 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 20492 | 24656 | (4164) |
| Total operating expenses | 953786 | 359677 | 594109 |
| Operating loss | (863385) | (242192) | (621193) |
| Other income (expense): |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | (244910) | (283830) | 38920 |
| &nbsp;&nbsp;&nbsp;Other income (expense) | (3020) | – | (3020) |
| Total other income (expense) | (247930) | (283830) | 35900 |
| Net loss | $(1111315) | $(526022) | $(585293) |

---

Our net income (loss) and comprehensive income (loss) for our year ended December 31, 2025, for our year ended December 31, 2024, and the changes between those periods for the respective items are summarized as follows:

For the years ended December 31, 2025, and 2024, we generated revenues of $236,234 and $284,095, respectively. The slight decrease in revenue year over year was the primarily the result of a decrease in the volume of goods sold. Management anticipates that revenue will grow in 2026 as a result of lab acquisitions, growth in current client revenue and the addition of new clients, as we continue to streamline our manufacturing process and bring in new clients.

For the years ended December 31, 2025, and 2024, we had cost of goods sold of $145,834 and $166,610, respectively. The slight decrease in costs of goods sold was due to a decrease in goods manufactured and sold and slight savings from moving manufacturing and sales in house following the termination of the services contract with Smile Dental. Management anticipates that costs of goods sold will remain consistent in proportion to revenues in 2026.

For the years ended December 31, 2025, and 2024, we had gross profit of $90,400 and $117,485, respectively. The slight decrease in gross profits was due primarily to the decrease in goods manufactured and sold. Management anticipates that gross profits will increase in 2026 as revenue increases as discussed above.

Operating expenses for the years ended December 31, 2025, and 2024 were $953,786 and $359,677, respectively. The increase in operating expenses was due primarily to an increase in general and administrative expenses from $65,138 in 2024 to $706,051 in 2025, attributable to Payments to contractors and accounting fees. Management expects that operating costs will remain steady in 2026 as we acquire more labs and seek to grow business from current and new clients. Selling and marketing expenses decreased from $123,836 in 2024 to $10,282 in 2025. The decrease came as we focused on lab acquisitions and streamlining our manufacturing and sales. We anticipate that selling and marketing expenses will increase in 2026 as we focus on growing business following lab acquisitions.

Net operating loss for the years ended December 31, 2025 and 2024 was $(863,385) and $(242,192), respectively. The increase in net operating loss was due primarily to the increase in general and administrative expenses, as discussed above.

Net loss for the years ended December 31, 2025, and 2024 was $(1,111,315) and $(526,022), respectively. The increase in net loss was due primarily to the increase in operating expenses as discussed above.

**Liquidity and Financial Condition**

As of December 31, 2025, we had cash of $2,266 and negative working capital of $3,250,845. Through December 31, 2025, the Company financed its operations primarily through proceeds from the sales of its equity securities and convertible notes through private placements and cash flow from its dental lab operations.

The Company believes that its current levels of cash will not be sufficient to meet its anticipated cash needs for its operations for at least the next 12 months. The Company will require additional capital resources to fund its operations and pay its obligations as they come due over the next twelve months. The Company may also need to implement a strategy to expand its business or other investments or acquisitions. The Company may sell additional equity or debt securities or enter into a debt facility to satisfy its capital requirements. The sale of additional equity securities could result in dilution to its shareholders. The incurrence of indebtedness would result in increased debt service obligations and could require the Company to agree to operating and financial covenants that would restrict its operations. Financing may not be available in amounts or on terms acceptable to the Company if at all. Any failure by the Company to raise additional funds on terms favorable to it, or at all, could limit its ability to expand its business operations and could harm its overall business prospects.

On August 18, 2025, the Company qualified its Offering Statement on Form 1-A under Regulation A under the Securities Act of 1933, as amended. The Company was not able to price the offering during the time period required under Regulation A and the Company has not offered or sold any securities under its qualified Offering Statement. The Company intends to file an amendment to the Form 1-A to provide updated information on the Company's business, provide the updated audited annual financial statements for December 31, 2025 and to insert pricing information for the proposed Regulation A offering.

 

*Cash Provided (used in) Operating Activities*

During the year ended December 31, 2025 cash used in operating activities was $(193,397), and consisted primarily of $20,492 in depreciation and amortization, $75,910 in interest payable on convertible notes, $169,000 in amortization of debt discounts and changes in certain assets and liabilities, including accounts receivable $(23,170), other current assets $(10,595), accounts payable and accrued liabilities of $471,361, accounts payable related parties of $125,862 and other current liabilities $86,919.

*Cash Provided by Investing Activities*

There was no cash used in investing activities in the years ended December 31, 2025, and 2024.

*Cash Provided by Financing Activities*

 

Cash provided by financing activities totaled $193,897 for the year ended December 31, 2025 all in proceeds from convertible notes.

Cash provided by financing activities totaled $345,000 for the year ended December 31, 2024, coming entirely from proceeds from convertible notes.

**Off-Balance Sheet Arrangements**

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

**Critical Accounting Policies**

Our financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles used in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management's application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financials.

**Going Concern**

We have suffered recurring losses from operations. The continuation of our Company as a going concern is dependent upon our Company attaining and maintaining profitable operations and/or raising additional capital. The financial statements do not include any adjustment relating to the recovery and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should our Company discontinue operations.

The continuation of our business is dependent upon us raising additional financial support and/or attaining and maintaining profitable levels of internally generated revenue. The issuance of additional equity securities by us could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments.

**Recently Issued Accounting Standards**

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging – Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. The new guidance, among other things, simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share ("**EPS**") guidance by requiring that an entity use the if converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. We adopted the new guidance effective from January 1, 2024.

**Controls and Procedures**

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the *Securities Exchange Act of 1934*, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our president (also our principal executive officer) and our secretary, treasurer and chief financial officer (also our principal financial and accounting officer) to allow for timely decisions regarding required disclosure.

As of September 30, 2022, the end of the third quarter covered by the comparative information of this prospectus, we carried out an evaluation, under the supervision and with the participation of our president (also our principal executive officer) and our secretary, treasurer and chief financial officer (also our principal financial and accounting officer), of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our president (also our principal executive officer) and who is also our secretary, treasurer and chief financial officer (also our principal financial and accounting officer) concluded that our disclosure controls and procedures were effective in providing reasonable assurance in the reliability of our financial reports as of the end of the period.

***Inherent limitations on effectiveness of controls***

Internal control over financial reporting has inherent limitations which include but is not limited to the use of independent professionals for advice and guidance, interpretation of existing and/or changing rules and principles, segregation of management duties, scale of organization, and personnel factors. Internal control over financial reporting is a process which involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements on a timely basis, however these inherent limitations are known features of the financial reporting process and it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

***Changes in Internal Control over Financial Reporting***

There have been no changes in our internal controls over financial reporting that occurred during the year ended December 31, 2025, that have materially or are reasonably likely to materially affect, our internal controls over financial reporting.

**ITEM 3. DIRECTORS AND OFFICERS**

**Directors and Executive Officers**

The following table sets forth certain information concerning our company's sole officer and our directors as of March 31, 2026.

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Age** | **Position(s)** | **Term of Office** |
| James D. Brooks | 55 | President, Chief Financial Officer, Secretary and Director | December 30, 2021-Present |
| Claire Ambrosio | 59 | Director | April 20, 2023-Present |

---

Our directors serve until a successor is elected and qualified. Our officers are elected by the Board of Directors to a term of one (1) year and serves until their successor(s) is duly elected and qualified, or until they are removed from office. There are no family relationships between our directors.

Our company believes that all of our directors' respective educational background, operational and business experience give them the qualifications and skills necessary to serve as directors and officers, respectively, of our company.

Certain information regarding the backgrounds of our officers and directors is set forth below.

***James D. Brooks*** has served as our President, Chief Financial Officer, Secretary, Treasurer and Director since December 30, 2021. Mr. Brooks first began working with public companies in 1998, and has founded and exited from two substantial companies in the transportation logistics sector since. The first, Urban Dispatch, where Mr. Brooks served as the CEO, COO and a board member was a Canadian logistics company, and employed more than 250 people, operating in 4 provinces in Western Canada. Following his time with Urban Dispatch, Mr. Brooks founded Oveldi Worldwide Shipping Company, based in Hong Kong, where he served as CEO, COO and a board member until divestiture in 2012.

From 2014 through 2019, Mr. Brooks served as an officer and director of Oveldi Strategic Capital Ltd. where he also provided services as a business consultant. Oveldi Strategic Capital assisted small businesses in a variety of industries with corporate structure, governance, business planning, exit strategies, strategic partnerships and overall corporate objectives and direction. Such clients included companies in moving and storage, transportation logistics, jewelry distribution, real estate development, clothing manufacturing, and others.

During the Covid-19 pandemic commencing in early 2019, Mr. Brooks repositioned his focus and chose to dedicate his business time exclusively to his next controlled corporation, Fastbend Holdings Inc. (formerly Standard Dental Labs), where he is the CEO, President, and a director. Fastbend Holdings is a consulting firm and project incubation facilitator, drawing on the experience gained from his former venture Oveldi Strategic Capital. Upon acquiring a controlling interest in Standard Dental Labs Inc. in December 2021 and becoming the sole officer and director, Mr. Brooks again reallocated his time resources to spend 90% of his time developing the ongoing business of Standard Dental Labs, with the remaining 10% allocated to oversight of his controlled private corporation, Fastbend Holdings.

Given his background and experience building operations from the ground up, Mr. Brooks has a clear vision of how to identify and acquire target companies for Standard Dental Labs, and how to execute our business plan. Mr. Brooks has been responsible for advancing our objectives, including financing the efforts made to date for Standard Dental Labs Inc., as our largest creditor, stockholder and CEO.

Mr. Brooks currently devotes approximately 90% of his professional time to the business and intends to continue to devote this amount of time in the future, or more as required.

***Claire Ambrosio*** has served as a Director since April 20, 2023. Ms. Ambrosio is a member of The State Bar of California and has practiced as a lawyer in California for the past 22 years. She has served as the Vice President of Legal for 4 Over, LLC, a trade printer, from 2022 to present, and as General Counsel for True Family Enterprises from 2019 through 2022. She holds a law degree from Southwestern University, School of Law (1991) and has been a member of the bar in California since 1996. Ms. Ambrosio holds an LL.M., Loyola University Chicago School of Law, Chicago, Illinois in Healthcare and Compliance (2021). Ms. Ambrosio has focused her legal practice in the area of Corporate Compliance. Her experience in this area makes her uniquely qualified to contribute as a board member of a publicly traded company.

**Changes to the Board**

On January 14, 2026, Mr. Nirmal Sekhri resigned as a director of the Company.

**Conflicts of Interest**

At the present time, we do not foresee any direct conflict between our officers and directors, and their respective other business interests and their involvement in our company.

**Family Relationships**

There are no family relationships between any of our officers and directors.

**Involvement in Certain Legal Proceedings**

To the best of our knowledge, none of our directors or executive officers has, during the past ten years:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offences);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

**Board Composition**

Our board of directors currently consists of three members. Each of our directors serve until the next annual meeting of stockholders and until his successor is elected and duly qualified, or until his earlier death, resignation or removal.

We have no formal policy regarding board diversity. In selecting board candidates, we seek individuals who will further the interests of our stockholders through an established record of professional accomplishment, the ability to contribute positively to our collaborative culture, knowledge of our business and understanding of our prospective markets.

**Board Leadership Structure and Risk Oversight**

The board of directors oversees our business and considers the risks associated with our business strategy and decisions. The board currently implements its risk oversight function as a whole. Each of the board committees, when and if established, will also provide risk oversight in respect of its areas of concentration and reports material risks to the board for further consideration.

**Board Committees and Audit Committee Financial Expert**

Our board of directors (currently consisting of two members) also acts as the audit committee and has determined that it does not have a member that qualifies as an "audit committee financial expert" as defined in Item 407(d)(5)(ii) of Regulation S-K. We currently have one "independent" director, Claire Ambrosio, as the term is used in Item 7(d)(3)(iv) of Schedule 14A under the Securities Exchange Act of 1934, as amended.

We believe that our board of directors is capable of analyzing and evaluating our financial statements We believe that retaining additional independent directors who would qualify as an "audit committee financial expert" would be overly costly and burdensome and is not warranted in our circumstances given the early stages of our development and the fact that we have not generated any material revenues to date.

In addition, we currently do not have nominating, compensation or audit committees or committees performing similar functions nor do we have a written nominating, compensation or audit committee charter. Our directors do not believe that it is necessary to have such committees because they believe the functions of such committees can be adequately performed by the members of our board of directors.

**Stockholder Communications with Our Board of Directors**

Our company welcomes comments and questions from our stockholders. Stockholders should direct all communications to our President, James D. Brooks, at our executive offices. However, while we appreciate all comments from stockholders, we may not be able to respond individually to all communications. We attempt to address stockholder questions and concerns in our press releases and documents filed with OTC Markets, so that all stockholders have access to information about us at the same time. Mr. Brooks collects and evaluates all stockholder communications. All communications addressed to our directors and executive officers will be reviewed by those parties, unless the communication is clearly frivolous.

**Code of Ethics**

Our Board of Directors has not adopted a Code of Ethics.

**Executive Compensation**

As of the year ended December 31, 2025, there are no annuity, pension or retirement benefits proposed to be paid to officers, directors or employees of our company, pursuant to any presently existing plan provided by, or contributed to, our company.

**Compensation Summary**

The following table summarizes information concerning the compensation awarded, paid to or earned by our sole executive officer for the year ended December 31, 2025.

---

| | | |
|:---|:---|:---|
| **Name and Principal Position** | **Other Compensation**<br> **($)** | **Total Compensation**<br> **($)** |
| **James D. Brooks**<br> ***President*** <br> **(1)**<br>240000<sup>(2)</sup> | 0 | 240000 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) On December 30, 2021, Mr. Brooks was appointed as our President and as a director.

(2) Mr. Brooks is paid $20,000 per month for his services as President to the Company. Of the $240,000 earned, billed and accrued in the fiscal year ended December 31, 2025, $128,000 was paid and $112,000 was earned and accrued but remains unpaid.

**Outstanding Equity Awards**

At the end of December 31, 2025, there were no outstanding equity awards held by our executive officers. During the years ended December 31, 2025 and 2024, our Board of Directors made no equity awards and no such award is pending.

**Long-Term Incentive Plans**

We currently have no long-term incentive plans.

**Director Compensation**

Our directors received no compensation for serving as directors of our company in December 31, 2025. We do not have a set compensation plan for our directors.

**ITEM 4. SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITYHOLDERS**

The following table sets forth, as March 31, 2026, information regarding beneficial ownership of our common stock by the following: (a) each person, or group of affiliated persons, known by our company to be the beneficial owner of more than five percent of any class of our voting securities; (b) each of our directors; (c) each of the named executive officers; and (d) all directors and executive officers as a group. Beneficial ownership is determined in accordance with the rules of the SEC, based on voting or investment power with respect to the securities. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock underlying convertible instruments, if any, held by that person are deemed to be outstanding if the convertible instrument is exercisable within 60 days of the date hereof. Unless otherwise indicated, the address of each listed person is in care of our company, 424 E. Central Boulevard, Suite 308, Orlando, Florida 32801.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Title of Class** | **Name and Address of Beneficial Owner** | **Amount and Nature of Beneficial Ownership<sup>(2)</sup>** | **Amount and Nature of Beneficial Ownership Acquirable** | **Percent of Class** |
| *Executive Officers and Directors* | *Executive Officers and Directors* |  |  |  |
| Common Stock | James D. Brooks, President and Director<sup>(1)</sup> | 15000001<sup>(3)</sup> | 75566899 <sup>(4)</sup> | 68.14% |
| Common Stock | Claire Ambrosio, Director<sup>(1)</sup> | 312500 | 0 | \*\* |
| *5% Shareholders* |  |  |  |  |
| Common Stock | Nirmal Sekhri | 1115900 | 15071884<sup>(5)</sup> | 30.0% |

---

\*\* - Less than 1%

(1) The address of the securityholder so indicated is 424 E. Central Boulevard, Suite 308, Orlando, Florida 3280.

(2) Based on 35,337,442 shares outstanding, before this annual report.

(3) Of the shares owned beneficially by Mr. Brooks, 1,583,188 shares are held in the name of Fastbend Holdings Inc., formerly Standard Dental Labs Inc., over which Mr. Brooks has voting and investment authority, and is the 63% stockholder of such entity.

(4) Includes 75,566,899 shares of common stock issuable upon conversion of a convertible note of $1,124,227.

(5) Includes 15,071,884 shares issuable upon conversion of convertible notes.

**ITEM 5. INTEREST OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS**

**James Brooks, Sole Officer and a Director, Controlling Stockholder**

Mr. Brooks was paid a total of $92,938 in the year ended December 31, 2024 against interest owing on the convertible note, leaving a balance owing of $0 as interest payable to Mr. Brooks at December 31, 2024 (December 31, 2023 - $0), which is reflected on the balance sheets as accounts payable – related party.

During the year ended December 31, 2024, we paid and/or accrued $20,000 to Mr. Brooks in respect to his agreement for a monthly stipend entered into in December 2023.

At December 31, 2024 a total of $0 (December 31, 2023 - $32,394) is reflected on our balance sheets as advances payable – related party.

At December 31, 2024 a total of $924,037 (December 31, 2023 - $1,161,727) is reflected on our balance sheets related to the convertible note to Mr. Brooks.

Mr. Brooks was paid a total of -0-in the year ended December 31, 2025 against interest owing on the convertible note, leaving a balance owing of 87,111 as interest payable to Mr. Brooks at December 31, 2025 (December 31, 2024 - $0), which is reflected on the balance sheets as a portion of interest expense on convertible notes.

During the year ended December 31, 2025, we paid and/or accrued 240,000 to Mr. Brooks in respect to his agreement for a monthly stipend entered into in December 2023.

At December 31, 2025 a total of 118,171 (December 31, 2024 - $0) is reflected on our balance sheets as advances payable – related party.

At December 31, 2024 a total of 1,124,227(December 31, 2024 - $924,037) is reflected on our balance sheets related to the convertible note to Mr. Brooks.

During the year ended December 31, 2025, we paid a total of $104,500 to Bravo Dental Lab, an entity owned by Mr. Brooks' spouse.

**ITEM 6. OTHER INFORMATION**

We have no information to disclose that was required to be in a report on Form 1-U during the fiscal year ended December 31, 2025, but was not reported.

**ITEM 7. FINANCIAL STATEMENTS**

**STANDARD DENTAL LABS INC.**

**Financial Statements**

**For the years ended December 31, 2025 and 2024**

---

| | |
|:---|:---|
|  | **Page** |
| **Audited Consolidated Financial Statements for the Years Ended December 31, 2025 and 2024** |  |
| [Report of Independent Registered Public Accounting Firm](#a_010) | F-1 |
| [Consolidated Balance Sheets](#a_011) | F-3 |
| [Consolidated Statements of Operations](#a_012) | F-4 |
| [Consolidated Statements of Changes in Stockholders' Equity (Deficit)](#a_013) | F-5 |
| [Consolidated Statements of Cash Flows](#a_014) | F-6 |
| [Notes to Consolidated Financial Statements](#a_015) | F-7 |

---

**Report of Independent Registered Public Accounting Firm**

**To the Board of Directors and Stockholders of Standard Dental Labs Inc.**

**<u>Opinion on the Financial Statements</u>**

We have audited the accompanying consolidated balance sheets of Standard Dental Labs Inc. (the 'Company') as of December 31, 2025, and 2024, and the related consolidated statements of operations, comprehensive income, changes in stockholders' equity and cash flows for period ended December 31, 2025, and 2024, and the related notes (collectively referred to as the "financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2025, and 2024, and the results of its operations and its cash flows for each of the period ended December 31, 2025, and 2024, in conformity with accounting principles generally accepted in the United States of America.

**<u>Going Concern</u>**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2, the Company suffered an accumulated deficit of $3,394,739 and net loss of $1,111,315. These matters raise substantial doubt about the Company's ability to continue as a going concern. Management's plans with regards to these matters are also described in Note 2 to the financial statements. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**<u>Basis for Opinion</u>**

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

**<u>Critical Audit Matters</u>**

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. Communication of critical audit matters does not alter in any way our opinion on the financial statements taken as a whole and we are not, by communicating the critical audit matters, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.

**<u>Equity Transactions</u>**

As disclosed in Note 9, on March 20, 2025, the Company effected a 1-for-20 reverse stock split. All common share amounts and per-share data presented in these financial statements have been retroactively adjusted to reflect the reverse stock split unless otherwise indicated.

The principal considerations for our determination of this as critical audit matter relate to the assumption used in determining the number of stocks split in arriving the outstanding stock.

*The primary procedures we performed to address this critical audit matter included the following:*

· Reviewed the entire general ledger for transactions that could potentially have an impact on equity.

· Review Board and Shareholders' Resolution.

· Inquired of management as to the existence and completeness of equity transactions.

· Obtained a stock transfer report as of year-end and agreed with activity reported in the books of the Company.

· Obtained an equity roll forward; recalculated common stock, additional paid in capital, and retained earnings.

/S/ Lateef Awojobi

**LAO PROFESSIONALS**

(PCAOB ID 7057)

Lagos, Nigeria

We have served as the Company's auditor since 2025.

April 5th, 2026

**Standard Dental Labs Inc.**

**Balance Sheet**

**As of December 31,**

---

| | | |
|:---|:---|:---|
|  | **As of December 31,** | **As of December 31,** |
|  | **2025** | **2024** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $2266 | $1766 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net of allowance for doubtful accounts of $2,139 and $-0- as of December 31, 2025 and 2024, respectively | 21031 |  |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | 10595 | – |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 33892 | 1766 |
| Property and equipment, net | 16484 | 30640 |
| Intangible assets | 8968 | 15304 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $59344 | $47710 |
| **LIABILITIES AND STOCKHOLDERS' DEFICIT** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | $529636 | $58697 |
| &nbsp;&nbsp;&nbsp;Convertible notes | 1140640 | 984900 |
| &nbsp;&nbsp;&nbsp;Interest payable on convertible notes | 183518 | 79388 |
| &nbsp;&nbsp;&nbsp;Convertible note - shareholder, net | 1124227 | 931727 |
| &nbsp;&nbsp;&nbsp;Advance payable - related party | 118171 | (7691) |
| &nbsp;&nbsp;&nbsp;Other current liabilities | 156919 | 70000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 3253111 | 2117021 |
| Stockholders' deficit |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, 2,000,000,000 shares authorized, $0.001 par value, and 35,337,442 and 30,447,818 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 35337 | 30448 |
| &nbsp;&nbsp;&nbsp;Additional paid-in-capital | (12314) | 173217 |
| &nbsp;&nbsp;&nbsp;Common stock to be issued | 167501 |  |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (3384291) | (2272976) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' deficit | (3193767) | (2069311) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' deficit | $59344 | $47710 |

---

The accompanying notes are an integral part of these interim financial statements

**Standard Dental Labs Inc.**

**Statement of Operations**

**For the Years Ended December 31,**

---

| | | |
|:---|:---|:---|
|  | **For the year ended December 31,** | **For the year ended December 31,** |
|  | **2025** | **2024** |
| Revenue | $236234 | $284095 |
| Cost of goods sold | 145833 | 166610 |
| Gross profit | 90401 | 117485 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;Selling and marketing expense | 10282 | 123836 |
| &nbsp;&nbsp;&nbsp;General and administrative expenses | 706051 | 65138 |
| &nbsp;&nbsp;&nbsp;Professional fees | 216961 | 146047 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 20492 | 24656 |
| Total operating expenses | 953786 | 359677 |
| Operating loss | (863385) | (242192) |
| Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp;Interest expenses | (244910) | (283830) |
| &nbsp;&nbsp;&nbsp;Other income (expense) | (3020) | – |
| Total other income (expense) | (247930) | (283830) |
| Net loss | $(1111315) | $(526022) |
| Net loss per common share - basis and diluted | $0.04 | $0.02 |
| Weighted average common shares outstanding - basis and diluted | 35337442 | 28160599 |

---

The accompanying notes are an integral part of these interim financial statements

**Standard Dental Labs Inc.**

**Statement of Stockholders' Deficit**

**As of December 31,**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock (a)** | **Common Stock (a)** | | | | |
|  | **Shares** | **Amount** |<br>**Additional**<br>**Paid-In-Capital** | **Common**<br>**Stock**<br>**to be Issued** |<br>**Accumulated**<br>**Deficit** | **Total**<br>**Stockholders'**<br>**Deficit** |
| **Balance at December 31, 2023** | 24123918 | $24124 | $172168 | $– | $(1746954) | $(1550662) |
| Beneficial conversion of features associated with convertible notes |  |  | 1049 |  |  | 1049 |
| Shares issued under acquisition agreements | 6323900 | 6324 |  |  |  | 6324 |
| Net loss | – | – | – | – | (526022) | (526022) |
| **Pre-Revsere Split Balance at December 31, 2024** | 30447818 | $30448 | $173217 | $– | $(2272976) | $(2069311) |
| Beneficial conversion of features associated with convertible notes | 1250000 | 1250 | 25000 |  |  | 26250 |
| Purchase of shares | 3639624 | 3640 | (210531) |  |  | (206891) |
| Shares to be issued under subscription agreements |  |  |  | 167501 |  | 167501 |
| Shares issued under acquisition agreements |  |  |  |  |  |  |
| Net loss | – | – | – | – | (1111315) | (1111315) |
| **Balance at December 31, 2025** | 35337442 | $35337 | $(12314) | $167501 | $(3384291) | $(3193767) |

---

(a) Amounts have been adjusted to reflect the reverse stock split that became effective on March 14, 2025.
 Refer to Note 9

The accompanying notes are an integral part of these interim financial statements

**Standard Dental Labs Inc.**

**Statement of Cash Flows**

**For the Years Ended December 31,**

---

| | | |
|:---|:---|:---|
|  | **For the year ended December 31,** | **For the year ended December 31,** |
|  | **2025** | **2024** |
| **Cash flows from operating activities:** |  |  |
| Net loss | $(1111315) | $(526022) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 20492 | 24656 |
| &nbsp;&nbsp;&nbsp;Allowance for doubtful accounts | 2139 |  |
| &nbsp;&nbsp;&nbsp;Amortization of debt discount | 169000 | 103812 |
| &nbsp;&nbsp;&nbsp;Interest payable on convertible notes | 75910 | 79388 |
| &nbsp;&nbsp;&nbsp;Gain on settlement of debts and liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Changes in certain assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (23170) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets | (10595) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | 470939 | 5373 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable related parties | 125862 | (32394) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 86919 | – |
| &nbsp;&nbsp;&nbsp;Net cash used in operating activities | (193819) | (345187) |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from convertible notes | 193897 | 345000 |
| &nbsp;&nbsp;&nbsp;Issuance of shares | – | – |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | 193897 | 345000 |
| **Net change in cash and cash equivalents** | 78 | (187) |
| Cash and cash equivalents at beginning of the year | 1766 | 1953 |
| Cash and cash equivalents at end of the year | $1844 | $1766 |

---

The accompanying notes are an integral part of these interim financial statements

**Standard Dental Labs Inc.**

**Notes to Financial Statements**

**As of and For the Years Ended December 31, 2025 and 2024**

**Note 1a – Nature of Operations and Basis of Presentation**

Standard Dental Labs Inc. ("Standard Dental" or the "Company") is a dental laboratory platform focused on serving dental clinics across the United States. The Company was originally incorporated in Nevada in 1998 as Costas, Inc. and formally changed its name to Standard Dental Labs Inc. in March 2024. In August 2022, the Company completed the acquisition of the operating assets of Prime Dental Lab, LLC ("Prime Dental" or the "Operating Company"), an Orlando-based dental laboratory, marking the commencement of its operating activities in the dental lab industry.

Since that time, the Company has focused on developing its business model, refining operational processes, and building a foundation for long-term growth. Key strategic initiatives include expanding client relationships, investing in platform infrastructure, and establishing a dedicated sales and outreach function to drive organic growth.

On August 15, 2022, Standard Dental completed the asset acquisition transaction with Prime Dental. The Company accounted for the August 15, 2022, transaction with Prime Dental as a reverse recapitalization whereby Prime Dental was determined as the accounting acquirer and Standard Dental as the accounting acquiree. This determination was primarily based on Standard Dental acquiring all the operating assets of Prime Dental, Standard Dental first commencing operating activities following completion of the transaction and the Prime Dental assets acquired in the transaction accounting for the majority of Standard Dental's operating assets upon commencement of operations. While Standard Dental was the legal acquirer, because Prime Dental was determined the accounting acquirer, the historical financial statements of Prime Dental became the historical financial statement of Standard Dental, upon consummation of the transaction, and the comparative financial information reflects the historical operations and financial position of Prime Dental prior to the transaction. As a result, the financial statements included in the accompanying consolidated financial statements reflect (i) the historical operating results of Prime Dental prior to the transaction; (ii) the combined results of Standard Dental and Prime Dental following the closing of the transaction; (iii) the assets and liabilities of Standard Dental at their historical cost with no goodwill or step-up in asset values; and (iv) Standard Dental's equity structure for all periods presented (restated to reflect the legal capital structure of Standard Dental). (See Note 5).

**Note 1b – Restatement of Previously Issued Financial Statements**

During the year ended December 31, 2024, the Company determined that its previously issued financial statements for the year ended December 31, 2022 and 2023 contained errors in the accounting treatment of the acquisition of Prime Dental. The transaction, completed on August 15, 2022, was originally accounted for as an asset acquisition under ASC 805-50, resulting in the recognition of property and equipment, customer relationship intangibles, and related amortization expense.

Upon further evaluation, management concluded that the transaction should have been accounted for as a reverse recapitalization in accordance with ASC 805-40, as Prime Dental was the accounting acquirer and Standard Dental Labs Inc. (formerly Costas Inc.) was a non-operating public shell at the time of the transaction. Prime Dental held the operations and management team that continued to lead the combined entity after the transaction.

**Note 2 – Going-Concern**

The accompanying financial statements have been prepared on a going-concern basis, which assumes the realization of assets and the settlement of liabilities in the normal course of business. As of December 31, 2025 and 2024, the Company had cash of $2,266 and $1,766, respectively, and an accumulated deficit of $3,394,739 and $2,283,002, respectively. The Company has not yet achieved sustained profitability and remains dependent on external financing to fund operations.

**Standard Dental Labs Inc.**

**Notes to Financial Statements**

**As of and For the Years Ended December 31, 2025 and 2024**

**Note 2 – Going-Concern (Continued)**

During the year ended December 31, 2025 and 2024, the Company raised $193,897 and $345,000, respectively, through the issuance of convertible notes. Management continues to evaluate opportunities to raise additional capital, the private placement of equity or debt securities. While these initiatives are intended to support the Company's operating and strategic objectives, there is no assurance they will be successful.

These factors raise substantial doubt about the Company's ability to continue as a going concern for the next twelve months. The financial statements do not include any adjustments that may result if the Company is unable to continue as a going concern.

**Note 3 – Use of Estimates**

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.

Significant estimates used in these financial statements include:

&nbsp;&nbsp;&nbsp;&nbsp;· The
determination of useful lives and recoverability of long-lived assets, including property and equipment

· Valuation
of convertible notes and associated beneficial conversion features

· Classification
of expenses associated with the Company's services agreement (e.g., determining amounts to be included in cost of goods sold versus
selling and marketing expenses)

· Assessment
of contingencies and going concern uncertainties

Estimates are reviewed on an ongoing basis and adjusted as necessary in the period they become known.

**Note 4 – Summary of Significant Accounting Policies**

<u>Basis of Presentation</u>

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and reflect the financial position and results of operations of the Company as of and for the years ended December 31, 2025 and 2024.

<u>Cash and Cash Equivalents</u>

Cash and cash equivalents include all highly liquid investments with original maturities of three months or less.

**Standard Dental Labs Inc.**

**Notes to Financial Statements**

**As of and For the Years Ended December 31, 2025 and 2024**

**Note 4 – Summary of Significant Accounting Policies (Continued)**

<u>Revenue Recognition</u>

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized when control of the promised product or service is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services. Revenue is generally recognized at the point in time when the lab product has been completed and delivered to the customer.

<u>Accounts Receivable</u>

Accounts receivable consists of amounts due from customers and are recorded at net realizable value. The Company evaluates the need for an allowance for doubtful accounts based on historical experience, aging of receivables, and specific customer account reviews.

<u>Inventory</u>

Inventory, if maintained, consists of work-in-progress materials or components used in production. Inventory is stated at the lower of cost or net realizable value. As of December 31, 2025 and 2024, there was no inventory.

<u>Property and Equipment</u>

Property and equipment are stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from one to eight years. Repairs and maintenance costs are expensed as incurred.

<u>Intangible Assets</u>

Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. The Company assesses intangible assets for impairment if indicators of impairment are present.

<u>Convertible Notes and Beneficial Conversion Features</u>

The Company evaluates convertible instruments under ASC 470 and ASC 718 to determine whether any embedded features require bifurcation and separate accounting. Beneficial conversion features are recognized as a debt discount and amortized over the term of the note.

<u>Income Taxes</u>

The Company accounts for income taxes under ASC 740, Income Taxes. Deferred taxes are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded if it is more likely than not that some or all deferred tax assets will not be realized.

<u>Loss Per Share</u>

Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding. Diluted loss per share is the same as basic loss per share in periods where the effect of common stock equivalents would be anti-dilutive.

**Standard Dental Labs Inc.**

**Notes to Financial Statements**

**As of and For the Years Ended December 31, 2025 and 2024**

**Note 4 – Summary of Significant Accounting Policies (Continued)**

<u>Recent Accounting Pronouncements</u>

In August 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. The guidance simplifies the accounting for convertible instruments by removing certain separation models and revises the derivative scope exception for contracts in an entity's own equity. It also requires the if-converted method for calculating diluted earnings per share. The Company adopted ASU 2020-06 on January 1, 2024. The adoption did not have a material impact on the Company's financial statements.

**Note 5 – Asset Acquisition and Reverse Recapitalization**

On May 6, 2022, the Company acquired certain intangible branding assets from Standard Dental Labs Inc., a Wyoming corporation controlled by the Company's CEO. These assets included a developed business model, logo, website, and other intellectual property. The transaction was treated as an asset acquisition between entities under common control. A total of 1,583,188 shares (31,663,760 pre-split) were issued as consideration. The assets were recorded at a value of $31,663 and assigned a useful life of five years. This acquisition was not part of the reverse recapitalization and was recorded separately under common control accounting. The Company began amortizing the intangible asset during the year ended December 31, 2024 and recorded a catch-up adjustment for the period from acquisition through 2023.

On August 15, 2022, the Company completed a transaction to acquire the operating assets of Prime Dental, an Orlando-based dental laboratory. The transaction was originally accounted for as an asset acquisition. During the year ended December 31, 2024, the Company restated its 2022 financial statements to reflect the transaction as a reverse recapitalization in accordance with ASC 805-40, Business Combinations – Reverse Acquisitions. Under this accounting treatment:

&nbsp;&nbsp;&nbsp;&nbsp;· Prime
Dental was deemed the accounting acquirer

· Standard
Dental Labs Inc. (formerly Costas, Inc.) was the legal acquirer

As a result of the restatement:

&nbsp;&nbsp;&nbsp;&nbsp;· The
previously recorded intangible and tangible asset allocations and related amortization were eliminated.

· No
goodwill was recognized.

· The
historical financial statements of Prime Dental replaced those of Standard Dental prior to the transaction date.

· Standard
Dental's equity structure was retroactively adjusted to reflect the legal capital structure of Standard Dental, including the issuance
of 1,837,500 shares (36,750,000 pre-split) to the Operating Company's shareholder.

**Standard Dental Labs Inc.**

**Notes to Financial Statements**

**As of and For the Years Ended December 31, 2025 and 2024**

**Note 6 – Related Party Transactions**

On December 23, 2021, the Company issued an 8% Convertible Promissory Note to Mr. James Brooks. The note was issued in the principal amount of $1,171,727 and bore interest at 8% per annum with an original maturity date of December 31, 2022. On an annual basis, Mr. Brooks has extended the maturity date by one year. The maturity date is currently extended to December 31, 2026.

The note is convertible into common shares of the Company at a price of $0.02 per share (post-split). A full beneficial conversion feature equal to the face value of the note was recognized and amortized over the original 12-month term.

During the years ended December 31, 2025 and 2024, Mr. Brooks assigned $37,500 and $230,000, respectively, to third parties who are not considered related parties. As of December 31, 2025 and 2025, the remaining principal held by Mr. Brooks was $1,124,227 and $931,727, respectively.

Interest accrues annually and is offset by expenses of Mr. Brooks. Any excess or shortfall is recorded as a related party receivable or payable. As of December 31, 2025 and 2024, Mr. Brooks had a net advance payable to the Company of $118,171 and a net advance receivable to the Company of $7,691, respectively, which is included in related party payables.

The remaining balance of the note represents a potentially dilutive equity instrument, but was excluded from diluted EPS due to the net loss position (see Note 12).

**Note 7 – Convertible Promissory Notes – Third Party**

During the years ended December 31, 2025 through 2024, the Company issued unsecured convertible promissory notes to third-party investors under two primary tranches: (i) 8% interest-bearing notes and (ii) zero-interest notes with a beneficial conversion feature ("BCF"). All instruments are convertible into the Company's common stock at fixed conversion prices. Share and per-share values presented are post-split unless otherwise noted.

<u>8% Convertible Notes</u>

As of December 31, 2025 and 2024, the Company reported $432,140 and $430,900, respectively, in 8% convertible promissory notes. These notes carry an annual interest rate of 8%, mature 12 months from issuance, and are convertible into common shares at fixed prices ranging from $0.02 to $0.10 per share. Interest payable on these convertible promissory notes in the amount of $96,407 and $79,388 remains payable to third-party holders as of December 31, 2025 and 2024, respectively. The remainder of accrued interest, attributable to related party James Brooks, is disclosed separately in Note 6.

At issuance, a beneficial conversion feature (BCF) was recognized on these notes and amortized over their respective terms. As all notes in this tranche exceeded their 12-month maturity as of year-end 2025, the associated BCF has been fully amortized.

<u>0% Convertible Notes</u>

As of December 31, 2025 and 2024, the Company reported $708,500 and $723,000, respectively, in zero-interest convertible notes. These notes are convertible into common shares at fixed prices ranging from $0.02 to $0.10 per share and contain embedded BCFs. Upon issuance, the Company recognized a total BCF of $169,000 on the 2024 issuances, which was recorded as a debt discount and amortized over the 12-month term. No interest expense was recorded on these notes due to the 0% coupon.

**Standard Dental Labs Inc.**

**Notes to Financial Statements**

**As of and For the Years Ended December 31, 2025 and 2024**

**Note 7 – Convertible Promissory Notes – Third Party (Continued)**

During the year ended December 31, 2025, holders converted $35,000 in principal and interest under these instruments, resulting in the issuance of 1,889,612 common shares.

During the year ended December 31, 2024, holders converted $121,240 in principle under these instruments, resulting in the issuance of 6,337,400 common shares (126,748,000 pre-split). Certain holders of $80,000 in these instruments have contested the validity of these conversions and are seeking cancelation of the 5,074,150 shares (101,483,000 pre-split) issued to them on conversion and payment of the $80,000 in principle plus interest.

The Company has applied consistent accounting treatment to all convertible promissory notes, recognizing any intrinsic BCF at issuance and amortizing the related discount over the respective contractual terms.

Summary of Outstanding Balances: As of December 31, 2024, the Company had the following convertible note balances outstanding with third parties:

---

| | | | |
|:---|:---|:---|:---|
| **Instrument** | **Principal** | **Unamortized<br> Discount (BCF)** | **Net Carrying <br> Value** |
| <u>As of December 31, 2025:</u> |  |  |  |
| 8% Convertible Notes | $432140 | $– | $432140 |
| 0% Convertible Notes | 708500 | – | 708500 |
| Total as of December 31, 2025 | $1140640 | $– | $1140640 |
| <u>As of December 31, 2024:</u> |  |  |  |
| 8% Convertible Notes | $430900 | $– | $430900 |
| 0% Convertible Notes | 723000 | (169000) | 554000 |
| Total as of December 31, 2024 | $1153900 | $(169000) | $984900 |

---

All third-party convertible promissory notes are classified as current liabilities as of December 31, 2025 and 2024. The Company excluded all potentially dilutive shares associated with these notes from the calculation of diluted earnings per share due to the net loss position for the periods presented (see Note 12).

**Note 8 – Services Agreement with Contracted Operator**

Following the August 2022 acquisition of Prime Dental, the Company entered into a services agreement with the former owner of the acquired business to support production and fulfillment operations at the acquired dental laboratory facility. Under this agreement, the contracted operator was responsible for managing daily operations, including staffing, materials procurement, and lab production workflow. On July 1, 2025, the Company terminated the services agreement with the contracted operator and started bringing those services in-house.

The Company maintains ownership and control of the facility, assets, and customer relationships. Revenue from customer contracts is recognized by the Company in accordance with ASC 606. Management has evaluated the arrangement under the principal-agent guidance in ASC 606-10 and concluded that the Company is acting as the principal, based on its control over pricing, customer invoicing, inventory risk, and the integration of services into the Company's operations.

The contracted operator was compensated through a services arrangement that entitles them to retain an agreed portion of gross proceeds, net of equipment usage fees and shared costs. These amounts were classified as selling and marketing expenses. All other direct production costs are reported as cost of goods sold.

**Standard Dental Labs Inc.**

**Notes to Financial Statements**

**As of and For the Years Ended December 31, 2025 and 2024**

**Note 9 – Stockholders' Equity and Share Roll forward**

As of December 31, 2025, the Company was authorized to issue up to 2,000,000,000 shares of common stock with a par value of $0.001 per share. On March 20, 2025, the Company effected a 1-for-20 reverse stock split. All common share amounts and per-share data presented in these financial statements have been retroactively adjusted to reflect the reverse stock split unless otherwise indicated. Pre and post-split share amounts are as follows:

---

| | | |
|:---|:---|:---|
|  | **Pre-Split** | **Post-Split** |
| Common Shares | $608956363 | $608956 |
| Common Stock at $0.001 par value | $30447818 | $30448 |

---

During the year ended December 31, 2025, the Company issued 1,889,612 common shares on conversion of convertible notes.

During 2025, the Company closed a private placement of units of the Company to certain investors with whom the Company has a pre-existing relationship. Pursuant to the private placement the Company is to issue 2,850,020 and 2,850,020 share purchase warrants ("Warrants") as units at a price of $0.05 and $0.10 per unit for aggregate cash proceeds to the Company of $117,501. The shares will be issued in the first quarter of 2026. The Warrants can be exercised for a period of one year from the date of issuance at an exercise price of $0.35 per share in relation to 450,000 shares and at a price of $0.25 per share in relation to 2,400,020 shares.

As of December 31, 2025 and 2024, the Company had 35,337,422 and 30,447,818 shares issued and outstanding, respectively.

**Note 10 – Income Taxes**

The Company accounts for income taxes in accordance with ASC 740, Income Taxes. No provision for income taxes has been recorded for the years ended December 31, 2025 or 2024, as the Company has not generated taxable income to date.

The Company has historically operated as a development-stage business and has incurred net losses since inception. As of December 31, 2025, management believes that the Company may have generated net operating loss carry forwards ("NOLs") for federal and state income tax purposes; however, the Company has not completed a formal tax analysis or filed federal or state income tax returns to confirm the existence or amount of such NOLs.

The Company intends to evaluate its tax filing obligations and assess its deferred tax position as part of future compliance efforts. A valuation allowance would likely be recorded for any deferred tax assets until such time as management determines it is more likely than not that the benefit will be realized.

No income tax expense or benefit has been recorded in the accompanying financial statements, and no uncertain tax positions have been identified.

**Standard Dental Labs Inc.**

**Notes to Financial Statements**

**As of and For the Years Ended December 31, 2025 and 2024**

**Note 11 – Earnings (Loss) per Share**

Basic earnings (loss) per share is computed by dividing net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed by including potentially dilutive securities, such as convertible instruments and stock options, using the treasury stock or if-converted method, as applicable. For the years ended December 31, 2025 and 2024, all such instruments were anti-dilutive and have been excluded from the computation of diluted loss per share.

The following table summarizes the earnings (loss) per share calculation for the years presented:

---

| | | |
|:---|:---|:---|
| **Year Net Loss** | **Weighted Average<br> Shares** | **Basic and Diluted<br> Loss Per Share** |
| 2025 $(1111315) | 35337442 | $0.04 |
| 2024 $(526022) | 28160599 | $0.02 |
| 2023 $(412385) | 24123913 | $0.02 |
| 2022 $(1651898) | 24123918 | $0.07 |

---

The 2022 and 2023 periods reflect a restatement pursuant to ASC 805-40, under which Prime Dental Lab, LLC is treated as the accounting acquirer. All share amounts and per-share data have been retroactively adjusted to reflect the Company's 1-for-20 reverse stock split effected on March 20, 2025.

**Note 12 – Commitments and Contingencies**

As of December 31, 2025 and 2024, the Company did not have any material commitments for capital expenditures. However, the Company maintains several contractual and operational arrangements that could give rise to future obligations, including:

&nbsp;&nbsp;&nbsp;&nbsp;· A
services agreement with the contracted operator of the Company's Orlando-based dental laboratory, as discussed in Note 8, which
is subject to six months' termination notice.

&nbsp;&nbsp;&nbsp;&nbsp;· Convertible
notes issued to related and third-party investors as described in Notes 6 and 7, which contain embedded features that may trigger conversion
or settlement depending on future financing events or maturity.

· Ongoing
legal and regulatory compliance expenses associated with preparing for a Regulation A Tier 2 offering.

Management has assessed all known contractual obligations, contingencies, and potential legal matters through the date these financial statements were available to be issued. There were no material loss contingencies that met the recognition criteria under ASC 450, Contingencies.

**Note 13 – Subsequent Events**

The Company has evaluated events subsequent to the balance sheet date through April 8, 2026, the date these financial statements were available to be issued.

In March 2026, the Company issued 2,850,020 share warrants at $0.001 par value with paid in capital of $164,651.

The Company has an asset purchase agreement to acquire the operating assets of Brlit Dental Laboratory, Inc., a Sarasota-based dental laboratory.

**ITEM 8. EXHIBITS**

**Index to Exhibits**

---

| | | |
|:---|:---|:---|
| **Exhibit No.:** | **Description of Exhibit** | **Incorporated by Reference to:** |
| **<u>2. Charter and Bylaws</u>** | **<u>2. Charter and Bylaws</u>** |  |
| 2.1 | [Articles of Incorporation](http://www.sec.gov/Archives/edgar/data/1178660/000168316825005894/standarddental_ex0201.htm) | 1-A/A (08/11/2025) |
| 2.2 | [Bylaws](http://www.sec.gov/Archives/edgar/data/1178660/000168316824002683/standarddental_ex0202.htm) | 1-A (04/25/2024) |
| **<u>4. Subscription Agreement</u>** | **<u>4. Subscription Agreement</u>** |  |
| 4.1 | [Subscription Agreement](http://www.sec.gov/Archives/edgar/data/1178660/000168316824002683/standarddental_ex0401.htm) | 1-A (04/25/2024) |
| **<u>6. Material Agreements</u>** | **<u>6. Material Agreements</u>** |  |
| 6.1 | [Smile Dental Subcontractor Agreement](http://www.sec.gov/Archives/edgar/data/1178660/000168316824005217/standarddental_ex0601.htm) | 1-A/A (08/01/2024) |
| 6.2 | [Smile Dental Subcontractor Agreement (as amended)](http://www.sec.gov/Archives/edgar/data/1178660/000168316824005217/standarddental_ex0602.htm) | 1-A/A (08/01/2024) |
| 6.3 | [PDL Lockup Agreement](http://www.sec.gov/Archives/edgar/data/1178660/000168316824005217/standarddental_ex0603.htm) | 1-A/A (08/01/2024) |
| 6.4 | [PDL Asset Purchase Agreement](http://www.sec.gov/Archives/edgar/data/1178660/000168316824005217/standarddental_ex0604.htm) | 1-A/A (08/01/2024) |
| 6.5 | [Convertible Promissory Note (James Brooks)](http://www.sec.gov/Archives/edgar/data/1178660/000168316824005217/standarddental_ex0605.htm) | 1-A/A (08/01/2024) |
| 6.6 | [Form of Investor Convertible Promissory Note](http://www.sec.gov/Archives/edgar/data/1178660/000168316824005217/standarddental_ex0606.htm) | 1-A/A (08/1/2024) |
| 6.7 | [Lease Agreement](http://www.sec.gov/Archives/edgar/data/1178660/000168316825005894/standarddental_ex0607.htm) | 1-A/A (08/11/2025) |
| 6.8 | [Dream Dentistry Asset Purchase Agreement](http://www.sec.gov/Archives/edgar/data/1178660/000168316825008153/standard_ex6.htm) | 1-U (11/10/2025) |
| 6.9 | [Amendment No. 1 to the Dream Dentistry Asset Purchase Agreement](http://www.sec.gov/Archives/edgar/data/1178660/000168316826000139/stddent_ex06.htm) | 1-U (01/07/2026) |
| 6.10 | [Bravo Dental Lab Agreement](standard_ex0610.htm) |  |
| 6.11 | [Brlit Denal Laboratory Asset Purchase Agreement](standard_ex0611.htm) |  |
| 6.12 | [Amendment No. 1 to the Brlit Dental Laboratory Asset Purchase Agreement](standard_ex0612.htm) |  |

---

**SIGNATURES**

Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: April 9, 2026 | **STANDARD DENTAL LABS INC.** | **STANDARD DENTAL LABS INC.** |
|  | By: | /s/ James D. Brooks |
|  |  | James D. Brooks<br> President |

---

Pursuant to the requirements of Regulation A, this report has been signed below by the following persons on behalf of the issuer and in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ James D. Brooks | President [Principal Executive Officer], Chief Financial Officer [Principal Financial Officer], Secretary and Director | April 9, 2026 |
| James D. Brooks |  |  |
| /s/ Claire Ambrosio | Director | April 9, 2026 |
| Claire Ambrosio |  |  |

---

## Ex1K-6

**Exhibit 6.10**

**SUBCONTRACT AGREEMENT**

This Subcontract Agreement (the "Agreement") is made and effective this **July 1<sup>st</sup>, 2025**,

---

| | |
|:---|:---|
| **BETWEEN:** | **STANDARD DENTAL LABS INC.** (the "Contractor"), a corporation organized and existing under the laws of the State of Nevada, with its head office located at: 424 E Central Blvd., Orlando, FL 32801 |

---

---

| | |
|:---|:---|
| **AND:** | **BRAVO DENTAL LAB LLC** (the "Subcontractor"), a corporation organized and existing under the laws of the STATE OF FLORIDA, with its head office located at: 1008 N Pine Hills Road, Orlando, FL 32808 |

---

WHEREAS Contractor has entered into an Asset Purchase Agreement, henceforth "The Management Contract" with BRAVO DENTAL LAB LLC, to perform in accordance with various contract documents and specifications certain work requested by the Contractor's clients, henceforth "Clients", and/or to furnish technical and lab management labor required to manufacture the following dental prosthetics and orthodontics:

The manufacturing of various dental prosthetics, henceforth to be known as "The Project", and to be manufactured at the business address of the contractor located at 1008 N Pine Hills Road, Orlando, FL 32808, and

WHEREAS Contractor desires to retain Subcontractor to perform certain contract work in accordance with various contract documents and specifications and/or to furnish labor, materials, supplies, labor and/or goods for The Project;

NOW THEREFORE Contractor and Subcontractor agree as follows:

1. SUBCONTRACT WORK

Subcontractor shall be employed as an independent contractor and shall provide and furnish all labor, supervision, and administration necessary for the proper and complete performance and acceptance of the following portions of the work, hereinafter "the Subcontract Work", for the Project, together with such other portions of the drawings, specifications and addendum as related thereto:

SEE EXHIBIT A: List of Products and Services.

2. SUBCONTRACTOR PRICE

In consideration of Subcontractor's performance of this Subcontract, and at the times and subject to the terms and conditions hereinafter set forth, Contractor shall pay to Subcontractor the total sum of mutually agreed upon amount relative to the work performed and billed, hereinafter "subcontract price." Said subcontract price is dependent upon the conditions set forth in Exhibit A being met. Should said conditions not be met, the subcontract amount shall be modified accordingly.

3. SPECIAL CONDITIONS

The Special Conditions to Subcontract are incorporated in this Subcontract as though fully set forth herein. Subcontractor hereby acknowledges receipt of the Special Conditions.

4. COMMUNICATION AND NOTICE

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. All communications between Subcontractor and Client shall include Contractor, and use the medium provided
by Contractor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Subcontractor shall furnish Contractor with periodic progress reports as required by Contractor, including
status of material, equipment, manpower and submittal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Subcontractor shall provide proof of completion and proof of delivery for each job, and furnished to
Contractor upon demand.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Subcontractor shall be deemed to have received notice of a fact, request, order, or demand when notified,
either orally or in writing, or 5 days after written notice is sent by registered or certified mail addressed to Subcontractor's last
known place of business, whichever is sooner.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. Contractor shall be deemed to have received notice of a fact, request, or demand 10 days after written
notice is sent by registered or certified mail addressed to the following address:

1008 N Pine Hills Road, Orlando, FL 32808

5. GOVERNING LAW AND RULES OF CONSTRUCTION

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. The validity, interpretation, and performance of this Subcontract shall be governed by the laws of
the jurisdiction where the Project is located.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Titles, captions, or headings to any provision, article, etc., shall not limit the full contents of
the same. These articles have the full force and effect as if no titles existed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. If any term or provision of this Subcontract is determined to be invalid, it shall not affect the validity
and enforcement of the remaining terms and provisions of this Subcontract.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. This contract shall be binding upon and inure to the benefit of the respective successors, assigns,
representatives, and heirs of the parties herein.

6. AMENDMENT

This Subcontract shall only be amended or modified by written document executed by authorized representatives of Contractor and Subcontractor. This Subcontract supersedes all prior representations made by Contractor.

7. ARBITRATION

Any and all disputes or claims between the Contractor and the Subcontractor arising out of this Subcontract shall be resolved by submission of the same to FLORIDA CIRCUIT-CIVIL MEDIATOR SOCIETY, for resolution by binding arbitration according to Florida's Rules of Arbitration. In so agreeing the parties expressly waive their right to a jury trial, if any, on these issues and further agree that the award of the arbitrator shall be final and binding upon them as though rendered by a court of law and shall be enforceable in any court having

jurisdiction over the same.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

---

| | |
|:---|:---|
| SUBCONTRACTOR | CONTRACTOR |
| /s/ Tiffany Boulton | /s/ James Brooks |
| Signed: Tiffany Boulton | James Brooks |
| BRAVO DENTAL LAB LLC | CEO Standard Dental Labs Inc. |

---

**<u>Exhibit A</u>**

List of Products and Services

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Material** | **Labor** | **Sales Price** |
| PFZ (Layer tech) | $35.00 | $25.00 | $109.00 |
| EMAX1 | $35.00 | $25.00 | $139.00 |
| E-MAX | $35.00 | $25.00 | $129.00 |
| Anterior Bruxir | $35.00 | $25.00 | $109.00 |
| N-PFM | $25.00 | $25.00 | $89.00 |
| PFM | $25.00 | $25.00 | $99.00 |
| PFM | $40.00 | $25.00 | $100.00 |
| PFM | $25.00 | $25.00 | $109.00 |
| Zirconia (Bruxer) | $30.00 | $25.00 | $79.00 |
| Zirconia (Bruxir) | $30.00 | $25.00 | $89.00 |
| All Ceramic | $30.00 | $25.00 | $99.00 |
| All Ceramic (layer tech) | $35.00 | $25.00 | $89.00 |
| All Ceramic (layer tech) | $35.00 | $25.00 | $99.00 |
| All Ceramic (layer tech) | $35.00 | $25.00 | $109.00 |
| All Ceramic (layer tech) | $35.00 | $25.00 | $129.00 |
| All Ceramic Crown | $30.00 | $25.00 | $99.00 |
| Post | $10.00 | $20.00 | $40.00 |
| Post | $10.00 | $20.00 | $50.00 |
| Metal Occlusion | $10.00 | $10.00 | $30.00 |
| Metal collar | $10.00 | $5.00 | $20.00 |
| Metal lingual | $10.00 | $10.00 | $30.00 |
| Full Gold Crown | $25.00 | $25.00 | $99.00 |
| Repair | $15.00 | $50.00 | $89.00 |
| Bridge Connection | $0.00 | $5.00 | $15.00 |
| Porcelain Veneer | $40.00 | $30.00 | $139.00 |
| Fit to Partial | $0.00 | $10.00 | $20.00 |
| Add Clasp | $0.00 | $10.00 | $20.00 |
| Rest | $0.00 | $10.00 | $20.00 |
| Soft Tissue | $5.00 | $10.00 | $20.00 |
| Flipper | $30.00 | $30.00 | $109.00 |
| Rush | $0.00 | $0.00 | $30.00 |
| Late Fee | $0.00 | $0.00 | $35.00 |
| Screw Implant | $100.00 | $70.00 | $299.00 |
| Implnat (Por) | $10.00 | $10.00 | $30.00 |

---

## Ex1K-6

**Exhibit 6.11**

**ASSET PURCHASE AGREEMENT**

**between**

**BRLIT DENTAL LABORATORY, INC.**

**(as Seller) and**

**STANDARD DENTAL LABS INC.**

**(as Buyer)**

**Dated as of January 30th, 2026**

**ASSET PURCHASE AGREEMENT**, dated _January 30th , 2026 (this "<u>Agreement</u>"), between

**BRLIT DENTAL LABORATORY, INC.,** a Florida corporation ("or the "<u>Seller</u>"); and

**STANDARD DENTAL LABS INC.**, a Nevada corporation ("<u>SDL</u>" or the "<u>Buyer</u>").

The Buyer and Seller are sometimes individually referred to herein as a " <u>Party</u>", and collectively as the "<u>Parties</u>".

**PREAMBLE**

The Buyer wishes to acquire from Seller, and Seller wishes to transfer to Buyer certain assets of Seller in consideration for the Purchase Price as a combination of Buyer's Common Shares and certain cash or other consideration as otherwise outlined herein (the "<u>Acquisition</u>").

**ARTICLE I**

**PURCHASE AND SALE OF ASSETS; SALES TAXES; DEFINITIONS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.1<u>Transfer of Purchased Assets</u>.**

On the terms and subject to the conditions contained in this Agreement, at the Closing the Seller shall sell, transfer, convey and assign to the Buyer, free and clear of all Encumbrances, and the Buyer shall purchase and acquire from Seller, all of Seller's right, title and interest in, to and under substantially all of Seller's assets, properties, interests in properties and rights, whether tangible or intangible and whether real, personal or mixed, as the same shall exist immediately prior to the Closing, but excluding the Excluded Assets (collectively, the "<u>Purchased Assets</u>").

The Purchased Assets shall include, but are not limited to: all client contracts for existing Seller clients; certain physical assets of the Seller including all dental lab equipment, furniture, computers and other office equipment; the assumption of certain contracts, equipment leases and office leases (if any); and specifically the right to continue to use the name **"BRLIT DENTAL LABORATORY, INC."** along with certain other rights, trademarks, intellectual property and intangible assets of the Seller. More specifically and subject to <u>Section 1.2</u>, the Purchased Assets include, but are not limited to the following assets, properties and rights of the Seller as of the Closing Date:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) all fixed assets, including furniture, fixtures, machinery, equipment, computer hardware and software, and all other tangible assets and personal property of the Seller as listed on <u>Schedule 1.1(a)</u>, other than Excluded Assets of the Seller as listed on <u>Schedule 1.2</u>;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) all rights and benefits of the Seller under the Contracts as listed on <u>Schedule 1.1(b)</u> (the "<u>Assigned Contracts</u>");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) all goodwill, going concern value, patents, patent applications, patent rights, copyrights, copyright applications, Websites, URL's, domain names, methods, know-how, software, technical documentation, computer programs, engineering drawings, product concepts, and ideas under development, processes, process charts, procedures, inventions, trade secrets, trademarks, trade names, trade dress, logos, business names (and specifically the right to continue to use the name "BRLIT DENTAL LABORATORY, INC.), telephone numbers, confidential information, franchises, customer lists, customer files, marketing materials, advertising records, advertising rights with respect to all media, service marks, service names, registered user names, technology, research records, data, designs, plans, drawings, manufacturing know-how and formulas, whether patentable or unpatentable, and other intellectual or proprietary rights (and all rights thereto and applications therefor), including the Intellectual Property;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) all rights to causes of action, lawsuits, judgments, claims, and demands of any nature available to or being pursued by the Seller, including all rights and claims against manufacturers and vendors of the Seller, relating to the subject matter of this Agreement, whether arising by way of counterclaim or otherwise, provided that for any claim, demand, action or lawsuit brought or asserted against Seller by a third-party, Seller shall retain and have all rights, claims, defenses, and remedies against such third-party;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) to the extent assignable, all rights in and under all express or implied guarantees, warranties, representations, covenants, indemnities, and similar rights in favor of the Seller related to the subject matter of this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) to the extent assignable, all Permits, licenses or similar rights to the extent that they are assignable, including those listed on <u>Schedule 1.1(i)</u> (the "<u>Transferred Permits</u>"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) all information, files, databases, correspondence, records, data, plans, reports, and Contracts, including any and all information and records relating to investment, insurance and other current and past customers, client files, customer, supplier, price and mailing lists, business contacts, and investment, underwriting, and claims files together with all usual and customary records in connection therewith, and all accounting or other books and records of Seller in whatever media retained or stored, including computer programs and disks.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.2 Excluded Assets.**

The Purchased Assets exclude, and the Buyer shall not purchase or acquire hereunder, any right, title or interest in, to and under any of the excluded assets of the Seller listed below and as outlined on Schedule 1.2 (collectively, the "<u>Excluded Assets</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) all ownership and other rights with respect to Seller Employee Benefit Plans;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) all rights of Seller under any excluded Contracts listed on Schedule 1.2;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (c) all accounts receivable outstanding as at the Closing Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (d) any Permit, license, warranty, or guarantee that by its terms is not transferable or assignable to Buyer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (e) all Contracts other than Assigned Contracts (the "**Excluded Contracts**"), which Seller may, in its sole discretion, terminate after Closing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (f) all equity interests in the Seller or any subsidiary of the Seller;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) all of such Seller's federal, state, and local income Tax Returns and records (provided that the Seller has made available copies of such Tax Returns and records to the Buyer prior to the Closing) and any rights to Tax refunds, including without limitation any rights to Employee Retention Tax Credits of the Seller;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (h) all personnel files and payroll records related to employees of the Seller;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) all causes of action, judgments, claims, reimbursements and demands, of whatever nature, in favor of Seller which relate to the Excluded Assets or Retained Liabilities and all counterclaims, crossclaims, and defenses in regard to any claims or causes of action currently or hereafter pending or threatened against Seller;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) all losses, loss carry forwards, loss carry backs, and rights to receive refunds, rebates, offsets, credits or credit carry forwards with respect solely to Taxes of Seller;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) any insurance policies maintained by Seller and any claims under such policies and all obligations under those insurance policies including costs associated with defense of any Actions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) the charter documents, minute books, stock ledgers, Tax Returns, books of account and other constituent records relating to the corporate organization of the Seller;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) all ability and control for Seller to hire additional employees and managers as needed to replace themselves or supplement operations; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (n) any other items listed on <u>Schedule 1.2</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.3 <u>Assumed Liabilities.</u>**

Subject to the terms and conditions set forth in this Agreement, Buyer hereby assumes and agrees to pay, perform and discharge when due any and all of the following liabilities (the "**Assumed Liabilities**") of the Seller:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) Subject to Section 1.4(a) below, Buyer shall assume, pay, fulfill, perform or otherwise discharge all Liabilities and obligations with respect to the Purchased Assets arising after the Closing Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) all Liabilities and obligations for (i) Taxes relating to the Purchased Assets or the Assumed Liabilities for any taxable period ending after the Closing Date and (ii) Taxes for which Buyer is liable pursuant to Section 4.4; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (c) the Liabilities set forth on <u>Schedule 1.3(c)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.4 <u>Retained Liabilities</u>**. Except for the Assumed Liabilities, the Buyer does not assume and shall in no event be liable for any Liability of the Seller, or any Affiliate or successor of such Seller, or any claim against any of the foregoing, whether known or unknown, contingent or absolute, or otherwise, including, without limitation, the following (collectively, the "**Retained Liabilities**");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Notwithstanding anything to the contrary in Section 1.3(a), Buyer shall not be required to assume, pay, fulfill, perform or otherwise discharge any of the following liabilities and obligations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. Except for those liabilities set forth on <u>Schedule 1.3(c)</u>, any obligations
and liabilities, if any, for rentals, advance royalty payments or production royalty payments under the Purchased Assets accruing prior
to the Closing Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. the Liabilities of the Seller under the Assigned Contracts that arises out of or
relates to any breach of such Assigned Contract that occurred prior to the Closing Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) all Liabilities of the Seller for Indebtedness for which Seller is liable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) all Liabilities of the Seller for Taxes, including, without limitation, (i) all Liabilities for Taxes with respect to ownership of the Purchased Assets arising or relating to taxable events occurring on or prior to the Closing Date for such Purchased Assets, (ii) all Liabilities for Taxes arising in connection with, or resulting from, the consummation of the transactions contemplated by this Agreement payable by Seller or for which Seller is liable to pay;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (d) all Liabilities arising from any Proceeding involving such Seller, its business or any Affiliate of the Seller, whether arising prior to, pending on, or arising after the applicable Closing Date relating to events occurring on or prior to the applicable Closing, including without limitation the litigation matters listed on <u>Schedule 1.4(d), if any</u>;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (e) all Liabilities of the Seller to its current or former employees;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (f) any Liabilities of the Seller under any Employee Benefit Plans, including any Liability for withdrawal from, or termination of, such Employee Benefit Plans, and any Tax arising from such Employee Benefit Plans or result of any transaction with or by such Employee Benefit Plans;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (g) all Liabilities of the Seller to any current or former member, manager, officer, employee or Affiliate of the Seller, including, without limitation, any Liability arising out of or related to any loan, or any accrued interest related thereto, from any member, manager, officer, employee or Affiliate to the Seller;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) any Liability to, or arising under any workers' compensation program to which premiums or contributions are required to be paid;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (i) any Liability as a result of, arising out of or relating to any events occurring prior to Closing as to any (i) billing or payment review, billing or payment audit, recoupment or repayment proceeding, or other Proceeding, or appeals related thereto or settlements arising therefrom, brought by, on behalf of or before, any commission, board, agency or other Government Authority, Payor or any other third party, including any state department of health or any other state or federal agency with respect to any payments received by such Seller for services rendered;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) all Liabilities related to the Excluded Assets, including any Liabilities arising at any time under any Excluded Contract;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (k) all Liabilities of the Seller or any Affiliate of such Seller with respect to releases of Hazardous Materials or violations of Environmental Laws, in each case arising out of events occurring prior to the Closing Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) any and all other Liabilities relating to the business of the Seller other than the Assumed Liabilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (m) any Liability of the Seller incurred in connection with the execution, delivery and performance of this Agreement or any Ancillary Agreement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (n) the Liabilities set forth on <u>Schedule 1.4(n), if any.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.5 <u>Assignment of Contracts and Rights</u>.**

Notwithstanding anything in this Agreement to the contrary, this Agreement does not constitute an agreement or an attempted agreement to sell, transfer, sublease or assign any Assigned Contract (or any claim or right or any benefit arising thereunder or resulting therefrom) if the attempted transfer, sublease or assignment thereof, without the consent of any other party thereto, would constitute a breach thereof or in any way affect the rights of the Buyer or the Seller thereunder, such Assigned Contracts being deemed Non-Assignable Assets (as defined in Section 2.6). Subject to the provisions of Section 2.6, the Seller shall use its commercially reasonable efforts to obtain the consent of the other party to any Assigned Contract to the transfer, sublease or assignment thereof to the Buyer in all cases in which such consent is required for the transfer, sublease or assignment of any such Assigned Contract. If any such consent is not obtained and the Closing occurs, the Seller shall use its commercially reasonable efforts to provide for the Buyer the benefits of such Assigned Contract.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.6 <u>Further Assurances</u>.**

The Seller shall, from time to time after the Closing, upon the written request of Buyer, do, execute, acknowledge and deliver, and cause to be done, executed, acknowledged or delivered, all such further acts, deeds, assignments, transfers, conveyances or assurances as may be reasonably required to transfer, assign, convey, grant and confirm to the Buyer, or to aid and assist in the reducing to possession by the Buyer of the Purchased Assets, or to vest in the Buyer good and marketable title to the Purchased Assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.7 <u>Sales Tax</u>.**

The Seller shall pay to applicable Taxing Authorities any and all sales Taxes, use Taxes, transfer Taxes, license Taxes, documentary charges, recording fees or similar Taxes, charges or fees (other than income Taxes of the Seller) that may become payable in connection with the sale, transfer and conveyance of the Purchased Assets to the Buyer (the "<u>Transaction Taxes</u>"). The Seller and the Buyer shall coordinate with each other the filing of any forms required in connection with such Taxes, charges or fees. The parties shall reasonably cooperate to minimize the amount of any Transaction Taxes imposed in connection with the sale of the Purchased Assets to the Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.8<u>Seller Consulting</u>**. From and after Closing, for a period of 90 days, Emil Brlit, David R. Damschroder, and Elena Brlit, and (the "Consultants") agree to perform, and Buyer shall hire the Consultants to perform, such consulting services consistent with their current positions with the Seller (the "Consulting Agreements"). Each Consulting Agreement shall include the following terms: (i) the Consultants shall be compensated at their current established salary pro rated for the period of service, indexed yearly to inflation using the Consumer Price Index, (ii) the term of the Consulting Agreement shall be for a period of 90 days after Closing, at which point continuance of the Consulting Agreement shall be terminable at will upon written notice by either the relevant Consultant or the Buyer and provided further the Consulting Agreement will provide for customary termination rights on behalf of either party for the non-performance, non-cured breach, fraud, gross negligence or other conduct materially detrimental to the other party (including providing for termination by the Buyer for any breach by the relevant Consultant of the provisions of Section 6.5 hereof), (iii) the Consultant will be required to provide services for a minimum total of 120 hours per month pursuant to the standards of performance as agreed to in the Consulting Agreement and (iv) the Consulting Agreement will contain such other terms and conditions customary for such consulting arrangements as mutually agreed to by the Buyer and the relevant Consultant. The form and substance of the Consulting Agreement shall be agreed to by the Parties prior to Closing, and shall be executed at Closing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.9 <u>Defined Terms</u>.**

Certain capitalized terms used in this Agreement are defined on <u>Annex I</u> attached hereto.

**ARTICLE II**

**CONSIDERATION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.1 <u>Purchase Price</u>.**

The Purchase Price is an aggregate total value of $900,000 (the "Gross Consideration") consisting of (i) share consideration and (ii) cash consideration, in each case, payable as follows:

**Share Consideration** - The share consideration will consist of such number of Common Shares (the "<u>Share Consideration</u>") equal to the quotient of (A) the Gross Consideration less the Cash Consideration, divided by (B) the volume weighted average price of the Common Shares as quoted on the OTCQB for the five trading days immediately preceding the Closing (the "<u>Per Share Value</u>") and shall be issued and payable by the Buyer to the Seller on the Closing Date, subject to the Share Holdback and the Share Lock-Up, as provided herein. The Share Consideration issuable to the Seller pursuant to Section 2.1 shall be issued as fully paid and non-assessable. The shares comprising the Share Consideration (the "Shares") shall be issued, pro rata (i.e., 25%) to and in the name of the shareholders of Seller executing this Agreement. The Seller acknowledges that the Share Consideration may be subject to regulatory hold periods, in which case the share certificates representing the Share Consideration shall bear the appropriate legends.

The Shares Consideration shall be subject to the Share Holdback and to the following contractual lock-up restrictions. Specifically, the Share Consideration shall be held in escrow by the Buyer at the Closing and released to the Seller in eight (8) equal quarterly installments beginning at the end of the first full fiscal quarter to occur after the Closing Date (the "<u>Share Lock-Up</u>"), further subject to reduction pursuant to the Earn-Out Adjustment described in Section 2.3 below; provided that following the release for the fourth installment of Common Shares, no further Share Consideration will be released for any subsequent quarterly installments unless and until either (i) the final Earn-Out Adjustment, if any, has been, or (ii) the determination has been made that no Earn-Out Adjustment is required, in each case, pursuant to the procedures set forth in Section 2.3 below and provided further that following the final Earn-Out Adjustment or the determination that no Earn-Out Adjustment is required, any Share Consideration that should have been released pursuant to a past quarterly installment but was delayed pending determination of the Earn-Out Adjustment, shall be promptly released to the Seller, with any remaining Share Consideration remaining subject to the Share Lock-up.

**Cash Consideration** – The cash consideration shall be $300,000.00, paid to Seller as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (i) $150,000 at Closing; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) $150,000 on the date that is 180 days following the Closing (or the next Business Day if such date is not a Business Day), conditioned upon maintaining a minimum of 80% of the Seller's current pro-rata revenue, averaged over the past 24 months.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.2 <u>Allocation of Purchase Price</u>.**

The Parties agree that the Purchase Price shall be allocated, for Tax purposes, among the Purchased Assets in a manner consistent with the provisions of Section 1060 of the Code and all regulations promulgated thereunder. Within twelve (12) months after the Closing, the Seller shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) complete and execute Form 8594 Asset Acquisition Statement Under Section 1060, consistent
with the Statement of Allocation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) deliver copies of such form to the Buyer

The Parties shall file a copy of the above-referenced form applicable to it with its Tax Returns for the period which includes the Closing Date.

If there is an increase or decrease in consideration (the Purchase Price under this Agreement) within the meaning of Section 1.1060-1(e)(1)(ii)(B) of the Treasury Regulations after the parties have completed the Statement of Allocation or have filed their initial Form 8594 Asset Acquisition Statement, the Parties shall allocate such increase or decrease in consideration as required by and consistent with Section 1060 of the Code and the applicable Treasury Regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.3 <u>Earn-Out Target</u>.**

The Share Consideration shall be subject to reduction, based on a one-time adjustment, based on the confirmation of the annual billings generated by the Purchased Assets (the "<u>Annual Gross Billings</u>") for the 12 months following the Closing Date (the "<u>Earn-Out Period</u>") relative to the Annual Earn-Out Target. The "<u>Annual Earn-Out Target</u>" shall be 80% of Seller Target Gross Billings. The "<u>Seller Target Gross Billings</u>" shall be the annualized average monthly billings of the Seller from the Purchased Assets for each of three months ended prior to the Closing Date as certified by the completion of an independent audit providing confirmation of such monthly billings for each such month. Within 60 days after the end of the Earn-Out Period, the Buyer will deliver a statement to the Seller setting forth the Annual Gross Billings (the "<u>Earn-Out Statement</u>"). Upon delivery of the Earn-Out Statement, the Seller shall have 30 days to object to the Earn-Out Statement (the "<u>Seller Objection Period</u>"), during which period the Buyer shall grant the Seller access to the records of the Company for the sole purpose of verifying the Earn-Out Statement. By the end of the Seller Objection Period, the Seller must deliver to the Buyer an objection letter setting forth in detail any objections of the Seller to the Earn-Out Statement (the "<u>Seller Objection Letter</u>"). If Seller does not deliver a Seller Objection Letter, then the Seller will be deemed to have approved the Annual Gross Billings set forth in the Earn-Out Statement ("<u>Deemed Approval</u>"). If Seller delivers a Seller Objection Letter, the Buyer and the Seller will reasonably cooperate to resolve the objections of the Seller set forth therein for a period of 30 days from the delivery of the Seller Objection Letter (the "<u>Resolution Period</u>"). If the Buyer and the Seller are unable to resolve the objections of the Seller set forth in the Seller Objection Letter, then the objections will be sent to the Buyer's independent public company accountants for a determination of the Annual Gross Billings. The determination of the Buyer's independent public company accountants will be binding upon each of the parties ("<u>Final Resolution</u>"). Upon occurrence of the Deemed Approval or the Final Resolution, if the Annual Gross Billings are less than the Annual Earn-Out Target, then the Share Consideration shall be reduced by a number of Common Shares in an amount equal to (A) the number of Common Shares in the Shares Consideration less (B) the product of (x) the number of Common Shares in the Share Consideration multiplied by (y) the quotient of the Annual Gross Billings divided by the Seller Target Gross Billings (the "<u>Earn-Out Adjustment</u>"). The Common Shares deducted from the Share Consideration as a result of the Earn-Out Adjustment shall be withdrawn from the Common Shares in the Share Lock-Up and delivered back to the Company for cancellation. The value of the Common Shares deducted from the Share Consideration (determined using the Per Share Value) will be treated as an adjustment to the Gross Consideration.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.4 <u>Tax Consequences</u>.**

The Parties acknowledge that due to the amount of the Cash Consideration relative to the Share Consideration and the status the Seller under the Code, that the Acquisition will likely not constitute a "reorganization" within the meaning of Section 368(a) of the Code, and that the Acquisition is likely a taxable transaction to the Seller. Each Party hereby acknowledges and agrees that such Party is relying solely upon its own tax advisors and counsel for advice concerning the Tax consequences of the Acquisition, and that no Party provides assurances to any other Party concerning such Tax consequences.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.5 <u>Prorations</u>.**

Except as otherwise set forth herein, (a) all items of income and expense arising from the operation of the Purchased Assets on or before the Closing Date shall be for the account of Seller, and all items of income and expense arising from the operation of the Purchased Assets after the Closing Date shall be for the account of Buyer. Prepaid items, deposits, credits and accruals such as property taxes, rent, utilities, other service charges, rental and other payments or advances under the Assigned Contracts shall be prorated as of the Closing Date on the basis of the period of time to which such Liabilities, prepaid items and accruals apply. After Closing, upon written request from either Party, which shall include sufficient supporting documentation, Buyer and Seller agree to promptly pay the other party any amounts which may become due based on any prorated items that are not quantified at the time of either Closing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.6 <u>Non-Assignable Assets</u>.**

Nothing in this Agreement will be construed as an attempt or agreement to assign any agreement, Contract or Permit the assignment of which requires the consent of a Governmental Entity or other third party (to the extent otherwise intended to be assigned to the Buyer in connection with this Agreement and the transactions contemplated hereby, each, a "<u>Non-Assignable Asset</u>") unless and until the relevant Governmental Entity's or other third party's consent to the assignment of such Non-Assignable Asset has been obtained. For each Non-Assignable Asset Buyer desires for Seller to obtain such consent for, Seller will, and will cause their respective Affiliates to, use commercially reasonable efforts to obtain the consents of the relevant third parties to the assignment to the Buyer of the Non-Assignable Assets and will cooperate with the Buyer at its request in endeavoring to obtain such consents. If, as a condition to obtaining such consent to the assignment or transfer of a Non-Assignable Asset, it shall be necessary for the Seller to cure any defaults thereunder or renew any expired Contract or Permit, then the Seller shall perform such acts, pay such sums and cure any such default and renew any such Contract or Permit. The Seller will pay when due all costs and expenses associated with obtaining such consents and will promptly reimburse the Buyer for any and all damages incurred by the Buyer or its Affiliates arising in connection with the failure to obtain a consent to a Non-Assignable Contract or the failure to obtain such consent prior to the applicable Closing at which such Contract or Permit was to be assigned. To the extent permitted by applicable Law, in the event consents to the assignment thereof cannot be obtained, the Seller shall hold such Non-Assignable Assets in trust for the Buyer and the covenants and obligations thereunder will be performed by the Buyer in the Seller's name, and all benefits and obligations existing thereunder will be for the Buyer's account. From and after the applicable Closing, the Seller will take or cause to be taken with respect to the Non-Assignable Assets, only such actions in its name or otherwise as the Buyer may reasonably request so as to provide the Buyer with the benefits of the Non-Assignable Assets and to effect collection of money or other consideration that becomes due and payable under the Non-Assignable Assets, and the Seller will promptly pay over to the Buyer all money or other consideration received by it in respect of all Non-Assignable Assets. As of and from the applicable Closing Date, the Seller authorizes the Buyer, to the extent permitted by applicable Law and the terms of the Non-Assignable Assets, at the Buyer's expense, to perform all the obligations and receive all the benefits of the Seller under the Non-Assignable Assets and appoints the Buyer its attorney-in-fact to act in its name on its behalf with respect thereto. Nothing in this section shall affect the Buyer's right to indemnification hereunder.

**ARTICLE III**

**CLOSING**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.1 <u>Closing</u>.**

Unless otherwise mutually agreed in writing between the Buyer and the Seller, the closing of the sale and purchase of the Purchased Assets (the "**Closing**") shall take place by electronic (unless originals of any documents are required) exchange of fully-executed agreement and related closing documents, on the third Business Day following the day on which the last to be satisfied or waived of the conditions set forth in <u>Article VII</u> (other than those conditions that by their nature are to be satisfied at or immediately prior to the Closing, but subject to the fulfillment or waiver of those conditions) shall be satisfied or waived by the Party entitled to the benefit thereof in accord ance with this Agreement. The date on which the Closing actually occurs is referred to hereinafter as the "**Closing Date**."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.2 <u>Seller Closing Deliverables</u>**

At the Closing the Seller will deliver to the Buyer the following (collectively, the "Seller Deliverables"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Any document necessary for the completion of the transaction in the following categories, the form and substance of which shall be agreed to by the Parties prior to Closing (the "**Related Documents**"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Bill of Sale, Assignment and Assumption Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) any Trademarks owned by Seller to be attached as Exhibit A;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) a copyright assignment for any copyright held by Seller;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) a Patent assignment for any Patents held by Seller;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) the Seller's books and records that are included in the Purchased Assets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) each owner of the Seller that is to receive Share Consideration will have completed,
executed and delivered to the Buyer an Investor Certificate attached hereto as Appendix A;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) all other documents required to be entered into by Seller pursuant to this Agreement
or reasonably requested by Buyer to convey the Purchased Assets to Buyer or to otherwise consummate the transactions contemplated by this
Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Permits</u>. The transferable/assignable permits held by Seller to be transferred to the Buyer if applicable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Certificates</u>. At the Closing, the Seller shall deliver the certificates set forth below to the Buyer, executed by the Person set forth below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) all written consents (or waivers with respect to thereto) for the assignment to Buyer of the Assigned Contracts;

(ii) to the extent applicable, evidence of satisfaction of all obligations for the Indebtedness attached or relating to the Purchased Assets
, including, if applicable, true, correct, and complete payoff letters or UCC termination statements with respect to the Indebtedness
and satisfactory evidence that all Liens affecting the Purchased Assets have been released;

(iii) a certificate of an officer of the Seller dated as of the Closing Date, certifying (A) as to the incumbency and genuineness of the signatures
of each officer of the Seller executing this Agreement or any of the Related Documents on behalf of the Seller; and (B) the genuineness
of the resolutions (attached thereto) of the Seller's Board of Directors authorizing the execution, delivery and performance of
this Agreement and the Related Documents to which the Seller is a party and the consummation of the transactions contemplated hereby
and thereby;

(iv) a certificate pursuant to Treasury Regulations Section 1.1445-2(b) that Seller is not a foreign person within the meaning of Section
1445 of the Code; and

(v) a certificate of the Florida Secretary of State certifying as to the good standing of the Seller, dated as of a date not more than five
(5) Business Days prior to the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.3 <u>Buyer Closing Deliverables</u>.**

At the Closing the Buyer will deliver to the Seller the following (collectively, the "Buyer Deliverables"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) <u>Related Documents</u>. At the Closing, the Buyer shall execute and deliver to the Seller each Related Document required to be executed by the Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) <u>Related Certificates</u>. At the Closing, the Buyer shall deliver the certificates set forth below to the Seller, executed by the Person set forth below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) a certificate of an officer of the Buyer dated as of the Closing Date, certifying
(A) as to the incumbency and genuineness of the signatures of each officer of the Buyer executing this Agreement or any of the Related
Documents on behalf of the Buyer; and (B) the genuineness of the resolutions (attached thereto) of the Buyer's Board of Directors
or similar governing body authorizing the execution, delivery and performance of this Agreement and the Related Documents to which the
Buyer is a party and the consummation of the transactions contemplated hereby and thereby; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) a certificate of the Nevada Secretary of State certifying as to the good standing
of the Buyer, dated as of a date not more than five (5) Business Days prior to the Closing
Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (c) <u>Cash Consideration</u>. At the Closing or as otherwise outlined herein, the Buyer shall deliver to the Seller the Cash Consideration, in accordance with the terms of this Agreement, including Section 2.1 above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (d) <u>Share Consideration</u>. At the Closing or as otherwise outlined herein, the Buyer shall deliver to the Seller the Share Consideration, subject to the Share Holdback, in accordance with the terms of this Agreement.

**ARTICLE IV**

**REPRESENTATIONS AND WARRANTIES OF THE SELLER**

The Seller hereby represents and warrants to the Buyer as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.1 <u>Organization; Good Standing; Qualification and Power</u>.**

The Seller is a corporation duly organized, validly existing and in good standing under the Laws of State of Florida and has all requisite power and authority to own, lease and operate its properties and carry on its business relating to the Products and the Purchased Assets as it is now conducting that business. The Seller is duly licensed or qualified to transact business and in good standing to do business in each jurisdiction in which the nature of its current operations related to the Business, including its ownership of any of the Purchased Assets and ownership or leasing of properties used in connection with the Business, makes such qualification necessary, <u>except</u> to the extent that the Seller's failure to be so licensed or qualified and in good standing would not have a Material Adverse Effect on the operation of the Business after the Closing or the transfer of the Purchased Assets to the Buyer. Seller does not have any Subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.2 <u>Authority; Noncontravention; Consents</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Seller has all requisite power and authority to enter into this Agreement and each Related Document to which it is a party and to perform its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by the Seller of this Agreement and each Related Document to which the Seller is a party, and the performance by the Seller of its obligations hereunder and thereunder, have been duly and validly authorized by all necessary action on the part of the Seller. This Agreement and each Related Document to which the Seller is a party have been duly and validly executed and delivered by the Seller and are the valid and binding obligations of the Seller, enforceable against the Seller in accordance with their terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Neither the execution and delivery by the Seller of this Agreement and each Related Document to which the Seller is a party nor the performance by the Seller of its obligations hereunder and thereunder (i) materially conflicts with, or results in a material violation of, or causes a material breach or default (with or without notice or lapse of time, or both) under, or gives rise to a right of termination, amendment, cancellation or acceleration of any material obligation contained in or the loss of any material benefit under, or results in the creation of any Encumbrance upon any of the Purchased Assets under, any term, condition or provision of (y) the Seller's Fundamental Documents or (z) any Assigned Contract or any other material Contract to which the Seller is a party or by which the Purchased Assets are bound, or (ii) violates any Laws applicable to the Seller or any of the Purchased Assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) No material (i) consent, (ii) approval, (iii) Order or authorization of, (iv) registration, declaration or filing with, or (v) notification to any Governmental Entity or any other third Person is required in connection with the execution and delivery by the Seller of this Agreement or the Related Documents to which the Seller is a party, the performance by it of its obligations hereunder or thereunder or the consummation by it of the transactions contemplated hereby or thereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.3 <u>Title to Purchased Assets.</u>**

The Seller has good and marketable title to all Purchased Assets free and clear of any Encumbrances and has the right to use and to transfer and assign to the Buyer all Purchased Assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.4 <u>Transferred Intellectual Property</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Seller owns, has the right to use, sell, license and dispose of, and has the right to bring actions for the infringement of, the Intellectual Property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Prior to Closing Seller shall provide to the Buyer a complete list of all Intellectual Property held by Seller;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) There are no royalties, honoraria, fees or other payments payable to any Person or claimed by any Person by reason of the ownership, use, license, sale or disposition of the Intellectual Property or the manufacture or sale of the Products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Seller has not received from any Person in the past five (5) years any written notice, charge, complaint, claim or assertion that its activities or contemplated activities with respect to the Products infringe or would infringe any Intellectual Property Rights of any Person, and no such claim is impliedly threatened by an offer to license from another Person under a claim of use.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Seller has not sent to any Person in the past five (5) years, or otherwise communicated to any Person, any written notice, charge, complaint, claim or other assertion of any present, impending or threatened infringement by or misappropriation of, or other conflict with, any Intellectual Property by such other Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) The Seller has not licensed any of the Intellectual Property to any third Person, other than implied licenses granted by the Seller in connection with the sale of its products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Other than the Intellectual Property already disclosed to the Buyer, the Seller does not own or license any Intellectual Property Rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.5 <u>Assigned Agreements, No Defaults</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Prior to closing, Seller shall provide a complete and accurate list of all the Assigned Contracts.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) All Assigned Contracts are in full force and effect, constitute legal, valid and binding obligations of the Seller and, to the Knowledge of the Seller, the other parties thereto, and are, subject to bankruptcy and other laws relating to or generally affecting the enforcement of creditors' rights, enforceable in accordance with their respective terms against the Seller, and to the Knowledge of the Seller, each other party thereto. The Seller has in all material respects performed all of the obligations required to be performed by it to date under each such Contract, and there exists no default by the Seller or, to the Knowledge of the Seller, any other party, or any event that upon the giving of notice or the passage of time, or both, would give rise to a claim of a default in the performance by the Seller or, to the Knowledge of the Seller, any other party, to any of their respective obligations thereunder. The Seller has made available to the Buyer correct and complete copies of all written Assigned Contracts.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.6 <u>Litigation Etc.</u>**

Except as disclosed on Schedule 4.6 attached hereto, there are no (i) Proceedings pending or, to the Knowledge of the Seller, threatened against the Seller, whether at law or in equity, or before or by any Governmental Entity or arbitrator or (ii) Orders of any Governmental Entity or arbitrator naming the Seller.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.7 <u>Compliance; Permits</u>.**

The Business is not being conducted in violation in any material respect of any Law, Order or Permit applicable in any jurisdiction in which the Seller operates the Business, including Environmental, Health and Safety Laws. To the Knowledge of the Seller, no investigation or review by any Governmental Entity with respect to the Products or the Business is pending or threatened, nor has any Governmental Entity notified the Seller of its intention to conduct the same. The Seller (a) possesses all Permits required under applicable Laws for the Seller's conduct of the Business as it is currently conducted, a list of which shall be provided by Seller to the Buyer prior to Closing, and each such Permit is valid and in full force and effect, (b) is in compliance, in all material respects, with each such Permit and (c) no Proceeding is pending or, to the Knowledge of the Seller, threatened to revoke, modify, suspend or limit any such Permit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.8 <u>Taxes</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All material Tax Returns that are required to be filed by or on behalf of the Seller with respect to the Business, the Purchased Assets and otherwise have been filed with the applicable Taxing Authorities and (b) all Taxes shown as due and payable on such Tax Returns have been paid. To Seller's Knowledge, no Tax Return filed by the Seller is currently being examined by any Taxing Authority, and there are no outstanding agreements or waivers extending the statute of limitations applicable to any such Tax Return. The Seller is not a "foreign person" as that term is defined in Section 1445 of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Seller has delivered to buyer copies of all Tax Returns filed since 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **4.9** <u>**Warranties**</u>

Prior to closing Seller shall provide to the Buyer a complete copy of each form of product warranty and guaranty issued by the Seller with respect to the Products that has not expired. No Person has asserted in writing in the past five (5) years any Proceeding against the Seller under any Law relating to unfair competition, false advertising or other similar claims arising out of warranties, guarantees, specifications, manuals or brochures or other advertising materials used in connection with the Business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.10 <u>Books and Records</u>**

The books of account and other records of Seller, which have been made available to Buyer, are complete and correct in all material respects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.11 <u>Financial Information</u>.**

Prior to Closing, Seller shall provide to the Buyer complete copies of (a) the unaudited balance sheets of Seller for the fiscal years ended December 31, 2023 and December 31, 2024 and the related statements of income for the fiscal years then ended and the related notes thereto, and (b) the unaudited balance sheets of Sellers as of October 31, 2025 and the statement of income for the Ten (10) month period ended October 31, 2025 (collectively, the <u>"Financial</u> Statements"). The Financial Statements (i) present fairly, in all material respects, the financial condition and results of operations of Sellers as of the dates thereof or for the periods covered thereby, as the case may be, and (ii) are in conformity with GAAP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.12 <u>Brokers</u>**

Neither the Seller nor any of its officers, directors, equity owners or employees nor any other Person acting on its or their behalf has employed any broker or finder or incurred any Liability for any brokerage fees, commissions or finders' fees in connection with the transactions contemplated hereby. To the extent that the Seller has incurred any Liability for any brokerage fees, commissions or finder's fees in connection with the transactions contemplated hereby, the Seller will be solely responsible for the payment of such commission or fee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.13 <u>Environmental Matters</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Seller is not, subject to or the subject of any Order or Contract arising under any Environmental, Health and Safety Laws, nor, to the Knowledge of the Seller, is any Proceeding pending or threatened against the Seller under any Environmental, Health and Safety Laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Seller has not received written notice from any Person (i) that it is potentially responsible under any Environmental, Health and Safety Laws for Hazardous Material or response costs or natural resource damages, as those terms are defined under the Environmental, Health and Safety Laws, (ii) alleging that it is not in compliance with any Environmental, Health and Safety Laws or (iii) seeking penalties, damages or injunctive relief for past non-compliance with any Environmental, Health and Safety Laws, in each case related to the Business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Seller is in Compliance with all environmental requirements of its Permits.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.14 <u>Solvency and Bankruptcy</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Seller is, and upon Closing will be, solvent, its assets exceed, and immediately after Closing will exceed, its liabilities, and it is able, and after Closing will be able, to pay its bills and obligations in the ordinary course as they become due. No order has been made, petition presented or meeting convened for the purpose of winding up of Seller or any of its Affiliates, or for the appointment of any provisional liquidation or in relation to any other process by which the business is terminated and the assets of the Seller (or such Affiliate) are distributed amongst the creditors and/or shareholders or other contributors, and there are no proceedings under any applicable insolvency, reorganization or similar laws in any relevant jurisdiction, and no events have occurred which, under applicable Laws, would be reasonably likely to justify any such cases or proceedings. No person has taken any step, legal proceeding or other procedure with a view to the appointment of an administrator or receiver whether out of court or otherwise, in relation to Seller or any of its Affiliates, and no receiver (including any administrative receiver) has been appointed in respect of the whole or any part of any of the property, assets and/or undertaking of the Seller or any of its Affiliates nor has any such order been made (including, in any relevant jurisdiction, any other order by which, during the period it is in force, the affairs, business and assets of the company concerned are managed by a person appointed for the purpose by any Governmental Entity). Neither Seller nor any of its Affiliates has taken any step with a view to a suspension of payments or a moratorium of any indebtedness or has made any voluntary arrangement with any of its creditors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Seller is not involved in any Proceeding by or against it as a debtor before any Governmental Entity under Title 11 of the United States Bankruptcy Code or any other insolvency or debtors' relief Law, whether state, federal or foreign, or for the appointment of a trustee, receiver, liquidator, assignee, sequestrator or other similar official for any part of the Seller's property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.15 <u>No Purchased Assets Held by Affiliates</u>.**

There are no assets, properties, interests in assets or properties or rights owned or held by any Affiliate of the Seller that would constitute Purchased Assets if owned or held by the Seller.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.16 <u>Equipment and Property</u>**

All equipment, property, and tangible assets purchased pursuant to this Agreement are in good repair and good operating condition, ordinary wear and tear excepted, is suitable for immediate use in the ordinary course of business and to Seller's Knowledge, is free from latent and patent defects. To Seller's Knowledge, no equipment, property, and tangible assets purchased pursuant to this Agreement are in need of repair or replacement other than as part of routine maintenance in the ordinary course of business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.17 <u>Contracts and Commitments</u>.**

Except for this Agreement and the Assigned Contracts, as of the date hereof, Seller is not a party to or bound by any Contract, other than those that can be terminated by the Seller without penalty upon not more than ninety (90) days' notice:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) that would be required to be filed by the Seller as a "material contract" pursuant to Item 601(b)(10) of Regulation S-K under the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) pursuant to which the Seller has any material continuing "earn-out" or other contingent payment obligations arising in connection with the acquisition or disposition by the Seller of any business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) that (A) limits in any material respect either the type of business in which the Seller (or in which the Buyer after the Closing Date) may engage or the manner or locations in which any of them may so engage in any business (including through "non-competition" or "exclusivity" provisions), (B) would require the disposition of any material assets or line of business of the Seller or, after the Closing Date, the Buyer or (C) grants "most favored nation" status that, following the purchase of the Purchased Assets, would apply to the Buyer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) that (A) is an indenture, loan or credit Contract, loan note, mortgage Contract, letter of credit or other Contract representing, or any guarantee of, indebtedness of the Seller or (B) is a guarantee by the Seller of the indebtedness of any Person other than the Seller;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) that grants with respect to any Purchased Asset (A) rights of first refusal, rights of first negotiation or similar pre-emptive rights, or (B) puts, calls or similar rights, to any Person (other than the Seller);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) that was entered into to settle any material litigation and which imposes material ongoing obligations on the Seller;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) pursuant to which (A) the Seller grants to any third party any license, release, covenant not to sue or similar right with respect to material Intellectual Property or (B) the Seller receives a license, release, covenant not to sue or similar right with respect to any material Intellectual Property owned by a third party (other than generally commercially available software in object code form);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) that relates to the acquisition or disposition of any business or assets or the sale or supply of any services pursuant to which the Seller has any liability in excess of $50,000 individually or $100,000 in the aggregate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) that requires or is expected to require in the next year aggregate annual payments by or to the Seller in excess of $100,000;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) to which the Seller or any of its Subsidiaries is a party, or by which any of them are bound, the ultimate contracting party of which is a Governmental Entity (including any subcontract with a prime contractor or other subcontractor who is a party to any such contract);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) pursuant to which the Seller or any of its Subsidiaries acquired, holds or disposed of any interest (whether in fee, a leasehold, a concessions or otherwise) in real property, or any rights to explore, mine or otherwise extract minerals, ore, metals or other substances.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) any revocable or irrevocable power of attorney relating to the Purchased Assets or the Business granted to any person, firm or corporation for any purpose whatsoever; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) any Contract or option relating to the acquisition or sale of any of the Purchased Assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.18 <u>Securities Law Matters</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Seller acknowledges and understands that the Share Consideration has not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "<u>Securities Act</u>") or any applicable state securities laws and it is acquiring the Share Consideration under this Agreement under a private placement in reliance upon the exemption from the registration requirements of the Securities Act, provided by Section 4(a)(2) of the Securities Act and/or Rule 506(b) thereunder and similar exemptions under applicable state securities laws. In no event shall Seller be liable for any violations of the Securities Act arising or resulting from Buyer's reliance on the foregoing exemptions from the registration requirements for the Share Consideration, unless such violation arises directly from a misrepresentation of the Seller hereunder or in the Investor Certificate of an owner of the Seller.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each owner of the Seller that will be receiving any part of the Share Consideration will complete and deliver an Investor Certificate in the form attached hereto as <u>Appendix A</u> (an "<u>Investor Certificate</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.19 <u>Relationship with Affiliates</u>.**

Except as disclosed by Seller, neither Seller nor any Affiliates has, since the first date of the next to last completed fiscal year, had any interest in any property (whether real, personal or mixed and whether tangible or intangible) used in or pertaining to the Business. Neither Seller, nor any Shareholder nor any Affiliates of any of them owns, since the first date of the next to last completed fiscal year, has owned of record or as beneficial owner, an equity interest or any other financial or profit interest in any Person that has (a) had business dealings or a material financial interest in any transaction with Seller other than business dealings or transaction disclosed by Seller to the Buyer, each of which has been conducted in the ordinary course of business with Seller at substantially prevailing market prices and on substantially prevailing market terms or (b) engaged in competition with Seller with respect to any line of products or services of Seller ("<u>Competing Business</u>") in any market presently served by Seller, except for ownership of less than one percent of the outstanding capital stock of any Competing Business that is publicly traded on any recognized exchange or in the over-the-counter market. Except as disclosed by Seller to the Buyer, neither Seller nor any Shareholder nor any Affiliates of any of them is a party to any Contract with, or has any claim or right against, Seller.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.20 <u>Absence of Certain Changes</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Seller and its Subsidiaries have conducted their respective businesses in the ordinary course of such businesses consistent with past practices in all material respects;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) there has not been any change in the financial condition, properties, assets, liabilities, business or results of the Seller's and its Subsidiaries' operations or any circumstance, occurrence or development that individually or in the aggregate, has had or would reasonably be expected to result in a Seller Material Adverse Effect;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) there has not been any material change in any method of accounting or accounting practices by the Seller or any of its Subsidiaries, except as required by changes in GAAP; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) there has not been any material increase in the compensation payable or to become payable to any of the Seller's or its Subsidiaries' officers or employees (except for increases in the ordinary course of business and consistent with past practice).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.21 <u>Undisclosed Liabilities</u>.**

To Seller's Knowledge, Seller has no Liability except for Liabilities reflected or reserved against in the balance sheets comprising the Financial Statements and current liabilities incurred in the Ordinary Course of Business of Seller since the date of the most recent balance sheet comprising the Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.22 <u>Compliance with OFAC</u>.**

Neither the Seller nor, to the Knowledge of the Seller, any director, manager, officer, agent, employee or Affiliate of the Seller is a Person that is, or is owned or controlled by a Person that is, currently the subject or target of any sanctions administered or enforced by the U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S. Treasury Department ("<u>OFAC</u>") or the U.S. Department of State and including, without limitation, the designation as a "specially designated national" or "blocked person"), the United Nations Security Council, or other relevant sanctions authority (collectively, "<u>Sanction</u>"). No Seller has knowingly engaged in and is not now knowingly engaged in any dealings or transactions with any Person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any country or territory that is the subject or the target of Sanctions, including, without limitation, Cuba, Iran, North Korea, Sudan, and Syria.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.23 <u>No Further Representations or Warranties</u>**. Except as set forth expressly in this Agreement, Seller has not made any warranties or representations concerning the Business, the Purchased Assets, or any component of thereof, or any of the materials supplied to Buyer during its due diligence, or the accuracy or completeness of any statement or other matter previously disclosed to Buyer. EXCEPT AS SPECIFICALLY PROVIDED FOR IN THIS AGREEMENT, THERE ARE NO EXPRESS OR IMPLIED WARRANTIES GIVEN TO BUYER IN CONNECTIONWITH THE SALE OF THE BUSINESS OR PURCHASED ASSETS. SELLER DISCLAIMS ANY AND ALL WARRANTIES OF MERCHANTABILITY AND FITNESS THAT MAY BE DUE FROM SELLER TO BUYER. NOTWITHSTANDING ANYTHING TO THE CONTRARY SET FORTH IN THIS AGREEMENT, THIS SUBSECTION SHALL SURVIVE THE CLOSING.

**ARTICLE V**

**REPRESENTATIONS AND WARRANTIES OF THE BUYER**

The Buyer hereby represents and warrants to the Seller as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.1 <u>Organization; Good Standing</u>.**

The Buyer is a corporation duly organized, validly existing and in good standing under the Laws of State of Nevada.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.2 <u>Authority, Noncontravention; Consents</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Buyer has all requisite corporate power and authority to enter into this Agreement and each Related Document to which it is a party and to perform its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by the Buyer of this Agreement and each Related Document to which the Buyer is a party, and the performance by the Buyer of its obligations hereunder and thereunder, have been duly and validly authorized by all necessary corporate action on the part of the Buyer. This Agreement and each Related Document to which the Buyer is a party have been duly and validly executed and delivered by the Buyer and are the valid and binding obligations of the Buyer, enforceable against the Buyer in accordance with their terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Neither the execution and delivery by the Buyer of this Agreement and each Related Document to which the Buyer is a party nor the performance by the Buyer of its obligations hereunder and thereunder (i) materially conflicts with, or results in a material violation of, or causes a material breach or default (with or without notice or lapse of time, or both) under, or gives rise to a right of termination, amendment, cancellation or acceleration of any material obligation contained in or the loss of any material benefit under, any term, condition or provision of (y) the Buyer's Fundamental Documents or (z) any material Contract to which the Buyer is a party or by which its assets are bound, or (ii) violates any Laws applicable to the Buyer or any of its assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) No material (i) consent, (ii) approval, (iii) Order or authorization of, (iv) registration, declaration or filing with, or (v) notification to any Governmental Entity or any other third Person is required in connection with the execution and delivery by the Buyer of this Agreement or the Related Documents to which the Buyer is a party or the consummation by it of the transactions contemplated hereby or thereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.3 <u>Valid Issuance</u>.**

The shares of Share Consideration to be issued to Seller pursuant to the terms of this Agreement, when issued as provided in this Agreement, will be duly authorized and validly issued, fully paid and nonassessable, and will be free of restrictions on transfer other than restrictions under applicable securities Laws in the United States.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.4 <u>Brokers</u>.**

Neither the Buyer nor any of its officers, directors, equity owners or employees nor any other Person acting on its or their behalf has employed any broker or finder or incurred any Liability for any brokerage fees, commissions or finders' fees in connection with the transactions contemplated hereby. To the extent that the Buyer has incurred any Liability for any brokerage fees, commissions or finder's fees in connection with the transactions contemplated hereby, the Buyer will be solely responsible for the payment of such commission or fee.

**ARTICLE VI**

**CONVENANTS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.1 <u>Interim Operations</u>.**

The Seller covenants and agrees that, from the date of this Agreement until the Closing Date (unless the Buyer shall otherwise approve in writing, such approval not to be unreasonably withheld, conditioned or delayed) and except as expressly contemplated by this Agreement, as required by applicable Laws, the Seller shall conduct its business that is conducted with the Purchased Assets (the "**Target Business**") in the ordinary course in all material respects and, to the extent consistent therewith, shall use its reasonable best efforts to maintain the Target Business' existing relationships with Governmental Entities and material customers, suppliers, distributors, creditors, lessors, insurers, employees, unions, and other material business associates relating to the Target Business. Without limiting the generality of and in furtherance of the foregoing, from the date of this Agreement until the Closing Date, except (x) as otherwise expressly required by this Agreement, (y) as the Buyer may approve in writing (such approval not to be unreasonably withheld, conditioned or delayed) or (z) as set forth in the Seller Disclosure Schedules, the Seller will not with respect to the Target Business or the Purchased Assets:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) (A) merge or consolidate itself with any other Person; (B) restructure, reorganize or completely or partially liquidate the Target Business or the Purchased Assets; (C) acquire.(by merger, consolidation, acquisition of stock or assets or otherwise), directly or indirectly, securities or assets for the Target Business or relating to the Purchased Assets outside of the ordinary course of business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) make any loans, advances or capital contributions to or investments in any Person that conduct the Target Business or hold the Purchased Assets, other than trade credit and similar loans and advances made to employees, customers and suppliers in the ordinary course of business of the Target Business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) other than trade debt incurred in the ordinary course of business, of the Target Business incur any indebtedness for borrowed money or guarantee any such indebtedness of another Person;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) make or authorize any capital expenditure for the Target Business other than for capital expenditures that do not, in any calendar year, exceed $50,000;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) (A) other than in the ordinary course of business of the Target Business amend, modify, terminate or waive any material right under any Assigned Contract, or (B) enter into any contract that would be an Assigned Contract had it been entered into prior to this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) (A) make any material changes with respect to accounting policies or procedures, except as required by changes after the date hereof in GAAP, (B) change the Seller's fiscal year, or (C) make any material change in internal accounting controls or disclosure controls and procedures that could reasonably be expected to negatively affect the Seller;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) settle, propose to settle or compromise any action before a Governmental Entity relating to the Target Business or the Purchased Assets if such settlement, proposed settlement or compromise (A) with respect to the payment of monetary damages, involves the payment of monetary damages that exceed $100,000 in the aggregate (together with all other settlements or compromises after the date of this Agreement), net of any amounts covered by insurance that the Seller expects to be promptly paid by the applicable insurer, (B) imposes any material equitable or non-monetary relief, penalty or restriction on the Seller (or, after the Closing Date, the Buyer) with respect to the Target Business or the Purchased Assets, or (C) would reasonably be expected to affect the rights or defenses available to the Seller in any related or similar claims that, individually or in the aggregate, are material to the Target Business or the Purchased Asset, taken as a whole;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) make, change or rescind any material Tax elections, change or consent to any change in its material method of accounting for Tax purposes (except as required by applicable Law), amend any material Tax Returns, settle, compromise, concede or abandon any material Tax liability, claim or assessment, enter into any material closing agreement, waive or extend any statute of limitations with respect to material Taxes or obtain any material Tax ruling;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) transfer, sell, lease, license, mortgage, pledge, surrender, encumber, divest, cancel, abandon or allow to lapse or expire or otherwise dispose of any of the Purchased Assets, except (other than with respect to equity interests of any Subsidiary of the Seller relating to the Target Business) (A) in connection with goods or services provided in the ordinary course of business, (B) sales of obsolete assets, (C) for sales, leases, licenses or other dispositions of assets with a fair market value not in excess of $50,000 in the aggregate, or (D) pursuant to Contracts in effect prior to the date of this Agreement that have been disclosed to the Buyer prior to the date of this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) enter into any transaction or take any action that, if entered into prior to the date hereof, would be a Related Party Transaction relating to the Target Business or Purchased Assets, or amend, waive, modify or terminate any existing Related Party Transaction relating to the Target Business or Purchased Assets; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (k) agree, authorize or commit to do any of the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.2 <u>Due Diligence</u>.**

During the period from the date of this Agreement until the Closing Date, upon reasonable advance notice to the Seller, the Seller shall, and shall cause its representatives to, provide the Buyer and the Buyer's Representatives with reasonable access (including electronic access) to each of the Seller's properties, personnel, offices, books and records, Contracts, commitments, work papers and other documents and information relating to the Seller and the Purchased Assets and provide copies of such books and records, Contracts, commitments, work papers and other documents and information relating to the Seller or the Purchased Assets, in each case as the Buyer reasonably requests solely for the purposes of a due diligence review of the Purchased Assets and the representations and warranties of the Seller made in this Agreement; provided, however, that any such access shall be conducted at Buyer's sole cost and expense, at a reasonable time during the Seller's normal business hours, under the supervision of appropriate personnel of the Seller and in such a manner as not to unreasonably interfere with the normal operation of the business of the Seller, and shall be subject to the Seller's reasonable security measures and insurance requirements and shall not include invasive testing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.3 <u>Asset Verification</u>.**

Seller shall provide such tags or other information as necessary or reasonably requested for Buyer's auditors to verify the existence and location of all of Seller's tangible assets as well as to confirm ownership of all of Seller's intellectual property and intangible assets. The Parties reaffirm that the agreement will be for the purchase of all of Seller's assets, tangible and intangible, except the Excluded Assets and those assets, contracts, and agreements that are specifically excluded as elected by the Buyers, and such excluded assets and obligations shall remain the separate property and/or separate obligation of Seller. If required, the Seller hereby agrees to provide full access to its books and records related to the Assets in order for the Buyer to discharge its continuous disclosure obligations under applicable securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.4 <u>Removal of Encumbrances</u>.**

Seller will use its reasonable best efforts to settle, pay off or remove any Encumbrances on the Purchased Assets, if any, which will be paid off at Closing, prior to the Closing and provide the Buyer with such reasonable evidence thereof at least three (3) Business Days prior to Closing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.5 <u>Noncompete Within Area of Interest; Non-Solicitation</u>.**

The Seller and each owner of the Seller covenants and agrees that, for a period beginning on the Closing Date and continuing until the date that is three (3) years from the Closing Date (the "<u>Restricted Period</u>"), it will not, directly or indirectly through any Person, compete with Buyer in any manner within the State of Florida (the "<u>AOI</u>") or engage in any activity in the AOI, whether directly, indirectly, by agreement or otherwise through a third party, which would be adverse to Buyer and the Purchased Assets. The Seller and each owner of the Seller covenants and agrees that, for a period beginning on the Closing Date and continuing until the date that is three (3) years following the Closing Date, the Seller will not, nor will any owner of the Seller, directly or indirectly through any Person, (i) solicit, aid or induce, or attempt to solicit, aid or induce, any employee, representative, contractor or agent to leave such employment or retention, as applicable, of the Buyer or any of its Affiliates or, in the case of employees, to accept employment with or render services to or with any other Person unaffiliated with the Seller; or (ii) hire or retain any such employee, or take any action to assist or aid any other Person in identifying, hiring or soliciting any such employee, or otherwise interfere with the relationship between the Buyer and any employee, representative, contractor or agent (the "<u>Non-Solicitation</u>"). The Parties agree that the limitations set forth in this Section 6.5 are reasonable and necessary for the protection of the Buyer. If any covenant in this Section 6.5 is found to be unreasonable, arbitrary, against public policy, or otherwise not enforceable in accordance with its terms, then such covenant will be considered to be divisible with respect to scope, time, and geographic area, and such lesser scope, time, or geographic area, or all of them, as a court of competent jurisdiction may determine to be reasonable, not arbitrary, or not against public policy, will be effective, binding, and enforceable against the Seller and its Affiliates. The Parties covenant that they will not challenge the reasonableness or enforceability of any of the covenants set forth in this Section 6.5. The Parties acknowledge and affirm that a breach of this Section 6.5 cannot be adequately compensated in any Proceeding for damages at Law, and equitable relief would be necessary to protect the non-breaching Party from a violation hereof and from the harm that this Section is intended to prevent. Accordingly, the Parties agree that in the event of any actual or threatened breach of such provisions, the non-breaching Party will (in addition to any other remedies which they may have) be entitled to enforce it s rights and the breaching Party's obligations hereunder not only by a Proceeding or Proceedings for damages, but also by a Proceeding or Proceedings for specific performance, temporary or permanent injunctive relief or other equitable relief in order to enforce or prevent any violations (whether anticipatory, continuing or future) of the provisions hereof and recover attorneys' fees and costs for the same, and such relief may be granted without the necessity of proving actual damages or the inadequacy of money damages, or posting bond. In the event of a breach or violation by the Seller of any of the provisions hereof, the running of the Restricted Period (but not Seller's obligations hereunder) will be tolled with respect to the Seller during the continuance of any actual breach or violation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.6 <u>Transfer of Purchased Assets</u>.**

Post-Closing, the Seller shall cooperate with the Buyer to facilitate the efficient and expeditious transfer to the Buyer of the Purchased Assets.

**ARTICLE VII**

**CLOSING CONDITIONS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.1 <u>Conditions to Each Party's Obligations</u>**<u>.</u> The respective obligation of each Party to effect the sale and purchase under this Agreement is subject to the satisfaction or waiver at or prior to the Closing Date of each of the following conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>No Order</u>. No court or other Governmental Entity of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any applicable Law, (whether temporary, preliminary or permanent) that is in effect and restrains, enjoins or otherwise prohibits consummation of the transactions contemplated by this Agreement (collectively, an "**Order**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Schedules.</u> All Schedules appended to this Agreement shall be completed and agreed to by Buyer and Seller.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.2 <u>Conditions to Obligations of the Buyer.</u>** The obligations of the Buyer to effect the sale and purchase under the Transaction Documents are also subject to the satisfaction or waiver by the Buyer at or prior to the Closing Date of the following conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Representations and Warranties</u>. Each of the representations and warranties of the Seller shall be true and correct in all respects as of the date of this Agreement and as of the Closing Date as though made on and as of such date (except to the extent that any such representation and warranty expressly speaks as of another date, in which case such representation and warranty shall only be required to be so true and correct as of such other date), and the Buyer shall have received at the Closing a certificate signed on behalf of the Seller by an executive officer of the Seller to such effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Performance of Obligations of the Seller</u>. The Seller shall have performed and complied with, in all material respects, all obligations under this Agreement required to be performed or complied with by it at or prior to the Closing, and the Buyer shall have received a certificate signed on behalf of the Seller by an executive officer of the Seller to such effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Encumbrances</u>. The Purchased Assets shall have no Encumbrances except Permitted Liens.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Seller Deliverables</u>. The Seller will have delivered into pre-Closing all of the Seller Deliverables to the reasonable satisfaction of the Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Due Diligence</u>. The Buyer shall have completed its due diligence review of the Seller and the Purchased Assets to the reasonable satisfaction of the Buyer and the Buyer's auditors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.3 <u>Conditions to Obligation of the Seller</u>**. The obligation of the Seller to effect the sales and purchased of the Purchased Assets is also subject to the satisfaction or waiver by the Seller at or prior to the Closing Date of the following conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Representations and Warranties</u>. Each of the representations and warranties of the Buyer shall be true and correct as of the date of this Agreement and as of the Closing Date as though made on and as of such date, and the Seller shall have received at the Closing a certificate signed on behalf of the Buyer an executive officer of the Seller to such effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Performance of Obligations of the Buyer</u>. The Buyer shall have performed and complied with, in all material respects, all of their respective obligations under this Agreement required to be performed or complied with by them at or prior to the Closing Date, and the Seller shall have received a certificate signed on behalf of the Buyer by an executive officer of the Buyer to such effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Buyer Deliverables</u>. The Buyer will have delivered into pre-Closing all of the Buyer Deliverables to the reasonable satisfaction of the Seller.

**ARTICLE VIII**

**TERMINATION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.1 <u>Termination by Mutual Consent</u>**. This Agreement may be terminated at any time prior to the Closing Date by mutual written consent of the Seller and the Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.2 <u>Termination by Either the Buyer or the Seller</u>**. This Agreement may be terminated at any time prior to the Closing Date by either the Buyer or the Seller if:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the purchase of the Purchased Assets shall not have been consummated by **March 31, 2026** (the "**End Date**") ; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) any Order permanently restraining, enjoining or otherwise prohibiting consummation of the purchase of the Purchased Assets shall become final and non-appealable.

The right to terminate this Agreement pursuant to this <u>Section 8.2</u> shall not be available to any Party that has breached in any material respect its obligations under this Agreement in any manner that shall have proximately contributed to the occurrence of the failure of a condition to, or the occurrence of, the consummation of the transactions hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.3 <u>Termination by the Seller</u>**. This Agreement may be terminated by action of the board of directors of the Seller at any time prior to the Closing Date, upon written notice to the Buyer specifying the provision of this Agreement pursuant to which such termination is effective, if there has been a breach of any representation, warranty, covenant or agreement made by the Buyer in this Agreement, or any such representation and warranty shall have become untrue after the date of this Agreement, in each case such that Section 7.3(a) or 7.3(b) would not be satisfied and such breach or condition is not cured within 30 days after written notice thereof is given by the Seller to the Buyer (with the Closing Date, including the End Date, to be extended to allow Buyer the full 30 days to cure the alleged breach).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.4 <u>Termination by the Buyer</u>**. This Agreement may be terminated at any time prior to the Closing Date by action of the Buyer at any time prior to the Closing Date, upon written notice to the Seller specifying the provision of this Agreement pursuant to which such termination is effective, if:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) there has been a breach of any representation, warranty, covenant or agreement made by the Seller in this Agreement, or any such representation and warranty shall have become untrue after the date of this Agreement, such that <u>Section 7.2(a)</u> or <u>7.2(b)</u> would not be satisfied and such breach or condition is not cured within 30 days after written notice thereof is given by the Buyer to the Seller(with the Closing Date, including the End Date, to be extended to allow Seller the full 30 days to cure the alleged breach); or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Buyer's due diligence review is not completed to the reasonable satisfaction of the Buyer by the third Business Day prior to the End Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.5 <u>Effect of Termination and Abandonment.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Except as otherwise provided in this <u>Section 8.5</u>, in the event of termination of this Agreement pursuant to this <u>Article VIII.</u>, this Agreement shall become void and of no effect with no liability to any Person on the part of any Party (or of any of its Representatives or Affiliates); <u>provided</u>, <u>however</u>, and notwithstanding anything in the foregoing to the contrary, that (i) no such termination shall relieve any Party of any liability or damages to the other Party resulting from fraud or any uncured breach of this Agreement, and (ii) the provisions set forth in <u>Article IX</u> and <u>Section 10.5</u> shall survive termination of this Agreement.

**ARTICLE IX**

**INDEMNIFICATION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.1 <u>Indemnification Generally; Etc</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) The Seller Indemnifying Persons, severally, shall indemnify, defend, and hold harmless the Buyer Indemnified Persons from, against and in respect of any and all claims, Liabilities, losses (whether or not involving a third party claim), costs, expenses, penalties, fines and judgments (at equity or at law), and damages whenever arising or incurred (including amounts paid in settlement, costs of investigation and reasonable attorneys' fees and expenses) arising out of, relating to or in connection with:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the untruth, inaccuracy or breach of any representation or warranty of the Seller
contained in this Agreement or in any Related Document to which the Seller is a party (or any facts or circumstances constituting any
such untruth, inaccuracy or breach);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the breach of any agreement or covenant of the Seller contained in this Agreement
or in any Related Document to which the Seller is a party;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the Excluded Liabilities; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) any sales, value added, excise or other Taxes payable in connection with sales
of the Products and the operation of the Business on or prior to the Closing Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) Buyer shall indemnify, defend, and hold harmless the Seller Indemnified Persons from, against and in respect of any and all claims, Liabilities, losses (whether or not involving a third party claim), costs, expenses, penalties, fines and judgments (at equity or at law), and damages whenever arising or incurred (including amounts paid in settlement, costs of investigation and reasonable attorneys' fees and expenses) (arising out of, relating to or in connection with:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the untruth, inaccuracy or breach of any representation or warranty of the Buyer
in this Agreement, or in any Related Document to which the Buyer is a party (or any facts or circumstances constituting any such untruth,
inaccuracy or breach);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the breach of any agreement or covenant of the Buyer contained in this Agreement
or in any Related Document to which the Buyer is a party;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the Assumed Liabilities; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) matters arising out of or relating to the Purchased Assets after Closing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.2 <u>Assertion of Claims</u>.**

All claims under <u>Section 9.1</u> must be brought within a period of time after the Closing Date equal to the maximum statute of limitations to which the Parties can contractually agree under applicable law with respect to any Fundamental Representation or Fraud, and within twenty-four (24) months after the Closing Date with respect to any Non-Fundamental Representation. The "<u>Fundamental Representations</u>" are those representations contained in <u>Sections 4.1</u>, (*Organization; Good Standing; Qualification and Power*), <u>4.3</u> (*Title to Purchased Assets*)*,* <u>4.8</u> (*Taxes*), <u>4.11</u> (*Financial Information*), <u>4.12</u> (*Brokers*), <u>4.13</u> (*Environmental Matters*), <u>4.14</u> (*Bankruptcy Etc.*), <u>4.18</u> (*Securities Law Matters*), <u>4.19</u> (*Relationships with Affiliates*), <u>5.1</u> (*Organization; Good Standing*), <u>5.4</u> (*Brokers*). "<u>Non-Fundamental Representations</u>" are all representations that are not Fundamental Representations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.3 <u>Limitations on Indemnification</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a)Indemnity Limitations for the Seller Indemnifying Persons. Except in the case of Fraud:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the Buyer Indemnified Persons shall not have the right to be indemnified pursuant
to <u>Section 9.1(a)(i)</u> unless and until the Buyer Indemnified Persons (or any of them) shall have incurred on a cumulative basis
aggregate Losses in an amount exceeding $5,000.00 (the " <u>Deductible</u> "),
in which event the Buyer Indemnified Persons' right to be indemnified shall apply only to the extent such Losses exceed the Deductible;
and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the sum of all Losses pursuant to which indemnification is payable by the Seller Indemnify
Persons pursuant to <u>Section 9.1(a)</u> shall not exceed $900,000.00 (the " <u>Cap</u> ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Indemnity Limitations for the Buyer Indemnifying Persons. Except in the case of Fraud:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the Seller Indemnified Persons shall not have the right to be indemnified pursuant to <u>Section 9.1(b)(i)</u> unless and until the Seller Indemnified Persons (or any of them) shall have incurred on a cumulative basis aggregate Losses
in an amount exceeding the Deductible, in which event the Seller Indemnified Persons' right to be indemnified shall apply only
to the extent such Losses exceed the Deductible; and

(ii) the sum of all Losses pursuant to which indemnification is payable by the Buyer Indemnifying Persons pursuant
to <u>Section 9.1(b)</u> shall not exceed the Cap.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (c) <u>Section 8(a)</u> and <u>8(b)</u> will not apply to any claim for indemnification if the representation and warrant to which the claim related is a Fundamental Representation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (d) If a Party would have a claim for indemnification under this <u>Article VII</u> if the representation and warranty to which the claim relates did not include a materiality qualifier and the aggregate amount of all such claims exceeds the Deductible, then the Indemnified Person shall be entitled to indemnification for the amount of such claims in excess of the Deductible in the aggregate notwithstanding the materiality qualification in the relevant provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>DAMAGES LIMITATION</u>. IN NO EVENT SHALL ANY PARTY TO THIS AGREEMENT BE LIABLE TO ANY OTHER PARTY TO THIS AGREEMENT, UNDER THIS AGREEMENT OR OTHERWISE IN CONNECTION WITH THE SUBJECT MATTER OF THIS AGREEMENT, FOR CONSEQUENTIAL, INDIRECT, INCIDENTAL, PUNITIVE OR SPECIAL DAMAGES OR LOST PROFITS, DIMINUTION IN VALUE OF THE BUSINESS OR THE PURCHASED ASSETS, MULTIPLIERS OF DIRECT DAMAGES OR DAMAGE TO REPUTATION OR GOODWILL, <u>EXCEPT</u>, IN EACH CASE, (i) IN THE EVENT OF ACTUAL FRAUD AND (ii) TO THE EXTENT THAT AN INDEMNIFIED PERSON IS REQUIRED TO PAY SUCH DAMAGES OR OTHER ITEMS TO A THIRD PERSON IN CONNECTION WITH A MATTER FOR WHICH SUCH INDEMNIFIED PERSON IS ENTITLED TO INDEMNIFICATION UNDER THIS <u>ARTICLE IX</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.4 <u>Notice and Defense of Third Person Claims</u>.**

The obligations and liabilities of an Indemnifying Person with respect to Losses resulting from the assertion of liability by third Persons (each, a "<u>Third Person Claim</u>") shall be subject to the following terms and conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) An Indemnified Person shall promptly give written notice to the Indemnifying Persons of any Third Person Claim that might give rise to any Losses by the Indemnified Persons, stating the nature and basis of such Third Person Claim, and the amount thereof to the extent known; <u>provided</u>, <u>however</u>, that no delay on the part of the Indemnified Persons in notifying any Indemnifying Persons shall relieve the Indemnifying Persons from any liability or obligation hereunder unless (and then solely to the extent that) the Indemnifying Person is prejudiced by the delay. Such notice shall be accompanied by copies of all relevant documentation with respect to such Third Person Claim, including any summons, complaint or other pleading which may have been served, any written demand or any other related document or instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If the Indemnifying Persons acknowledge in a writing delivered to the Indemnified Persons that the Indemnifying Persons shall be obligated under the terms of their indemnification obligations hereunder in connection with such Third Person Claim, then the Indemnifying Persons shall have the right to assume the defense of any Third Person Claim at their own expense and by their own counsel, which counsel shall be reasonably satisfactory to the Indemnified Persons.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If the Indemnifying Persons shall assume the defense of a Third Person Claim, the Indemnifying Persons shall not be responsible for any legal or other defense costs subsequently incurred by the Indemnified Persons in connection with the defense thereof and the Indemnifying Persons shall nevertheless be entitled to participate in such defense with their own counsel and at their own expense. If the Indemnifying Persons do not exercise their right to assume the defense of a Third Person Claim by giving the written acknowledgement referred to in <u>Section 8.4(b)</u>, the Indemnified Persons may defend the Third Person Claim and seek indemnity from the Indemnifying Persons for Litigation Expenses incurred in connection with such defense.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) If the Indemnifying Persons exercise their right to assume the defense of a Third Person Claim, they shall not make any settlement of any claims without the written consent of the Indemnified Persons, which consent shall not be unreasonably withheld; <u>provided</u>, <u>however</u>, that if the Indemnifying Persons propose the settlement of any claim that is capable of settlement by the payment of money only and the Indemnified Persons do not consent thereto within twenty (20) days after the receipt of written notice thereof, any Losses incurred by the Indemnified Persons in excess of such proposed settlement shall be at the sole expense of the Indemnified Persons.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.5 <u>Survival of Representations and Warranties and Covenants</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The representations and warranties of the Seller contained in this Agreement or in any certificate delivered in connection with this Agreement shall survive the Closing Date and shall terminate on the second anniversary of the Closing Date, <u>provided</u> that the Fundamental Representations of the Seller shall survive the Closing until the expiration of the applicable statute of limitations. The covenants and other agreements of the Seller in this Agreement that are explicitly provided to survive Closing shall survive the Closing Date unless and until they terminate in accordance with the terms of such provisions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The representations and warranties of the Buyer contained in this Agreement or in any certificate delivered in connection with this Agreement shall survive the Closing Date and shall terminate on the second anniversary of the Closing Date, <u>provided</u> that the representations and warranties of the Buyer contained in <u>Section 6.4</u> shall survive the Closing until the expiration of the applicable statute of limitations. The covenants and other agreements of the Buyer contained in this Agreement that are explicitly provided to survive Closing shall survive the Closing Date unless and until they terminate in accordance with the terms of such provisions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) For convenience of reference, the date upon which any representation, warranty, covenant or agreement contained herein shall terminate, if any, is referred to herein as the "<u>Survival Date</u>".

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.6 <u>Payment of Claims, Holdbacks; Right of Setoff</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Except for settlement through cancellation of the Share Consideration that is part of the Share Holdback, , payment of Indemnifiable Claims shall be effected by wire transfer in federal funds or other immediately available funds from the Indemnifying Party to an account designated in writing by the Indemnified Party within two (2) Business Days after such Indemnifiable Claims have been finally determined. To the extent permitted by applicable law, any indemnification payments made under this Article 9 shall be characterized for all tax and other purposes as an adjustment to the Purchase Price, as applicable. In order cover the payment of Indemnifiable Claims to the Buyer from the Seller, the Buyer will withhold 20% of the Share Consideration (the "**Share Holdback**") deliverable to the Seller for a period of 12 months following the Closing. Upon final determination of an Indemnifiable Claim payable to Buyer from Seller, the Buyer shall remove and cancel from the Share Holdback such number of Common Shares as is equal to the dollar value of the Indemnifiable Claim divided by the agreed upon per share value of the Common Shares set forth in Section 2.1 for the Purchase Price. Following settlement of any Indemnifiable Claims occurring during the 12 months following the Closing, the Buyer will release and deliver all remaining Share Holdback to the Seller by delivery of a share certificate or DRS advice statement registered in the name of the Seller within 2 Business Days of the end of the 12-month period. In relation to any Indemnifiable Claim finally determined and payable by the Buyer to the Seller, the Buyer shall have the option, in the Buyer's sole discretion, to settle such Indemnifiable Claim through the issuance of Common Shares at the Per Share Value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.7 <u>Exclusive Remedy</u>.**

Except in the case of Fraud, the rights and remedies provided for in this <u>Article IX</u> shall be the sole and exclusive rights and remedies of the Indemnified Persons with respect to any matter relating to this Agreement, or otherwise relating to the transactions contemplated hereby or arising under or in connection with this Agreement. Neither party shall avoid the limitations on liability set forth in this <u>Article IX</u> by seeking monetary damages for tort or pursuant to any other theory of liability other than a claim for indemnification under this <u>Article IX</u>. To the extent that the rights and remedies provided for in this <u>Article IX</u> are determined by a court of competent jurisdiction not to be exclusive under circumstances in which no exception to exclusivity contained in this <u>Section 9.7</u> applies, the provisions of <u>Sections 9.3</u> and <u>9.5</u> shall apply to any remedy available to the Parties.

**ARTICLE X**

**MISCELLANEOUS PROVISIONS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.1 <u>No Third Party Beneficiaries</u>.**

This Agreement shall not confer any rights or remedies upon any Person, other than the Parties and their respective successors and permitted assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.2 <u>Entire Agreement</u>.**

This Agreement and the Related Documents (including the schedules and the exhibits attached hereto) contain all of the agreements between the parties hereto with respect to the transactions contemplated hereby and supersede all prior agreements or understandings, whether written or oral, between the Seller and the Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.3 <u>Successors and Assigns</u>.**

All the terms and provisions of this Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns. Notwithstanding anything herein to the contrary, no party shall assign this Agreement without the prior written consent of the other Parties, provided that the Buyer may assign this Agreement to any of its Affiliates or a successor in interest to substantially all of its business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.4 <u>Amendment; Waiver</u>.**

This Agreement shall not be altered or otherwise amended except pursuant to an instrument in writing signed by each Party. No obligation of the Seller to the Buyer shall be waived except by means of a writing signed by the Buyer, and no obligation of the Buyer to the Seller shall be waived except by means of a writing signed by the Seller. No waiver by any Party of any default, misrepresentation, or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.5 <u>Fees and Expenses</u>.**

Each Party hereto shall bear its own fees and expenses incurred in connection with this Agreement and the Related Documents and the transactions contemplated hereby and thereby, including the legal, accounting and due diligence fees, costs and expenses incurred by such Party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.6 <u>Notices</u>.**

All notices, amendments, waivers, or other communications pursuant to this Agreement shall be in writing and shall be deemed to be sufficient if delivered personally, faxed, sent by e-mail, sent by nationally-recognized overnight courier or mailed by registered or certified mail (return receipt requested), postage prepaid, to the parties at the following addresses (or at such other address for a party as shall be specified by like notice):

To Buyer: Standard Dental Labs Inc.

Suite 308

424 E Central Blvd.

Orlando, FL 32801

Attention: James D. Brooks

Email: james.brooks@standarddentallabs.com

To Seller: BRLIT DENTAL LABORATORY, INC.

4232 MCINTOSH LANE

SARASOTA, FL 34232

Attention: EMIL BRLIT

Email: brlitdl@verizon.net

With a copy to: Syprett Meshad, P.A.

1900 Ringling Blvd.

Sarasota, FL 34236

Email: bsorrell@smrl.com

All such notices and other communications shall be deemed to have been delivered and received (i) in the case of personal delivery or delivery by e-mail, on the date of such delivery if delivered during business hours on a Business Day or, if not delivered during business hours on a Business Day, the first Business Day thereafter, (ii) in the case of delivery by nationally-recognized overnight courier, on the Business Day delivered, and (iii) in the case of mailing, on the fifth Business Day following such mailing. A copy of any notice or other communication sent by e-mail shall also be sent on the same day by registered or certified mail (return receipt requested) or by nationally-recognized overnight courier.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.7 <u>Governing Law; Arbitration.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Governing Law</u>. To the extent not prohibited by state law all questions concerning the construction, interpretation and validity of this Agreement and all claims or causes of action (whether in contract or tort) that may be based upon, arise out of or relate to this Agreement or the negotiation, execution or performance of this Agreement shall be governed by and construed and enforced in accordance with the domestic Laws of the State of Nevada, without giving effect to any choice or conflict of Law provision or rule, whether in the State of Nevada or any other jurisdiction, that would cause the Laws of any jurisdiction other than the State of Nevada to apply. In furtherance of the foregoing, the internal Law of the State of Nevada shall control the interpretation and construction of this Agreement, even if under the State of Nevada's choice of Law or conflict of Law analysis, the substantive Law of some other jurisdiction would ordinarily or necessarily apply.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Arbitration</u>. Except to the extent prohibited by law, any dispute or controversy or claim between Seller and Buyer arising out of or relating to this Agreement, or the breach thereof, shall be submitted to arbitration in accordance with the commercial rules of the American Arbitration Association. The site of the arbitration shall be Florida. The arbitration shall be conducted in accordance with the Rules of the Commercial Arbitration Association prevailing at the time the demand for arbitration is made hereunder. Judgment upon any award rendered by the arbitrator(s) may be entered in any court of competent jurisdiction and shall be binding and final. The costs of the arbitration, including administrative and arbitrator's fees, shall be fully paid by the non-prevailing party. Notwithstanding the foregoing, the parties shall bear the expense of their own attorneys' fees in accordance with this section.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.8 <u>Interpretation; Construction.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) "<u>Agreement</u>" means this agreement together with all schedules and exhibits hereto, as the same may from time to time be amended, modified, supplemented or restated in accordance with the terms hereof. "<u>Knowledge</u>" of any Person means the actual knowledge of such Person. When used in the case of the Seller, the term "<u>Knowledge</u>" shall mean the actual conscious knowledge, without the duty of inquiry or investigation, and not the constructive, implied, or imputed knowledge, of Emil Brlit. The use in this Agreement of the term "<u>including</u>" or "<u>include</u>" means "<u>including, without limitation</u>" or "<u>include, without limitation</u>." The words "<u>herein</u>", "<u>hereof</u>", "<u>hereunder</u>", "<u>hereby</u>", "<u>hereto</u>", "<u>hereinafter</u>", and other words of similar import refer to this Agreement as a whole, including the schedules and exhibits, as the same may from time to time be amended, modified, supplemented or restated, and not to any particular article, section, subsection, paragraph, subparagraph or clause contained in this Agreement. All references to articles, sections, subsections, clauses, paragraphs, schedules and exhibits mean such provisions of this Agreement and the schedules and exhibits attached to this Agreement, except where otherwise stated. The title of and the article, section and paragraph headings in this Agreement are for convenience of reference only and shall not govern or affect the interpretation of any of the terms or provisions of this Agreement. The use herein of the masculine, feminine or neuter forms shall also denote the other forms, as in each case the context may require.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Where specific language is used to clarify by example a general statement contained herein, such specific language shall not be deemed to modify, limit or restrict in any manner the construction of the general statement to which it relates. The language used in this Agreement has been chosen by the parties to express their mutual intent, and no rule of strict construction shall be applied against any party. Accounting terms used but not otherwise defined herein shall have the meanings given to them under GAAP. Unless expressly provided otherwise, the measure of a period of one month or year for purposes of this Agreement shall be that date of the following month or year corresponding to the starting date, provided that if no corresponding date exists, the measure shall be that date of the following month or year corresponding to the next day following the starting date. For example, one month following February 18 is March 18, and one month following March 31 is May 1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.9 <u>Incorporation of Exhibits.</u>**

The Exhibits and Annexes identified in this Agreement are incorporated herein by reference and made a part hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.10 <u>Independence of Covenants and Representations and Warranties.</u>**

All covenants hereunder shall be given independent effect so that if a certain action or condition constitutes a default under a certain covenant, the fact that such action or condition is permitted by another covenant shall not affect the occurrence of such default, unless expressly permitted under an exception to such initial covenant. In addition, all representations and warranties hereunder shall be given independent effect so that if a particular representation or warranty proves to be incorrect or is breached, the fact that another representation or warranty concerning the same or similar subject matter is correct or is not breached shall not affect the incorrectness of or a breach of a representation and warranty hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.11 <u>Counterparts; Electronic Signatures</u>**

This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Electronic counterpart signatures to this Agreement shall be deemed to be original and shall be acceptable and binding.

EXPIRATION OF OFFER: Buyer's offer is open for the Seller's acceptance ONLY UNTIL Dated (MM/DD/YYYY) at . AM PM. Time zone

SELLER'S RESPONSE: (Check one only).

☐ COUNTER OFFER: Seller accepts the terms of this Agreement subject to the attached COUNTER OFFER #1 dated:

☐ REJECTION: Seller hereby informs Buyer the offer presented herein is NOT accepted.

Seller's rejection signature(s):

☐ ACCEPTANCE: I/We the Seller(s) accept this Asset Purchase Agreement in its entirety and agree to sell the assets of the named Business in accordance with all the terms and conditions stated herein without exception.

[*Signature Page Follows*]

WITNESS WHEREOF, each of the undersigned has executed this Agreement as of the date first written above.

**THE BUYER**

**STANDARD DENTAL LABS, INC.**

---

| | | |
|:---|:---|:---|
| By: | /s/ James D. Brooks | **Name: James D. Brooks** |

---

**Title: CEO, President**

**THE SELLER**

BRLIT DENTAL LABORATORY, INC.

---

| | | |
|:---|:---|:---|
| By: | /s/ Emil Brlit | Name: EMIL BRLIT |

---

Title: President

---

| | | |
|:---|:---|:---|
| By: | /s/ Elena Brlit | Name: ELENA BRLIT |

---

Title: Treasurer

---

| | |
|:---|:---|
| By: | /s/ David R Damschroder |

---

Name: DAVID R DAMSCHRODER

Title: Vice President

---

| | |
|:---|:---|
| By: | /s/ Elizabeth Damschroder |

---

Name: ELIZABETH DAMSCHRODER

Title: Limited Partner

**ANNEX I**

**CERTAIN DEFINITIONS**

"<u>Affiliate</u>" means, with respect to any Person (i) a director, officer or 5% or greater shareholder of such Person, (ii) a spouse, parent, sibling or descendant of such Person (or spouse, parent, sibling or descendant of any director or executive officer of such Person), and (iii) any other Person that, directly or indirectly through one or more intermediaries, Controls, or is Controlled by, or is under common Control with, such Person.

"<u>Business</u>" means the business of the Seller, as it exists now or may exist in the future.

"<u>Business Day</u>" means any day that is not a Saturday, Sunday or a day on which banking institutions in New York, New York are not required to be open.

"<u>Code</u>" means the Internal Revenue Code of 1986, as amended.

"<u>Contract</u>" means any loan or credit agreement, note, bond, mortgage, indenture, lease, sublease, purchase order or other agreement, commitment, instrument, permit, concession, franchise or license.

"<u>Control</u>" means, with respect to any Person, the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

"<u>Employee Benefit Plan</u>" means (a) all "employee benefit plans" (within the meaning of Section 3(3) of ERISA) and (b) all other compensation or employee benefit plans, programs, policies, agreements or other arrangements, whether or not subject to ERISA, including, cash, equity-based, incentive, bonus, employment, individual consulting, retention, change of control, health, medical, dental, disability, accident, life insurance, vacation, relocation, loan, fringe benefit, severance, retirement, supplemental retirement, profit sharing, pension, deferred compensation, savings, or termination, in each case of <u>clauses (a)</u> and <u>(b)</u> that are sponsored, maintained, contributed to or required to be contributed to by the relevant party or any of its subsidiaries, or with respect to which the relevant party or any of its subsidiaries has any current, potential, or contingent liability.

"<u>Encumbrances</u>" means any security interests, mortgages, deeds of trust, liens, pledges, charges, claims, easements, reservations, restrictions, clouds, equities, rights of way, options, rights of first refusal, grants of power to confess judgment, conditional sales and title retention agreements (including any lease in the nature thereof) and all other encumbrances, whether or not relating to the extension of credit or the borrowing of money.

"<u>Environmental, Health and Safety Laws</u>" means all Laws, Permits and Contracts with Governmental Entities relating to or addressing pollution or protection of the environment or natural resources, releases of Hazardous Materials, public health and safety or employee health and safety, including the Solid Waste Disposal Act, as amended, 42 U.S.C. §6901, <u>et seq</u>., the Clean Air Act, as amended, 42 U.S.C. §7401 <u>et seq</u>., the Federal Water Pollution Control Act, as amended, 33 U.S.C. §1251 <u>et seq</u>., the Emergency Planning and Community Right-to-Know Act, as amended, 42 U.S.C. §11001 <u>et seq</u>., the Comprehensive Environmental Response, Compensation, and Liability Act, as amended, 42 U.S.C. §9601 <u>et seq</u>., the Hazardous Materials Transportation Uniform Safety Act, as amended, 49 U.S.C. §1804 <u>et seq</u>., the Occupational Safety and Health Act of 1970, as amended, the regulations promulgated thereunder, and any similar Laws and other requirements having the force or effect of Law, and all Orders issued or promulgated thereunder, and all related common law theories.

"<u>Fraud</u>" means any material misrepresentation made with the intention of misleading the Party alleging any breach of a representation or warranty.

"<u>Fundamental Documents</u>" means the documents by which any Person (other than an individual) establishes its legal existence or which govern its internal affairs. For example, the "Fundamental Documents" of a corporation are its certificate of incorporation and by-laws.

"<u>GAAP</u>" means United States generally accepted accounting principles as consistently applied by the Seller.

"<u>Governmental Entity</u>" means any federal, state, local, foreign, political subdivision, court, administrative agency, commission or department or other Governmental Entity or instrumentality.

"<u>Hazardous Materials</u>" means any hazardous or toxic chemicals, materials or substances, pollutants, contaminants or crude oil or any fraction thereof (including as such terms are defined under any Environmental, Health and Safety Law).

"<u>Indemnified Persons</u>" means and includes the Seller Indemnified Persons or the Buyer Indemnified Persons, as the case may be.

"<u>Indemnifying Persons</u>" means and includes the Seller Indemnifying Persons or the Buyer Indemnifying Persons, as the case may be.

"<u>Intellectual Property</u>" means the Intellectual Property Rights of the Seller.

"<u>Intellectual Property Rights</u>" means all intellectual property rights including all Patents, Trademarks, Trade Names, domain names, websites, internet addresses and applications for any of the foregoing, copyrights, copyright rights, manufacturing and other know-how, trade secrets, proprietary processes, formulae and information, computer software, confidential information, franchises, licenses, inventions, marketing materials and other intellectual property, and all documentation and media constituting, describing or relating to the foregoing, including software, manuals, memoranda and records of a Person.

"<u>Inventory</u>" means inventory, including inventories of raw materials, work in process, and finished goods.

"<u>Law</u>" means any law, statute, treaty, rule, directive, regulation, guideline or Order of any Governmental Entity.

"<u>Liability</u>" means any liability or obligation, whether known or unknown, asserted or unasserted, absolute or contingent, accrued or unaccrued, liquidated or unliquidated and whether due or to become due, regardless of when asserted.

"<u>Litigation Expense</u>" means any expenses incurred in connection with investigating, defending or asserting any claim, legal or administrative action, suit or Proceeding incident to any matter indemnified against under <u>Article VIII</u>, including court filing fees, court costs, arbitration fees or costs, witness fees and fees and disbursements of legal counsel, investigators, expert witnesses, accountants and other professionals.

"<u>Losses</u>" means any and all losses, claims, shortages, damages, Liabilities, expenses (including reasonable attorneys' and accountants' and other professionals' fees and Litigation Expenses), assessments, Tax deficiencies, and Taxes (including interest or penalties thereon) arising from or in connection with any such matter that is the subject of indemnification under <u>Article VIII</u> net of any amounts recovered by the Indemnified Persons under insurance policies with respect to such Loss.

"<u>Material Adverse Effect</u>"' means any event, occurrence, fact, condition or change that is, or could reasonably be expected to become, individually or in the aggregate, materially adverse to (a) the Business, results of operations, prospects, condition (financial or otherwise) or assets of Seller, or (b) the ability of Seller to consummate the transactions contemplated hereby on a timely basis.

"<u>Orders</u>" means judgments, writs, decrees, compliance agreements, injunctions or orders of any Governmental Entity or arbitrator.

"<u>Patents</u>" means all pending, abandoned, expires, completed and issued U.S. and foreign patents and applications therefor, including all reissues, re-examinations, divisions, continuations, continuations-in-part and extensions thereof, foreign equivalents thereto and provisional and non-provisional applications, including Patent Cooperation Treaty (PCT) and regional patent applications.

"<u>Payoff Letter</u>" means a written document provided by a lender or creditor that confirms the outstanding amount owed on a loan or debt as of a specific date, including principal, interest, and any applicable fees, and outlines the terms for fully satisfying the obligation.

"<u>Permits</u>" means all permits, licenses, authorizations, registrations, franchises, approvals, certificates, variances and similar rights obtained, or required to be obtained, from Governmental Entities.

"<u>Person</u>" shall be construed broadly and shall include an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization or another entity including a Governmental Entity.

"<u>Proceedings</u>" means actions, suits, claims, investigations or legal or administrative or arbitration proceedings.

"<u>Products</u>" means all goods and services produced, distributed, sold, offered or provided by the Seller.

"<u>Buyer Indemnified Persons</u>" means the Buyer, its Affiliates, successors and assigns, and the shareholders, directors, officers, managers, members, partners, trustees, subsidiaries, employees, contractors, subcontractors, attorneys, intermediaries, brokers or other agents, or representatives of the foregoing.

"<u>Buyer Indemnifying Persons</u>" means the Buyer and its successors and assigns.

"<u>Buyer Losses</u>" means any and all Losses sustained, suffered or incurred by any of the Buyer Indemnified Persons.

"<u>Representatives</u>" means officers, directors, employees, agents, attorneys, accountants and financial advisors of the Buyer or the Seller, as the case may be.

"<u>Seller Indemnified Persons</u>" means the Seller and its Affiliates, successors and assigns and the officers and directors of each of the foregoing.

"<u>Seller Indemnifying Persons</u>" means the Seller and its Affiliates, including the owners of the Seller, and their successors and assigns.

"<u>Seller Losses</u>" means any and all Losses sustained, suffered or incurred by any Seller Indemnified Person.

"<u>Shareholder</u>" means any individual or entity holding shares or membership units of a company or corporation.

"<u>Share Consideration</u>" means the Buyer's Common Shares.

"<u>Tax</u>" or "<u>Taxes</u>" means, with respect to any Person, (i) all income taxes (including any tax on or based upon net income, gross income, income as specially defined, earnings, profits or selected items of income, earnings or profits) and all gross receipts, sales, use, ad valorem, transfer, franchise, license, withholding, payroll, employment, excise, environmental (including taxes under Code Section 59A), social security, severance, stamp, occupation, premium, property or windfall profits taxes, alternative or add-on minimum taxes, customs duties and other taxes, fees, assessments or charges of any kind whatsoever, together with all interest and penalties, additions to tax and other additional amounts imposed by any Taxing Authority (domestic or foreign) on such Person (if any) and (ii) any liability for the payment of any amount of the type described in clause (i) above as a result of (A) being a "<u>transferee</u>" (within the meaning of Section 6901 of the Code or any other applicable Law) of another Person, (B) being a member of an affiliated, combined or consolidated group or (C) a contractual arrangement or otherwise.

"<u>Tax Return</u>" means any return, declaration, report, claim for refund, or information return or statement relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.

"<u>Taxing Authority</u>" means any Governmental Entity that has the authority to determine the amount of or collect any Taxes.

"<u>Trademarks</u>" means all pending, expired, abandoned, registered, unregistered, and common law U.S. and foreign trademark applications and trademarks, service mark applications and service marks, designs, logos, and trade dress, including the goodwill related to the foregoing, and all federal and state registrations thereof.

"<u>Trade Names</u>" means (i) names, (ii) brand names, (iii) business names and (iv) logos and all other names and slogans.

"<u>Trading Price</u>" means (i) as to the Share Consideration, the five (5) day volume weighted average trading price for shares of Share Consideration for the five (5) Business Day period immediately preceding the Closing Date (the "<u>Closing Trading Price</u>");

**SCHEDULE 1.1(a)**

**PURCHASED ASSETS**

**[List Purchased Assets]**

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**1** | &nbsp;&nbsp;Cyclone Dust Collector x 3 |
| &nbsp;&nbsp;&nbsp;**2** | &nbsp;&nbsp;Voyager Dust Collector x 8 |
| &nbsp;&nbsp;&nbsp;**3** | &nbsp;&nbsp;Ray Forest Model Trimmer x 2 |
| &nbsp;&nbsp;&nbsp;**4** | &nbsp;&nbsp;Whip Mix Combination Unit x 3 |
| &nbsp;&nbsp;&nbsp;**5** | &nbsp;&nbsp;Nobilium Duplication Material Melting |
| &nbsp;&nbsp;&nbsp;**6** | &nbsp;&nbsp;Denture Hydraulic Press |
| &nbsp;&nbsp;&nbsp;**7** | &nbsp;&nbsp;Injector Dentsply success |
| &nbsp;&nbsp;&nbsp;**8** | &nbsp;&nbsp;Steemer Grobet usa |
| &nbsp;&nbsp;&nbsp;**9** | &nbsp;&nbsp;Index System Mark 2 x 3 |
| &nbsp;&nbsp;&nbsp;**10** | &nbsp;&nbsp;Comeo Microblaster x2 |
| &nbsp;&nbsp;&nbsp;**11** | &nbsp;&nbsp;Jelrus Temp Marter Furnace |
| &nbsp;&nbsp;&nbsp;**12** | &nbsp;&nbsp;DLS Furnace |
| &nbsp;&nbsp;&nbsp;**13** | &nbsp;&nbsp;Work Benches -14 Dental Techncians |
| &nbsp;&nbsp;&nbsp;**14** | &nbsp;&nbsp;intentionally deleted |
| &nbsp;&nbsp;&nbsp;**15** | &nbsp;&nbsp;Style Pocelain |
| &nbsp;&nbsp;&nbsp;**16** | &nbsp;&nbsp;Zircornia Pucks |
| &nbsp;&nbsp;&nbsp;**17** | &nbsp;&nbsp;Denture Teeth |
| &nbsp;&nbsp;&nbsp;**18** | &nbsp;&nbsp;TCS Melting Unit Furnace |
| &nbsp;&nbsp;&nbsp;**19** | &nbsp;&nbsp;Air Compressor x 2 |
| &nbsp;&nbsp;&nbsp;**20** | &nbsp;&nbsp;Computers |
| &nbsp;&nbsp;&nbsp;**21** | &nbsp;&nbsp;Laser Welder |
| &nbsp;&nbsp;&nbsp;**22** | &nbsp;&nbsp;Boilout Tank |
| &nbsp;&nbsp;&nbsp;**23** | &nbsp;&nbsp;Denture Flasks |
| &nbsp;&nbsp;&nbsp;**24** | &nbsp;&nbsp;D. Springs |
| &nbsp;&nbsp;&nbsp;**25** | &nbsp;&nbsp;Attachments/Implants |
| &nbsp;&nbsp;&nbsp;**26** | &nbsp;&nbsp;Porcilain Furness / Programat P-200 x 2 |
| &nbsp;&nbsp;&nbsp;**27** | &nbsp;&nbsp;Porcilain Furness / Programat P-310 |
| &nbsp;&nbsp;&nbsp;**28** | &nbsp;&nbsp;Porcilain Furness / Programat P-500 |
| &nbsp;&nbsp;&nbsp;**29** | &nbsp;&nbsp;Porcilain Furness / Programat EP-5000 |
| &nbsp;&nbsp;&nbsp;**30** | &nbsp;&nbsp;IPS - Empess Ivoclar |
| &nbsp;&nbsp;&nbsp;**31** | &nbsp;&nbsp;Infinity L-30 Jelrus |
| &nbsp;&nbsp;&nbsp;**32** | &nbsp;&nbsp;Ceramill Therm S |
| &nbsp;&nbsp;&nbsp;**33** | &nbsp;&nbsp;&nbsp;Ceramill Therm / Girrbach |
| &nbsp;&nbsp;&nbsp;**34** | &nbsp;&nbsp;&nbsp;Ceramill Map 400 Scaner |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**35** | &nbsp;&nbsp;&nbsp;3 Shape |
| &nbsp;&nbsp;&nbsp;**36** | &nbsp;&nbsp;&nbsp;Ceramill Motion 2 Dry/WEt - Milling |
| &nbsp;&nbsp;&nbsp;**37** | &nbsp;&nbsp;&nbsp;Ceramill Motion 2 Dry milling |
| &nbsp;&nbsp;&nbsp;**38** | &nbsp;&nbsp;&nbsp;E-Tec - 3D Printer |
| &nbsp;&nbsp;&nbsp;**39** | &nbsp;&nbsp;&nbsp;Sonic Mini 8k 3D Printer x 3 |
| &nbsp;&nbsp;&nbsp;**40** | &nbsp;&nbsp;&nbsp;Electric Hadpiece Buffalo x4 |
| &nbsp;&nbsp;&nbsp;**41** | &nbsp;&nbsp;&nbsp;Buffalo - Lathe x 2 |
| &nbsp;&nbsp;&nbsp;**42** | &nbsp;&nbsp;&nbsp;Redwing Lathe x 2 |
| &nbsp;&nbsp;&nbsp;**43** | &nbsp;&nbsp;&nbsp;Wells Hadpiece x 3 |
| &nbsp;&nbsp;&nbsp;**44** | &nbsp;&nbsp;Hyundai delivery vehicle |
| &nbsp;&nbsp;&nbsp;**45** | &nbsp;&nbsp;Kia delivery vehicle |
| &nbsp;&nbsp;&nbsp;**46** | &nbsp;&nbsp;Business telephone land lines |
| &nbsp;&nbsp;&nbsp;**47** |  |
| &nbsp;&nbsp;&nbsp;**48** |  |
| &nbsp;&nbsp;&nbsp;**49** |  |
| &nbsp;&nbsp;&nbsp;**50** |  |
| &nbsp;&nbsp;&nbsp;**51** |  |
| &nbsp;&nbsp;&nbsp;**52** |  |
| &nbsp;&nbsp;&nbsp;**53** |  |
| &nbsp;&nbsp;&nbsp;**54** |  |
| &nbsp;&nbsp;&nbsp;**55** |  |
| &nbsp;&nbsp;&nbsp;**56** |  |
| &nbsp;&nbsp;&nbsp;**57** |  |
| &nbsp;&nbsp;&nbsp;**58** |  |
| &nbsp;&nbsp;&nbsp;**59** |  |
| &nbsp;&nbsp;&nbsp;**60** |  |
| &nbsp;&nbsp;&nbsp;**61** |  |
| &nbsp;&nbsp;&nbsp;**62** |  |
| &nbsp;&nbsp;&nbsp;**63** |  |
| &nbsp;&nbsp;&nbsp;**64** |  |

---

**SCHEDULE 1.1(b)**

**ASSIGNED CONTRACTS & CONSENTS TO TRANSFER**

**[List any assigned Contracts or Consents here]**

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1** | &nbsp;&nbsp;&nbsp;To be determined prior to closing |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**13** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**14** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**15** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**16** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**17** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**18** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**19** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**20** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**21** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**22** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**23** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**24** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**25** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**26** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**27** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**28** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**29** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**30** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**31** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**32** |  |

---

**SCHEDULE 1.1(i)**

**TRANSFERRED PERMITS**

**[List any Transferred Permits here]**

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1** | &nbsp;&nbsp;&nbsp;To be determined prior to closing |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**13** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**14** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**15** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**16** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**17** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**18** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**19** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**20** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**21** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**22** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**23** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**24** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**25** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**26** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**27** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**28** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**29** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**30** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**31** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**32** |  |

---

**SCHEDULE 1.2**

**ADDITIONAL EXCLUDED ASSETS**

Certain assets of the Seller shall be excluded from the list of included Purchased Assets as follows:

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1** | &nbsp;&nbsp;&nbsp;Business Checking |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2** | &nbsp;&nbsp;&nbsp;Business Savings |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3** | &nbsp;&nbsp;T-Mobile cellular phone plan |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**13** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**14** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**15** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**16** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**17** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**18** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**19** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**20** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**21** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**22** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**23** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**24** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**25** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**26** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**27** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**28** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**29** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**30** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**31** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**32** |  |

---

**SCHEDULE 1.3(c)**

**ASSUMED LIABILITIES**

Certain liabilities of the Seller shall be assumed by the Buyer as follows:

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1** | &nbsp;&nbsp;&nbsp;Current Lease |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**13** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**14** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**15** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**16** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**17** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**18** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**19** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**20** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**21** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**22** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**23** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**24** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**25** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**26** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**27** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**28** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**29** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**30** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**31** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**32** |  |

---

**SCHEDULE 1.4(n)**

**RETAINED LIABILITIES**

Certain liabilities of the Seller shall be retained by the Seller as follows:

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1** | &nbsp;&nbsp;&nbsp;To be completed |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**13** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**14** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**15** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**16** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**17** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**18** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**19** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**20** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**21** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**22** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**23** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**24** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**25** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**26** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**27** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**28** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**29** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**30** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**31** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**32** |  |

---

**SCHEDULE 4.6**

**LITIGATION**

Seller confirms the following litigation (and related legal matters) is pending against DDL:

---

| | |
|:---|:---|
| **1** | &nbsp;&nbsp;&nbsp;To be completed |
| **2** | |
| **3** | |
| **4** | |
| **5** | |

---

**SCHEDULE 4.8**

**PERMITS**

**[List any included Permits here]**

---

| | |
|:---|:---|
| **1** | &nbsp;&nbsp;&nbsp;To be determined prior to closing |
| **2** | |
| **3** | |
| **4** | |

---

---

| |
|:---|
| **5** |
| **6** |
| **7** |
| **8** |
| **9** |
| **10** |

---

**SCHEDULE 4.10**

**WARRANTIES**

**[List any included Warranties here]**

---

| | |
|:---|:---|
| **1** | &nbsp;&nbsp;&nbsp;To be determined prior to closing |
| **2** | |
| **3** | |
| **4** | |
| **5** | |
| **6** | |
| **7** | |
| **8** | |
| **9** | |

---

**10**

**SCHEDULE 4.21**

**RELATIONSHIPS WITH AFFILIATES**

**[List any Relationships with Affiliates here]**

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1** | &nbsp;&nbsp;&nbsp;To be determined prior to closing |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**13** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**14** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**15** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**16** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**17** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**18** |  |

---

---

| |
|:---|
| **19** |
| **20** |
| **21** |
| **22** |
| **23** |
| **24** |
| **25** |

---

**SCHEDULE 5.4**

**INTELLECTUAL PROPERTY**

**[List any included Intellectual Property here]**

---

| | |
|:---|:---|
| **1** | &nbsp;&nbsp;&nbsp;To be determined prior to closing |
| **2** | |
| **3** | |
| **4** | |
| **5** | |
| **6** | |
| **7** | |
| **8** | |
| **9** | |
| **10** | |

---

**APPENDIX A**

**INVESTOR CERTIFICATE**

TO:Standard Dental Labs, Inc. (the "**Company**")

RE:**Purchase of Common Shares of the Company**

Ladies and Gentlemen:

1. The undersigned owner of Brlit Dental Laboratory, Inc. ("BDL") hereby delivers this certificate in connection with their receipt of shares of common stock of the Company pursuant to that certain Asset Purchase Agreement by and between BDL and the Company to which this Investor Certificate is attached.

2. By executing this Investor Certificate, the undersigned represents, warrants and covenants (on its own behalf and, if applicable, on behalf of each beneficial purchaser for whom it is contracting hereunder) to the Company that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) it has received a copy, for its information only, of the Offering Memorandum dated
November 25, 2025, and it has had access to such additional information, if any, concerning the Company as it has considered necessary
in connection with its investment decision to acquire the Common Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) it understands and acknowledges that the Common Shares have not been and may never
be registered under the Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state of
the United States, and that the offer and sale of the Common Shares to it are being made in reliance upon Rule 506(b) of Regulation D
("Regulation D") under the Securities Act and/or Section 4(a)(2) of the Securities Act and similar exemptions under applicable
securities laws of any state of the United Sta tes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) it is an either (check one):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o "accredited investor"
meeting one or more of the criteria described in Rule 501(a) of Regulation D ("Accredited Investor"), or

o not an Accredited Investor,
but either alone or with his or her representative(s) has such knowledge and experience in financial and business matters that he is capable
of evaluating the merits and risks of the prospective investment in the Common Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) it is not acquiring the Common Shares with a view to any resale, distribution
or other disposition of the Common Shares in violation of United States federal or state securities laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) it alone, or with the assistance of its own professional advisors, has such knowledge
and experience in financial and business affairs as to be capable of evaluating the merits and risks of its investment in the Common Shares,
and it is able, without impairing its financial condition, to hold the Common Shares for an indefinite period of time and bear the economic
risk, and withstand a complete loss, of its investment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) it acknowledges that it has not purchased the Common Shares as a result of any
"general solicitation" or "general advertising" (as those terms are used in Regulation D), including advertisements,
articles, notices or other communications
published in any newspaper, magazine or similar media or on the internet, or broadcast over radio, television or the internet, or any
seminar or meeting whose attendees have been invited by general solicitation or general advertising;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) it understands and acknowledges that the Common Shares are "restricted securities"
within the meaning of Rule 144(a)(3) under the Securities Act, and may not be offered, sold, pledged or otherwise transferred, directly
or indirectly, unless pursuant to a registration statement declared effective by the Securities and Exchange Commission (the "SEC")
or pursuant to an exemption from the registration requirements of the Securities Act and in compliance with any restrictive legend imprinted
thereon;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) upon the original issuance of the Common Shares and until such time as it is no
longer required under applicable requirements of the Securities Act or applicable securities laws of any state of the United States, all
certificates or statements representing the Common Shares and all certificates or statements issued in exchange therefor or in substitution
thereof, shall bear a legend substantially in the following form:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) "**THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT"), OR ANY STATE SECURITIES LAWS. THE HOLDER HEREOF, BY PURCHASING THESE SECURITIES, AGREES FOR THE BENEFIT OF STANDARD DENTAL LABS INC. (THE "CORPORATION") THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY: (A) TO THE CORPORATION, (B) PURSUANT TO REGISTRATION UNDER THE U.S. SECURITIES ACT AND IN ACCORDANCE WITH ANY APPLICABLE STATE SECURITIES LAWS, (C) IN ACCORDANCE WITH (1) RULE 144A UNDER THE U.S. SECURITIES ACT OR (2) RULE 144 UNDER THE U.S. SECURITIES ACT, IF AVAILABLE, OR (D) PURSUANT TO ANOTHER EXEMPTION OR EXCLUSION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT, AND IN EACH CASE, IN ACCORDANCE WITH ALL APPLICABLE STATE SECURITIES LAWS, AFTER, IN THE CASE OF TRANSFERS PURSUANT TO CLAUSE (C)(2) OR (D) (OR IF REQUIRED BY THE CORPORATION, OR ITS TRANSFER AGENT, CLAUSE (B)) ABOVE, THE HOLDER HAS PROVIDED TO THE CORPORATION A LEGAL OPINION OF COUNSEL OF RECOGNIZED STANDING OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE CORPORATION, TO THE EFFECT THAT THE SALE OF SUCH SECURITIES IS NOT REQUIRED TO BE REGISTERED UNDER THE U.S. SECURITIES ACT OR APPLICABLE STATE SECURITIES LAWS..** "

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) it consents to the Company making a notation on its records or giving instructions
to any transfer a gent of the Common Shares to implement the restrictions on transfer set out herein;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) it understands and acknowledges that the Company is not obligated to file and
has no present intention of filing with the SEC or with any state securities administrator any registration statement in respect of re-sales
of the Common Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) it is relying on the information contained in the Offering Memorandum in making
its investment decision with respect to the Common Shares. It further acknowledges that the Company has not made any representation or
given any information to it with respect to the Company or the offering or sale of the Common Shares other than the information contained
in the Offering Memorandum. It has had access to such financial and other information concerning the Company and the Common Shares as
it has deemed necessary in connection with its decision to purchase the Common Shares, including an opportunity to ask questions of, and
request information from, the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) it understands that the investment in or holding, acquisition, exercise or disposition,
as applicable, of the Common Shares may have tax consequences under the laws of the United States and that it is the sole responsibility
of the purchaser to determine a nd assess such tax consequences as may apply to its particular circumstances;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) it acknowledges that it has obtained independent legal, income tax and investment
advice with respect to its receipt of the Common Shares under the APA and, accordingly, has had an opportunity to acquire an understanding
of the meanings of all terms contained herein relevant to the purchaser for purpose of giving the representations, warranties and covenants
contained herein; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) if the Company is ever deemed to be, or to have been at any time previously, an
issuer with no or nominal operations and no or nominal assets other than cash and cash equivalents, Rule 144 under the Securities Act
may not be available for re-sales of the Common Shares, and (ii) the Company is not obligated to take, and has no present intention of
taking, any action to make Rule 144 under the Securities Act (or any other exemption) available for re-sales of the Common Shares.

3. The undersigned understands and acknowledges that it is making the representations, warranties and agreements contained herein with the intent that they may be relied upon by the Company in determining its eligibility to purchase Common Shares.

4. The Company shall be entitled to rely on delivery of a facsimile or electronic copy of this certificate, and acceptance by the Company of a facsimile or electronic copy of this certificate shall create a legal, valid and binding agreement among the undersigned and the Company in accordance with the terms hereof.

**SIGNATURE OF OWNER**

(Full Name of Owner - please print)

(Authorized Signature)

(Name and Official Capacity - please print)

[*Signature Page Follows*]

**APPENDIX A**

**INVESTOR CERTIFICATE**

**Seller Signature Page**

---

| | | |
|:---|:---|:---|
| By: | /s/ Emil Brlit | Name: EMIL BRLIT |

---

Title: President

---

| | | |
|:---|:---|:---|
| By: | /s/ Elena Brlit | Name: ELENA BRLIT |

---

Title: Treasurer

---

| | |
|:---|:---|
| By: | /s/ David R Damschroder |

---

Name: DAVID R DAMSCHRODER

Title: Vice President

---

| | |
|:---|:---|
| By: | /s/ Elizabeth Damschroder |

---

Name: ELIZABETH DAMSCHRODER

Title: Limited Partner

## Ex1K-6

**Exhibit 6.12**

**AMENDMENT NO. 1**

**TO**

**ASSET PURCHASE AGREEMENT**

**THIS AMENDMENT NUMBER ONE TO THE ASSET PURCHASE AGREEMENT** (this "<u>Amendment</u>"), dated March 30<sup>th</sup>, 2026, amends the Asset Purchase Agreement, dated January 30<sup>th</sup>, 2026 (the "<u>Original Agreement</u>"), between BRLIT DENTAL LABORATORY, INC. , a Florida limited liability company (or the "<u>Seller</u>"); and Standard Dental Labs Inc., a Nevada corporation ("<u>SDL</u>" or the "<u>Buyer</u>"). The Buyer and Seller are sometimes individually referred to herein as a "<u>Party</u>", and collectively as the "<u>Parties</u>".

**PREAMBLE**

The Buyer and the Seller desire to amend the Original Agreement as set forth below. Other than the amendments set forth in this Amendment, the Original Agreement is not otherwise amended, altered or changed and remains in full force and effect pursuant to its terms.

**AMENDMENTS**

Pursuant to Section 10.4 of the Original Agreement, the parties hereby agree to amend the Original Agreement as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Section 8.2(a) of the Original Agreement is amended and restated as follows:

"(a) the purchase of the Purchased Assets shall not have been consummated by April 30<sup>th</sup>, 2026 (the "**End Date**"); or"

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Section 10.2 of the Original Agreement is amended and restated as follows:

"This Agreement, as amended by the Amendment, and the Related Documents (including the schedules and the exhibits attached hereto) contain all of the agreements between the parties hereto with respect to the transactions contemplated hereby and supersede all prior agreements or understandings, whether written or oral, between the Seller and the Buyer."

To the extent not prohibited by state law all questions concerning the construction, interpretation and validity of this Amendment and all claims or causes of action (whether in contract or tort) that may be based upon, arise out of or relate to this Amendment or the negotiation, execution or performance of this Amendment shall be governed by and construed and enforced in accordance with the domestic Laws of the State of Nevada, without giving effect to any choice or conflict of Law provision or rule, whether in the State of Nevada or any other jurisdiction, that would cause the Laws of any jurisdiction other than the State of Nevada to apply. In furtherance of the foregoing, the internal Law of the State of Nevada shall control the interpretation and construction of this Amendment, even if under the State of Nevada's choice of Law or conflict of Law analysis, the substantive Law of some other jurisdiction would ordinarily or necessarily apply.

This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Electronic counterpart signatures to this Agreement shall be deemed to be original and shall be acceptable and binding.

[*Signature Page Follows*]

WITNESS WHEREOF, each of the undersigned has executed this Agreement as of the date first written above.

**THE BUYER:**

**STANDARD DENTAL LABS, INC.**

By: <u>/s/ James D. Brooks</u> 

Name: James D. Brooks

Title: CEO, President

**THE SELLER**

BRLIT DENTAL LABORATORY, INC.

---

| | | |
|:---|:---|:---|
| By: | /s/ Emil Brlit | Name: EMIL BRLIT |

---

Title: President

---

| | | |
|:---|:---|:---|
| By: | /s/ Elena Brlit | Name: ELENA BRLIT |

---

Title: Treasurer

---

| | |
|:---|:---|
| By: | /s/ David R Damschroder |

---

Name: DAVID R DAMSCHRODER

Title: Vice President

---

| | |
|:---|:---|
| By: | /s/ Elizabeth Damschroder |

---

Name: ELIZABETH DAMSCHRODER

Title: Limited Partner

## Form 1-K Filing Summary

### Filer Information

**Issuer CIK:** 0001178660

**Issuer CCC:** XXXXXXXX

**Is filer a shell company?:** No

**Is this filing by a successor company?:** No

### Submission Contact Information

**Is this a LIVE or TEST Filing?:** LIVE

**Period:** 12-31-2025

### Item 1: Issuer Information (Tab 1 Notification)

**Type of Report:** Annual Report

**Fiscal Year End:** 12-31-2025

**Exact Name of Issuer:** Standard Dental Labs Inc.

**CIK:** 0001178660

**Jurisdiction of Incorporation:** NV

**IRS Number:** 88-0411500

**Address:** .424 E CENTRAL BLVD, ORLANDO, FL 32801

**Issuer Phone Number:** 321-465-9899

**Title of each class of securities issued pursuant to Regulation A:** Common Stock

### Item 2: Ongoing Reporting Requirements

**Is the issuer relying on the relief provided by Rule 257(d) for this filing?** Yes